Mechanisms of enhanced natural resistance to infection induced by interleukin-1: studies in mice by Vogels, M.T.E.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/145848
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.


MECHANISMS OF 
ENHANCED NATURAL RESISTANCE 
TO INFECTION INDUCED BY INTERLEUKIN-1 
STUDIES IN MICE 
CIP-DATA KONINKLIJKE BIBLIOTHEEK, DEN HAAG. 
Vogels, Maria Theresia Elisabeth 
Mechanisms of enhanced natural resistance to infection 
induced by interleukin-1 : studies in mice / Maria 
Theresia Elisabeth Vogels. - [S.l. : s.n.] (Wageningen : 
Ponsen & Looyen). - 111. 
Thesis Nijmegen. - With ref. - With summary in Italian and 
Dutch. 
ISBN 90-9007610-7 
Subject headings: natural resistance / infections / 
interleukin-1. 
MECHANISMS OF 
ENHANCED NATURAL RESISTANCE 
TO INFECTION INDUCED BY INTERLEUKIN-1 
STUDIES IN MICE 
Een wetenschappelijke proeve op het gebied van 
de Medische Wetenschappen 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op 
woensdag 16 november 1994 
des namiddags te 1.30 uur precies 
door 
MARIA THERESIA ELISABETH VOGELS 
geboren op 3 september 1959 te Delft 
PROMOTOR Prof Dr J W M van der Meer 
The research presented in this thesis was performed at the 
Department of Medicine, Division of General Internal Medicine, 
University Hospital Nijmegen, Nijmegen, The Netherlands 
These studies were in part supported by grants from the 
University Research Pool Nijmegen 
It is remarkable that al* human beings have legs which are 
just long enough to reach the ground. 
Mark Twain 
Aan mijn ouders 
Aan Vincenzo en Giuseppe 
CONTENTS 
List of abbreviations 8 
Chapter 1 Introduction 11 
Chapter 2 Use of immune modulators in nonspecific therapy of 19 
bacterial infections. 
Antimicrobial Agents and Chemotherapy 1992;36:1-5 
Chapter 3 Effects of interleukin-8 on nonspecific resistance to 33 
infection in neutropenic and normal mice. 
Antimicrobial Agents and Chemotherapy 1993;37:276-280 
Chapter 4 Interleukin-1-induccd nonspecific resistance to bacterial 49 
infection in mice is not mediated by glucocorticosteroids. 
Antimicrobial Agents and Chemotherapy 1992;362785-2789 
Chapter 5 Role of acute-phase proteins in interleukin-1-induced 63 
nonspecific resistance to infections in mice. 
Antimicrobial Agents and Chemotherapy 1993;37:2527-2533 
Chapter 6 The role of TNFa, GM-CSF, PAF and arachidonic acid 81 
metabolites in interleukin-1-induced resistance to 
infection in neutropenic mice. 
Infection and Immunity 1994;62:2065-2070 
Chapter 7 Differential gene expression for interleukin-1 receptor 97 
antagonist, interleukin-1 (IL-1) and tumor necrosis factor 
(TNF) receptors and IL-1 and TNF synthesis may explain 
IL-1-induced resistance to infection. 
J. Immunology 1994, in press 
Chapters Interleukin-1 (IL-1) induced resistance to bacterial 119 
infection: the role of the macrophage and soluble TNT 
receptors. 
Submitted for publication to Infection and Immunity 
Chapter 9 Interleukin-1 (IL-1) induced resistance to bacterial 135 
infection: a role of the type 1 IL · ! receptor and 
amelioration of pathology. 
Submitted for publication to Antimicrob. Agents Chemother. 
Chapter 10 Summary and conclusions 155 
Riassunto e conclusioni 165 
Samenvatting en conclusies 169 
Bibliography 179 
Dankwoord 182 
Curriculum vitae 184 
LIST OF ABBREVIATIONS 
AA 
ACTH 
APP 
CFU 
cpm 
DMDPL 
EDTA 
ELISA 
GALN 
GM-CSF 
IFN-γ 
Ig 
IL-1 
IL-1R 
IL-IRa 
IL-8 
kDa 
LIF 
LPS 
LTB4 
mAb 
η 
NO 
PAF 
PBS 
Pg 
PMA 
PMN 
RIA 
RNI 
ROI 
SAA 
SD 
SEM 
SDS 
sTNFR 
TNFa 
TNFR 
arachidonic acid 
adrenocorticotropic hormone 
acute phase protein 
colony-forming units 
counts per minute 
diphosphonate-containing liposomes 
ethylene diamino tetra acetic acid 
enzyme-linked immunosorbent assay 
galactosamine 
granulocyte macrophage-colony stimulating factor 
interferon-γ 
immunoglobulin 
interleukin 1 
interleukin 1 receptor 
interleukin 1 receptor antagonist 
interleukin 8 
kilodalton 
leukemia-inhibiting factor 
lipopolysaccharide 
leukotriene B4 
monoclonal antibody 
number 
nitric oxide 
platelet-activating factor 
phosphate buffered saline 
prostaglandin 
phorbol myristate acetate 
polymorphonuclear cell 
radioimmunoassay 
reactive nitrogen intermediates 
reactive oxygen intermediates 
serum amyloid A 
standard deviation 
standard error of the mean 
sodium dodecyl sulfate 
soluble tumor necrosis factor receptor 
tumor necrosis factor α 
tumor necrosis factor receptor 
8 
CHAPTER 1 
Introduction. 
10 
INTRODUCTION 
During an assault of microbial pathogens, a battle occurs between 
aggressive forces of the pathogen and defensive forces of the host. The 
host defense mechanisms can be divided in two categories. The first 
category is innate, and operative at very short notice after the microbial 
assaul t . It is nonspecific, i.e., similar reactions occur largely 
independent on the type of pathogen. This innate, nonspecific immunity 
includes chemical influences and physical barriers. In addition, other 
lines of defense play a role: humoral systems including the complement 
system and acute phase proteins, and inflammatory cells, including 
macrophages, granulocytes, and natural killer cells. Superimposed on 
the nonspecific response is a second defense system, i.e., a specific 
response to the pathogen. This acquired immunity involves specific 
immunological mechanisms, which can be divided in humoral 
mechanisms mediated through antibodies, and cellular mechanisms, 
depending on T-lymphocytes. The essential difference between 
nonspecific and specific host defense is that the latter has the ability to 
build up immunological memory. In both types of host defense, a large 
array of polypeptide intercellular messengers, called cytokines, play a 
role. 
Nowadays, serious infections in patients present an increasing problem, 
not only because of development of resistance of pathogens to 
antimicrobial agents, but also because host defenses are compromised in 
increasing numbers of patients (e.g. due to immunosuppressive therapy, 
cancer and cancer chemotherapy). Today's research is not only focusing 
on the development of new antibiotics and on enhancement of acquired 
imunity by vaccinations, but also on enhancement of nonspecific 
immunity of the host. A major advantage of the latter approach is its 
applicability to a wide spectrum of microorganisms. The research 
presented in this thesis is an illustration of this approach. 
Recently, several investigators have reported that pretreatment with a 
low dose of the cytokine interleukin-1 (IL-1) enhances resistance to a 
variety of micro-organisms, including Gram-negative and Gram-positive 
bacteria, fungi and protozoa. The mechanism of this IL-1-induced 
enhancement of nonspecific resistance has not yet been elucidated. The 
purpose of the research presented in this thesis was to gain 
understanding of the mechanisms of IL-1-induced enhanced nonspecific 
resistance to infection. 
IL-1, exists in two forms, IL-lct and IL-lß, products of two different 
genes. It is synthesized by various cells in réponse to infectious agents, 
injury, toxins and inflammatory mediators. IL-1 affects nearly every 
tissue and organ system. These effects are produced by interaction of IL-1 
with two types of IL-1 surface receptors which have been completely 
characterized. The vast array of biological changes mediated by IL-1 
appear to have a role in host defense against infection, local reaction to 
injury and subsequent reparative processes (Table 1). 
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Table 1 Major effects of IL·! 
induction of fever 
anorexia 
slow wave sleep 
muscle breakdown, amino acid turnover, body protein loss 
myocardial suppression 
hypotension, shock 
hypoferremia, hypozincemia, hypercupremia 
increased hepatic acute phase protein synthesis 
effects on glucose homeostasis 
induction of CRF and ACTH 
neutrophil production from bone marrow (direct and via IL-3, IL-6, G-CSF, GM-CSF) 
neutrophil release from bone marrow, and tissue infiltration (via IL-8) 
neutrophil priming 
eosinophil degranulation 
thrombocytosis 
natural killer cell activion (synergy with IL 2 and IFNY) 
T-cell activation, via IL-2 (synergy with IL-6) 
induction of IL-2 synthesis and IL-2 receptor expression 
B-cell activation (via of IL-6, synergy with IL-4) 
fibroblast proliferation 
osteoblast activation 
endothelial procoagulant effect, endothelial activation, adhesion molecule expression 
toxicity for pancreatic p-cells 
induction of cyclooxygenase and lipooxygenase 
induction of IL-1, IL-2, IL-3, IL 4, IL-5, IL 6, IL 7, IL 8, TNFa, TNFß, IFN-ßl 
GM-CSF, G-CSF, M-CSF 
induction of manganese superoxide dismutase 
suppression of gene expression of 
-albumin, transferrin 
-cytochrome P-450 
-thyroglobuhn 
-type 1 IL-1 receptor 
(Table adapted from С A Dinarello 1991 Blood 771627-1652) 
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Since a spectrum of side effects occurs after IL-1 administration in 
h u m a n s (e.g. fever, chills, headache and generalized myalgia), 
understanding of the mechanisms of IL-1-induced enhanced nonspecific 
resistance to infection would allow a more specific therapeutic approach. 
For invest igat ions on this subject, the previously established 
experimental models models of infectious challenge of mice with 
Klebsiella pneumoniae (in normal mice) or Pseudomonas aeruginosa 
(in severely neutropenic mice) were chosen. In these models, a low dose 
of IL-1 (3-30 μg/kg) administered 24 h before this challenge enhances 
survival in the 48 h post infection in comparison to control mice. The 
effectiveness of similar dose schedules of IL-1 has been shown in other 
infection models as well, and these are reviewed in Chapter 2. 
If one reviews the studies in which IL-1 shows improved survival of 
infections, the experiments have the following in common: 
1) effects are induced by low dose of IL-1 
2) IL-1 effects is protective in a wide spectrum of infections (i.e. the effects 
are non-specific) 
3) the induced effects need some time to become effective, and persist 
during the initial phase of establishment of the infection. Considering the 
short half-life of IL-1 in vivo, the latter criterium points to indirect IL-1 
effects. Figure 1 shows a schematic representation of the cytokine 
pathways during lethal infection (lower part of the scheme, represented 
in bold) and the possible mechanism of protection by IL-1 which have 
been studied in this thesis (upper part of the scheme). When the studies 
presented in this thesis were started, a number of other mechanisms had 
already been excluded (Table 2); these mechanisms of protection are 
reviewed in detail in Chapter 2. In addition, the effects of other cytokines 
on nonspecific resistance are reviewed in this chapter. 
Table 2. IL-1-induced protection against lethal infections: mechanisms that were ruled 
out and mechanisms that still should be investigated at the start of these studies 
О No direct antimicrobial effect of IL-1 
О No potentiation by gentamicin 
О Not mediated by granulocytes 
G Not due to increased hematopoiesis 
O Role of macrophages? 
Π Humoral mechanisms? 
-secondary cytokine? 
-acute phase proteins? 
-glucocorticosteroids? 
О Protection against lethal cytokinemia? 
-decreased cytokine production? 
-induction of cytokine inhibitors? 
-desensitisation of target cells? 
13 
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In the following chapters, we have addressed the question whether a 
cytokine induced by IL-1, namely interleukin-8 (IL-8) could mediate the 
effect of IL-1. In Chapter 4 we investigated whether IL-1-induced 
glucocorticosteroids were responsible for the beneficial effects. In 
Chapter 5, involvement of acute phase proteins was studied. The issue of 
a role of mediators like platelet-activating factor, arachidonic acid 
metabolites, tumor necrosis factor and granulocyte-macrophage colony-
st imulat ing factor, and also protection via an effect on glucose 
homeostasis, is approached in Chapter 6. The next chapter deals with 
possible protection through reduction of proinflammatory cytokines and 
their effects during infection by IL-1 pretreatment. In Chapter 8, a role of 
macrophages a t the site of injected IL-1 in IL-1-induced protection, of 
induced reactive oxygen and nitrogen metabolites, and of induced soluble 
TNF receptors is studied. Finally, in Chapter 9, it was addressed which 
IL-1 receptor was involved in IL-1-induced protection, and whether this 
protection was associated with ameliorated histopathology in IL-1-treated 
infected mice. 
14 
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CHAPTER 2 
Use of Immune modulators in nonspecific therapy 
of infections. 
M.T.E. Vogels and J.W.M. van der Meer. 
Department of Internal Medicine, University Hospital Nijmegen, 
Nijmegen, The Netherlands. 
Antimicrob. Agents Chemother. 1992;36:1-5 
Reprinted with permission. 

IMMUNE MOnmATORS 
INTRODUCTION 
Despite the availability of a wide variety of potent antimicrobial agents, 
severe bacterial and fungal infections represent a continuing threat to 
patients. This is due not only to the antimicrobial resistance of the 
involved microorganisms, but also to the increasing number of patients 
with severely hampered host defense mechanisms. 
This failure of antimicrobial therapy has led to attempts to enhance the 
nonspecific resistance of the host. Since the beginning of this century, 
many studies have demonstrated that nonspecific resistance to infection 
can be enhanced by administration of killed microorganisms like 
mycobacteria {Mycobacterium bovis bacillus Calmette-Guerin, [BCG]) 
(21), Corynebacterium parvum (now called Propionibacterium 
acnes)(l), Listeria monocytogenes and Candida albicans (68). 
Several preparations derived from microorganisms are capable of 
duplicating these effects: bacterial endotoxin (lipopolysaccharide [LPS]), 
a major component of the cell wall of Gram-negative microorganisms, 
muramylpeptides, glucan and protodyne increase the survival of Gram-
positive and Gram-negative bacteria, some viruses, fungi and 
protozoans (4,14,74). However, most of these substances are too toxic for 
clinical use. The exact mechanism by which these immunomodulators 
enhance nonspecific resistance are unknown. Since most of these 
immunostimulants are potent inducers of cytokines like interleukin-1 
(IL-1), tumor necrosis factor (TNF) and interleukin-6 (IL-6) (10,28,52,54), 
it is logical to ask whether these cytokines are able to induce nonspecific 
resistance. This minireview examines the effects of these cytokines on 
nonspecific resistance to infection. In addition, a brief review is given on 
the effects of interferons, colony-stimulating factors, and IL-2. The use 
of cytokines like IL-1, gamma interferon (IFNy), and IL-2 as adjuvants 
for vaccines are beyond the scope of this review. 
INTERLEUKIN-1 
IL-1 is an inflammatory glycopeptide that is produced by many types of 
cells (Table 1) after stimulation with various physical, chemical or 
microbial agents (19). There are two structurally different IL-1 
molecules, IL-la and IL-lß, coded for by separate genes. Although these 
17-kDa protein products have only limited amino acid homology (26%), 
they bind to the same receptor, and their pleiotropic biological effects are 
similar (19). 
Administration of IL-1 has been shown to prevent death in a variety of 
experimental infections in both normal and granulocytopenic animals 
(Table 1). If IL-1 were the endogenous mediator responsible for 
enhanced non-specific resistance induced by the immunomodulators 
mentioned above, very low dosages of IL-1 should provide protection, 
since the IL-1 concentrations produced by injection of an 
immunomodulator like LPS are low and short-lived (10). 
19 
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Indeed, a single low dose of IL-1 (0.3 μg/kg) was found to be protective. 
IL-1 needs some time to generate its protective effect; the agent works 
only if given an appreciable interval (e.g., 24 hours) before the 
production of an infection with a rapidly fatal course (63,64). In 
infections with a relative slow course, IL-1 administration can be 
delayed until shortly after the infectious challenge (15,43,67). 
In spite of many investigations, the mechanism of the protective effect of 
IL-1 has not been elucidated. The possible mechanisms are summarized 
in Table 2. Since a direct antimicrobial effect of IL-1 has been excluded, 
indirect mechanisms are to be considered; these indirect mechanisms 
should be in agreement with the short half-life of IL-1 in vivo (5 min in 
the circulation) and with the above-mentioned necessity of a time lag 
between pretreatment with IL-1 and infectious challenge. 
Since phagocytic cells (monocytes/macrophages and neutrophils) are of 
major importance in the defense against bacterial and fungal infection, 
they could represent the major effector mechanism. However, IL-1 did 
not seem to produce macrophage activation (64). It is controversial 
whether the clearance of microorganisms, which is effectuated by 
phagocytic cells, is enhanced (15,43,47,56,64,67) (Table 2). 
Table 2. Mechanisms of protection of IL-1 
Possible mechanism Comments References 
Direct antimicrobial effect 
Enhanced clearance of microorganisms 
Macrophage activation 
Neutrophil accumulation/activation 
Induction of IL-8 
Induction of TNF 
Induction of IL-6 
Induction of acute phase proteins 
Induction of hypoferremia 
Induction of cyclo oxygenase metabolites 
Interference with cytokmemia 
No inhibition of in vitro growth of bacteria 
by IL-1 
No reduced numbers of microorganisms 
Reduced numbers ol microorganisms 
No enhanced superoxide production after IL-1 
Protective eflect of IL-1 in neutropenic mice 
No enhanced granulocyte accumulation after 
IL-1 at foci ol infection 
No protection after treatment with IL-8 
Limited protection after treatment with TNF 
Negligible protection after treatment with IL-6 
No protection after passive transfer of 
plasma or serum from IL-1 treated mice 
No protection after treatment with IL-6, a 
major inducer of acute phase proteins 
No difference in serum iron in mice treated 
with IL-1 and control mice 
No influence of cyclooxygenase inhibitors on 
the protective effect of IL-1 
Downregulation of cytokine receptors (in vitro) 
15,64,67 
4 3 , 4 7 , 5 6 
6 4 
4 3 . 6 4 , 6 7 
43 
70 
63 
65 
6 4 , 6 7 
6 5 
5 6 
63,64 
37, 76 
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Although several authors do report lower numbers of microorganisms 
in IL-1 treated animals (21,42,46,55), it has not been shown whether this 
is the explanation for increased survival. At least in murine malaria, 
the effect of IL-1 on parasitemia does not seem to be linked to the actual 
cause of death, i.e. cerebral malaria (15). Also the reports on neutrophil 
counts in IL-1 treated mice and controls are conflicting: while some 
investigators find no difference (Table 2), others report increased 
numbers in IL-1 treated normal and granulocytopenic mice (44,46). 
Another argument against a role of neutrophils in the IL-1 induced 
nonspecific resistance is the observation that IL-8, a cytokine which is 
induced by IL-1 in many cell types (73) and which is considered a major 
chemoattractant and activator of neutrophils, does not protect against 
infection under most circumstances (70). 
Many microorganisms need iron for their growth, and although LPS 
protects to some extent via induction of hypoferremia (22), no such effect 
of IL-1 was found (Table 2). 
In the lethal phase of infection, circulating endogenous cytokines, such 
as IL-1 and TNF, contribute to death (10,63,71). It may well be that IL-1 
preexposure counteracts the production or effects of these cytokines. 
This might occur by lower production at the cellular level, by induction 
of IL-1 inhibitors, such as the IL-1 receptor antagonist and the soluble 
IL-1 receptor (23,31) or TNF inhibitor, such as the soluble TNF receptor 
(59), or by downregulation of receptors for IL-1 and TNF (37,76). Further 
studies are needed to evaluate whether these changes take place in vivo. 
OTHER ENHANCERS OF ANTIBACTERIAL RESISTANCE 
It is likely that the increase of resistance to infection by bacterial 
products is not mediated by IL-1 alone. Studies have been performed on 
other cytokines and growth factors that are induced by endotoxin and 
other aspecific immunostimulants. 
One of these is tumor necrosis factor (TNFa; syn-cachectin), a 17-kDa 
protein that is produced mainly by mononuclear phagocytes (7) (Table 1). 
Its spectrum of activity is very similar to that of IL-1. 
TNF has also been reported to increase host resistance. Endogenously 
produced TNF plays a role as a mediator in the host defense against 
infections caused by facultative intracellular bacteria such as Listeria 
monocytogenes, since early administration of neutralizing antibody to 
TNF accelerates death (33). Enhancement of macrophage bactericidal 
capacity has been suggested as a mechanism (32). 
A protective effect of exogenous TNF has been demonstrated in vitro and 
in vivo in infections with a wide range of microorganisms (Table 1). 
In our experiments (63), TNF was much less effective than IL-1 in 
providing protection against lethal K. pneumoniae infections. To some 
extent these results may be explained by the use of human TNFa in 
mice. 
The mechanism of the protective effect of exogenous TNF has not been 
clarified. As in the case of IL-1, an early administration (up to 24 h 
22 
TMMUNE MODULATORS 
before infection) of low dosages of TNF is optimal in most cases (50,61). 
Considering the wide variety of microorganisms against which TNF 
exerts its protective effect, several mechanisms, both cellular and 
noncellular, are probably involved. Although conflicting results with 
regard to the numbers of microorganisms after TNF treatment in vivo 
have been reported (36,50), enhanced killing of organisms by 
macrophages or neutrophils has been found in vitro (5,8,20). Several 
other mechanisms are possible. TNF might directly destroy infected 
cells (33). Also, TNF is known to induce other cytokines like IL-1, IFN-γ, 
IL-6 and colony-stimulating factors (CSFs), which in turn could 
enhance aspecific protective mechanisms in the host (48,51). TNF might 
induce reduced sensitivity of target cells to TNF in the phase of "lethal 
cytokinemia" by downregulation of TNF receptors (37), or might protect 
cells by inducing shedding of TNF receptors, which then may act as 
TNF-antagonists. In view of the above observations, the possibility of 
treatment of infectious diseases with this potent cytokine should be 
further explored. 
IFNs could also be of use to increase host defense in a non-specific 
fashion. Preexposure to either IFN-a, -β, or -γ has been shown to protect 
mice against infections caused by obligate or facultative intracellular 
pathogens (25; for a review on IFNy see reference 49), and by other 
microorganisms (13,36,53,77). The protection by the IFNs is thought to be 
through activation of macrophages and, possibly, neutrophils, resulting 
in enhanced phagocytosis and killing of pathogens. Also, induction of 
secondary mediators may play a role (58). The IFNs have already been 
used as immunomodulators in infections in humans. In acute visceral 
leishmaniasis in humans, a combination of IFNy with pentavalent 
antimony was efficacious (3). In a multicenter, double-blind placebo-
controlled study, recombinant IFNy has recently been shown to be able to 
prevent infections in chronic granulomatous disease, a group of 
disorders of the oxidative microbicidal capacity of phagocytes. The mode 
of action of IFNy in these disorders is not fully understood (40). 
Some of the biological response modifiers that enhance nonspecific 
resistance to infection also induce CSFs (2,68), either directly or via 
induction of IL-1 and TNF (69). Apart from their effect on hematopoyesis, 
CSFs are also able to activate macrophages and neutrophils (75). In 
addition, granulocyte-macrophage CSF has been shown to induce IL-1 
and TNF (62). Some studies that have been performed on the effects of 
CSFs in in vitro and in animal models are reviewed in Table 1. In vivo, 
protection was observed in nongranulocytopenic (9,24,27,34,36) as well as 
in granulocytopenic (44,47) animals . Under both conditions, an increase 
of neutrophil numbers as well as functional activation of macrophages 
and neutrophils were shown to play a role. 
Interleukin-2, a 15-kDa protein, has been shown to possess a broad 
23 
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spectrum of immunoregulatory activities. Although it does not directly 
activate macrophages, it enhances the activities of natural killer cells 
and cytotoxic T-cells (35,60). In animal models, a protective effect 
against several microorganisms has been shown (Table 1). In many 
instances, relatively high doses of IL-2 were given. Since it is known that 
IL-2 stimulates the production of IFN-γ, TNF-ct and IL-1, it is possible 
that the effects of IL-2 in such models are largely mediated by these 
cytokines (42). 
IL-2 also has negative effects: with systemic administrations of high-
dose IL-2 for cancer therapy in humans, an increased incidence of S. 
aureus bacteremia has been encountered, most likely due to an 
impairment of neutrophil Chemotaxis induced by IL-2 (41). 
CONCLUSION 
As may have become clear from the above discussion, cytokines seem to 
have a great potential for reducing the mortality of a variety of 
infections. Whether they are useful as such in clinical medicine will 
become clear in the next couple of years. Some of the cytokines (such as 
granulocyte-macrophage-CSF, IFNy and, to some extent IL-2) are 
beginning to find their way to use as therapy for infections in humans. 
Their toxicities appear to be acceptable. Whether the proinflammatory 
cytokines IL-1 and TNF can be used for treatment of infections should be 
invest igated. Their t h e r a p e u t i c index is lower, but perhaps 
administration of low dosages via the subcutaneous routes is feasible. 
Also, premedication with cyclooxygenase inhibitors, which do not seem 
to interfere with the beneficial effects, should be further explored. The 
use of certain combinations of cytokines should be examined in order to 
find the greatest degree of protection with the least side effects. 
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TNTERLEUKIN-8 
ABSTRACT 
Interleukin-8 (IL-8), a neutrophil-activating and chemoattractant 
cytokine, is produced by macrophages and other cell types after 
stimulation by Interleukin-1 (IL-1), whereas pretreatment with IL-1 
prolonged survival in several animal models of infection. Therefore we 
investigated the effect of IL-8 treatment in normal and granulocytopenic 
mice infected with a lethal dose of P. aeruginosa, K. pneumoniae or 
P. berghei. 
Bacterial and granulocyte counts were performed, histology was 
examined and survival was scored. Results indicated an unexpected 
detrimental effect of IL-8 in both normal and granulocytopenic mice, 
indicating that neutrophils probably do not play an important role in the 
IL-8 dependent exacerbation. Histopathological analyses demonstrated a 
tendency to more severe organ lesions in IL-8 treated mice. 
Only in non-granulocytopenic mice which receive IL-8 shortly before an 
infectious challenge and at the same site of infection, could a protective 
effect of IL-8 be demonstrated. Thus, whether the effect of IL-8 on 
survival of infection is protective or detrimental seems to depend on 
presence of bacteria at the injection site and on numbers of 
granulocytes. 
In conclusion, IL-8 does not seem to mediate the protective effect of IL-1. 
IL-8 may be an important participant in the cascade of interacting 
cytokines that is induced by the lethal infectious challenge. 
INTRODUCTION 
Interleukin-8 (IL-8) is a polypeptide of approximately 8 kDa, produced by 
several types of cell. Stimuli for IL-8 production include cytokines (IL-1, 
T N F a ) , LPS and lectins (1-3). IL-8 elicits Chemotaxis of 
polymorphonuclear neutrophils, T-lymphocytes and basophils. It also 
activates neutrophils, leading to expression of surface adhesion 
molecules, oxidative burst and degranulation (4-7). In addition, IL-8 
induces production of LTB4 and PAF by the neutrophils; these lipids 
recruit other neutrophils, and prime them for activation signals or even 
activate them directly (8,9). Recently, some intra-species differences of 
IL-8 have been reported (10). 
Interleukin-1 (IL-1) is a 17 Kd cytokine produced by a variety of cell types. 
Treatment of both granulocytopenic and normal mice with low dosages 
of IL-1 (3 μg/kg) 24 hours before an infection with Gram-negative 
bacteria enhances survival (11-13). Recently, protection against lethal 
cerebral malaria has been obtained in mice treated with low dosages of 
IL-1 (14). The exact mechanism of protection in these systems remains 
to be determined. 
Since IL-1 is able to induce IL-8 in monocytes, macrophages, endothelial 
cells, keratinocytes, fibroblasts and other cells (2,6,15), IL-8 might be a 
mediator of the protective effect induced by IL-1. Therefore, we 
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investigated the effect of recombinant IL-8 (16) in lethal bacterial 
infection in both neutropenic and normal mice and in murine cerebral 
malar ia . 
MATERIALS AND METHODS 
Recombinant human cytokines 
Recombinant human interleukin-8 (rHuIL-8) was prepared at Sandoz 
Research Insti tute, Vienna, Austria as published (16). Endotoxin 
contamination as assessed by the limulus amoebocyte (LAL) assay 
amounted to 0.15 ng/mg. Recombinant human interleukin-lß (rHuIL-
lß) was kindly provided by Dr. Alan Shaw (Glaxo, Geneva, Switzerland). 
Endotoxin content, as measured by LAL assay, was less than 1.53 
ng/mg. The cytokines were stored at -80°C and diluted immediately 
before use in pyrogen free isotonic phosphate buffered saline (PBS), 
pH 7.4, with addition of 2% (v/v) normal mouse serum. IL-1 was 
inactivated by heat treatment at 90°C for 30 min. All other materials 
were sterile and pyrogen free. 
Mice 
Female outbred Swiss mice (20-25 g), purchased from TNO (Rijswijk, 
The Netherlands) were used in the bacterial infection studies. Female 
inbred C57BL/6J mice of similar weight, used in the malaria 
experiments, were obtained from a local colony. All mice were allowed 
to acclimatise for 6 days prior to initiation of the studies and kept under 
specific pathogen free conditions with a light-dark cycle of 12 h (7.00 
a.m.-7.00 p.m.). Standard lab chow (Hope farms) and tap water were 
available ad libitum. Acidified water and irradiated food was given to 
granulocytopenic mice. 
Infections 
Mice were made granulocytopenic (<0.5x10^/1) by subcutaneous (s.c.) 
injection of cyclophosphamide (ASTA Pharma, Frankfurt, Germany) 
dissolved in sterile pyrogen-free distilled water. Mice that were to receive 
Pseudomonas aeruginosa (ATCC 27853) infection on day 0 received two 
dosages, 150 mg/kg on day -4, and 100 mg/kg on day 1. In a number of 
experiments mice infected with Klebsiella pneumoniae (ATCC 43816) 
were rendered less severely granulocytopenic (0.8-2χ10^Λ) by giving 
them 150 mg/kg on day -1. Non-granulocytopenic mice were also infected 
with this Klebsiella strain. Bacterial challenges (0.1 ml/mouse) were 
prepared by appropriate dilution of overnight cultures. Mice received P. 
aeruginosa in a dose of 0.5-1 χ 10? CFU/mouse, or K. pneumoniae in a 
dose of 1-5 χ 10^ CFU/mouse, either intraperitoneal ly (i.p.) or 
intramuscularly (i.m.) in the right thigh muscle. Before infection, mice 
were randomized per cage and assigned to different treatment groups. 
Solutions containing cytokines were injected into the peritoneal cavity at 
34 
TNTERLEUKIN-8 
several time points before or after the bacterial infection. Six hours after 
infection, 120 mg/kg gentamicin (Schering, Kenilworth, New Jersey, 
USA) was administered s.c. to all mice. Mortality was recorded for a 
period of at least 48 h after challenge. Since hrIL-8 is heat stable (6), 
control animals received 80 ng of heat-inactivated (90°C for 30 min) 
hrIL-Ια, 24 h before infection. 
For malaria experiments, Plasmodium berghei (Strain K173) was 
maintained by weekly subinoculation of parasitezed erythrocytes (РБ) 
from infected into naive mice. Parasitemia was determined from thin 
blood films made from a drop of tail blood and stained with May-
Grunwald Giemsa's solutions. Injections with 800 ng of IL-8 or 
inactivated control material were given on six consecutive days, starting 
on the day of infection. Mortality of infected mice was scored twice daily. 
Succumbed mice were processed for histopathological analysis. 
Differential counts of white blood cells and peritoneal cells 
Tail blood of mice was used to prepare thin blood films, which were 
stained with May-Grunwald Giemsa's solutions. EDTA blood was taken 
by orbital or heart puncture in ether anaestesized mice, that were 
subsequently killed by cervical dislocation. Five ml of ice cold PBS with 
0.38% (w/v) sodium citrate was injected into the peritoneal cavity. After 
massage of the abdomen, the peritoneal content was aspirated and put 
immediately into a polyethylene tube kept on ice. The cells were counted 
by flow cytometry (H-l, Technicon Instruments Corporation, Tarrytown, 
NY, USA). A cytocentrifuge preparation of the peritoneal cells was 
made and stained with May-Grunwald Giemsa's solutions. Differential 
counts of blood and peritoneal cells was performed by counting 200 
nucleated cells from randomly selected fields with oil immersion. 
Bacterial counts 
For determination of the in-vitro effect of IL-8 on bacterial growth, 
overnight cultures of P. aeruginosa and K. pneumoniae were 
inoculated in brain heart infusion broth and cultured at 37°C in the 
presence of different concentrations of IL-8, or vehicle (PBS). At 2,3,4 
and 5 hours after inoculation, 100 μΐ of 10-fold dilutions were plated in 
duplicate on blood agar to perform bacterial counts. The bacterial 
density of the undiluted suspension was also determined by reading the 
optical density at 650 nm using a Lambda 15 spectrophotometer (Perkin 
Elmer). 
To assess an effect of IL-8 on proliferation of bacteria in vivo, counts of 
viable bacteria were performed 30 h after i.m. or i.p. infection with P. 
aeruginosa or K. pneumoniae, a time point at which there was a clear 
difference in survival between IL-8 and control treated groups. At this 
time point mice were anaestesized with ether, bled and killed by cervical 
dislocation. Liver, spleen, kidneys and thigh muscles were removed 
aseptically, weighed and homogenized with an Ultraturrax (Janke & 
Kunkel, Staufen, Germany) in sterile saline. 10 or 20 μΐ of 10-fold serial 
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dilutions were inoculated onto blood agar (P. aeruginosa) or Levine-
EMB-agar (K. pneumoniae) in duplicate. After overnight incubation at 
37°C, the number of CFU was determined. 
Histology 
Groups of 8 mice received 800 ng of IL-8 0.5 h before infection or control 
treatment. Histopathological analysis was performed on mice sacrificed 
30 h after i.p. P. aeruginosa challenge, a time point that shows clear 
differences in survival between the treatment groups. In a second 
experiment, sections were prepared of the organs (see below) of all mice 
that died after P. berghei infection and that were pretreated with 800 ng 
of IL-8 0.5 h before infection or with control therapy. 
Histological sections of brain, lungs, heart, liver, spleen and kidneys 
were prepared by routine procedures and analyzed by light microscopy. 
Statistical analysis 
Survival curves were analyzed using the Kaplan Meyer/ log rank test 
(17). The significance of differences in bacterial counts was assessed 
using one-way analysis of variance or the Gehan Wilcoxon test, 
(depending on the censoring of data), and those of differential leukocyte 
counts using the Kruskal Wallis test (18). P-values of less than 0.05 were 
considered statistically significant. 
RESULTS 
Effect of IL-8 treatment on survival of P. aeruginosa infection in 
granulocytopenic mice 
When P. aeruginosa was given intramuscularly, a single dose of 800 ng 
IL-8, administered intraperitoneally 24 or 0.5 hours before, or 6 hours 
after infection, did not influence survival significantly (Fig 1A). 
However, as shown in Fig. IB, intraperitoneal inoculation of P. 
aeruginosa resulted in a significant enhancement of death rate, if IL-8 
was given 0.5 h before or 6 h after infection (χ^ = 5.96, p<0.05 and χ^ = 
6.69, p<0.01 respectively). Administration of IL-8 at 24 h before the 
infectious challenge did not lead to differences in survival compared to 
controls. Intraper i toneal administrat ion of 800 ng of h r IL- lß 
significantly enhanced survival in intramuscularly as well as in 
intraperitoneally infected mice (results not shown). 
Effects of IL-8 treatment on survival ofK. pneumoniae infection in 
normal and granulocytopenic mice 
In normal, as well as in granulocytopenic mice, IL-8 administration i.p. 
at 24 h or 0.5 h before or 6 h after intramuscular challenge with K. 
pneumoniae had no effect on survival (Fig. 2A,B). In the case of 
intraperitoneal infection, however, death rate was enhanced by 
intraperitoneal IL-8 administration 6 h after the challenge (in normal 
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Figure 1 A Survival of granulocytopenic Swiss m№$ after t reatment with 800 ng IL-8 
ι ρ 24 or 0 5 h before or 6 h after infection with 0 5-1x10 Ρ aeruginosa in the right 
thigh muscle Control mice received heat-inactivated IL-1 (90° С for 30 min) Each 
treatment group consists of at least 90 mice The differences between the groups are not 
significant В A similar experiment performed with Ρ aeruginosa injected 
mtrapentoneal ly Results of three independent experiments, each t rea tment group 
represents at least 30 mice Survival of mice receiving IL-8 24 h before infection does 
not differ from the control group Death in the mice receiving IL 8 0 5 h before or 6 h 
after infection is significantly accelerated (p<0 001) 
Tabic 1 CondStione and survival outcome after bacterial challenges 
Bacteria Route of bacterial Effect on Polymorphonuclear Figure Time (h) IL 8 was 
administration survival leukocyte condition no given before or after 
bacterial challenge 
Ρ aeruginosa 
Ρ aeruginosa 
К pneumoniae 
К pneumoniae 
К pneumoniae 
К pneumoniae 
К pneumoniae 
ι m 
ι Ρ 
ι m 
ι m 
> Ρ 
ι Ρ 
ι Ρ 
None Neutropenic 
Detrimental Neutropenic 
Normal 
Neutropenic 
None 
None 
Detrimental Normal 
Protective Normal 
Detrimental Neutropenic 
1A 
IB 
2A 
2B 
2C 
2C 
2D 
24, -0 5, +6 
05, +6 
24, -0 5, +6 
24, 05, +6 
+6 
05 
0 5, +6 
37 
я 
> 
3 
СП 
cd 
> 
а 
ОТ 
О 12 24 36 48 
Hours 
^ *"""—* ' • 
· " — · — » · 
12 24 36 48 
12 24 36 
Hours 
48 
Figure 2 A Survival m normal Swiss mice receiving 800 ng of IL-8 24 or 0 5 h before 
or 6 h after infection with 1-5x10 К pneumoniae in the right thigh muscle Control 
mice received heat inactivated IL 1 (90°C for 30 mm) Each treatment group consists of 
60 mice The differences between the groups are not significant В The same 
experiment performed in granulocytopenic mice (at least 70 mice/gToup), differences 
are not significant С A similar experiment performed with К pneumoniae injected 
intraperitoneal^/ in normal mice Each treatment group represents at least 125 mice 
Administration of 800 ng of IL-8 6h after infection resulted in a statistically 
significant deteriorating effect (χ2=8 62, p<0 005) Mice receiving IL-8 0 5 h before the 
challenge are protected (χ2=12 17, p<0 001) D The same experiment as in Fig lc 
performed in granulocytopenic mice Survival of mice (at least 40/group) receiving 
IL-8 at 24 h before infection does not differ from the control group Death in the mice 
receiving IL 8 О 5 h before or 6 h after infection is significantly accelerated (χ -3 46, ρ 
-0 05 and χ 2=4 26, p<0 05, respectively) 
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mice χ 2 =8.62, ρ<0.005, in granulocytopenic mice χ 2 =4.26, p<0.05)(Fig. 
2C,D). 
In contrast, IL-8 given to normal mice 0.5 h before the intraperitoneal 
challenge, resulted in a significant protective effect in normal (χ* =12.17, 
p<0.001) but not in granulocytopenic mice. 
Table 1 summarizes the conditions and the outcomes of mouse survival 
after the bacterial challenges. 
Effect oflL-8 treatment on survival of Plasmodium berghei infection 
Mice receiving 6 daily injections of 800 ng of IL-8 starting on the day of 
infection exhibited the same degree of parasitemia, change of body 
temperature and death rate after infection as observed in mice treated 
with control material (results not shown). 
• 
Η 
BU 
m 
control 
IL-8 t=-24h. 
IL-81=-0.5 h. 
IL-81=+6 h. 
F i g u r e 3. Counts of colonies of P. aeruginosa in blood, peritoneal cavity and organs 
performed in different t reatment groups 30 h after P. aeruginosa infection A) i.m. or 
B) i.p. . Treatment consisted in 800 ng IL-8 i.p. 24 or 0.5 h before or 6 h after infection. 
Control mice received heat-inactivated IL-1 (90° С for 30 min). All groups received a 
single s.c. injection of gentamicin (120 mg/kg) 6 h postinfection (each bar represents 
the median CFU/g tissue of six mice). 
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Bacterial multiplication after IL-8 in-vitro and in vivo 
To examine whether the effects of IL-8 on the course of infection were 
due to increased bacterial outgrowth, bacterial counts of blood, liver, 
spleen, kidneys and thigh muscles of mice of each treatment group were 
performed 30 h after i.m. or i.p. infection by P. aeruginosa. 
As shown in Fig. 3, no significant differences in bacterial counts in the 
various tissues were observed in relation to different treatments. Also in 
mice infected with K. pneumoniae i.p., no significant difference in 
bacterial counts was found in liver, spleen, kidneys or lungs of mice in 
the different treatment groups (8 mice/group) (data not shown). 
We also examined whether IL-8 enhanced multiplication of P. 
aeruginosa and K. pneumoniae in culture, as some pathogenic 
bacteria use cytokines as growth factors (19). At concentrations from 0.1 
ng/ml up to 1 μg/ml IL-8, no effect on bacterial growth was detected 
(Fig.4). 
о 
Рч Ü 
ω 
о 
control 
IL-8 0.1ng/ml 
IL-8 lng/ml 
IL-8 10ng/ml 
IL-8100 ng/ml 
IL-8 1 ug/ml 
Figure 4 In vitro growth of Ρ aeruginosa (A) and К pneumoniae (B) in presence of 
IL-8 in concentration of 0 1 ng/ml to 1 μg/m] Results of duplicate experiments 
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Differential leukocyte counts in blood and peritoneal cavity 
The number of peritoneal granulocytes in granulocytopenic mice 30 hrs 
after P. aeruginosa i.p. or i.m. were low and not different in mice 
treated with IL-8 at the various time points or controls (0.004-0.015 
xlO^/L); also peritoneal macrophage numbers did not differ between IL-8 
treated and control treated infected mice (0.1-0.3xH)9/L) nor did the total 
white blood cell count or the number of blood granulocytes (0.2-0.7xl09/L 
and 0.28-0.38xl09/L, respectively). 
In normal mice infected i.p. with K. pneumoniae, total and differential 
white cell counts of blood and peritoneal fluid at 30 hrs after infection did 
not differ significantly between IL-8 treated and control treated mice 
(data not shown). Apparently the neutrophil attractant effects of IL-8 are 
somehow negated by the bacterial infections. 
Histology 
Hemorrhages were the most severe changes in organs of mice 
challenged with a lethal dose of P. aeruginosa. These hemorrhages 
could be found in the brains, liver, lung, kidney or spleen, but not in all 
organs at the same time and not in all animals. In most organs, no 
clear differences between the treatment groups were present. In the 
lungs, petechiae were more frequent in the control group (seven out of 
eight in the control group versus three out of eight in the IL-8 treated 
group). In the brain, however, the IL-8 treated group had more 
pronounced and more frequent lesions: four out of eight animals had 
extensive hemorrhages (Fig. 5), whereas in the control group only one 
out of seven exhibited an extensive bleeding. 
In mice challenged with P. berghei, histopathological analyses 
confirmed that IL-8 treatment did not prevent the development of 
cerebral malaria, in contrast to findings with IL-1 treatment (14). In 
general, changes were observed in several organs, e.g. brains, lungs, 
kidneys and spleen. Although the number of mice used in the 
experiments was too smal to reach statistical significance, there was a 
tendency for more severe pathological changes in the IL-8 treated mice 
with malaria. All mice that died within 2 weeks after infection exhibited 
hemorrhages in their brains and these tended to be more severe and 
more frequent in IL-8 treated animals. In the lungs, infiltration of the 
parenchyma was often found, and some mice also exhibited 
hemorrhages, being more frequently observed in the IL-8 treated group. 
Pathological changes in other organs were similar in both treatment 
groups. In the liver, no hemorrhages were present, but in both groups 
there was glycogen depletion and a vacuolar fatty degeneration, 
particularly in the midzonal area. The kidneys showed hemorrhages 
and tubular necrosis in some cases. The spleen exhibited the involution 
of the white pulp typical of malaria infection, with a considerable 
expansion of the red pulp wit accumulation of malaria pigment. 
Occasionally a hemorrhage was found. 
In addition to these organ related phenomena, margination of 
leukocytes in the vascular system (among which released pigment 
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containing macrophages) was systematically and frequently found both 
in IL-8 treated and control mice. 
Figure 5. Hemorrhages and ghosts of erythrocytes in the brain of an IL-8 treated mouse 
30 h after infection with P. aeruginosa. 
DISCUSSION 
Under most experimental circumstances reported in this paper, IL-8 
does not protect mice against a lethal infection with P. aeruginosa, K. 
pneumoniae or P. berghei. This is in contrast to previous findings with 
IL-1, which, administered in dosages of 80-800 ng, strongly enhances 
survival of normal and granulocytopenic mice from infection caused by 
Gram-negative and Gram-positive microorganisms or Plasmodium 
berghei (11-14,20-22). 
It is remarkable that under most conditions, survival and morbidity 
were even negatively affected by IL-8. After intraperitoneal infection 
with P. aeruginosa, a significantly enhanced mortality was observed in 
neutropenic mice that received IL-8 shortly before or 6 h after the 
infectious challenge. A different picture emerged from results of mice 
infected with K. pneumoniae intraperitoneally. Whereas mice treated 
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with IL-8 6 h after infection fared worse than controls, IL-8 given 0.5 h 
before infection induced protection, but only in normal and not in 
granulocytopenic mice. In the case of intramuscular infection, IL-8 did 
not change the survival rate significantly. 
In the experiments with P. berghei infections, no effect of IL-8 was 
found on survival or on parasitemia. Histological evaluation confirmed 
that IL-8 treatment did not prevent and probably even exacerbated the 
development of cerebral malaria. 
The difference in results between intramuscular and intraperitoneal 
infection with bacteria suggests that the effect of IL-8 is largely local, 
i.e., acceleration of death occurs if both IL-8 and bacteria are present at 
the same site. As the acceleration of death by IL-8 occurs only if it is 
administered shortly before or after the infectious challenge, the effect of 
IL-8 seems to be fast and short-lived. It is intriguing that the negative 
effects are most prominent where there is neutropenia. 
One explanation for the negative effect of IL-8 could be an enhancement 
of multiplication of bacteria. However, IL-8 neither stimulated bacterial 
growth in-vitro, nor did it lead to higher bacterial counts in vivo. 
Accelerated death might be explained by a chemotactic and/or activating 
effect of IL-8 on neutrophils, one of the few known targets of IL-8 in 
vivo. Secretory products of these cells could be responsible for tissue 
damage, and thereby contribute to death (23). If an IL-8 evoked 
neutrophil response were the explanation, one would have expected to 
find more outspoken effects of IL-8 in non-neutropenic rather than in 
neutropenic mice, but this is not the case. In addition, a similar and 
very low number of neutrophils (<0.015xlO^/L) found in the peritoneal 
cavities of both the IL-8 group and the control group also argue against 
such a mechanism. 
Since cyclophosphamide p r e t r e a t m e n t also strongly affects 
monocytopoiesis, effects of IL-8 on mononuclear phagocytes are probably 
not responsible either. In addition, we found that the numbers of 
macrophages in the peritoneal cavity were also virtually identical in IL-
8 treated and control mice. Our experiments in the malaria model, in 
which lymphocytes and macrophages, but not neutrophils play a role, 
did not elucidate this issue, since no effect on survival was seen after 
IL-8 treatment. 
One possibility is that IL-8 participates in the "lethal cytokinemia", the 
overshoot of cytokine production which is thought to mediate most 
symptoms of serious infections, and which we think is ameliorated by 
IL-1 preexposition (11). In other words, IL-8 could synergize with the 
lethal effects of other cytokines like TNF, IL-1, IFN-γ and PAF. Since 
hemorrhages and other pathological changes are similar in mice with 
cerebral malaria and mice challenged with a lethal dose of bacteria, a 
common lethal pathway, in which these cytokines are involved, can be 
assumed. The observation that IL-8 treated animals have more 
pronounced brain hemorrhages, would be in agreement with the above 
hypothesis. 
The protective effect of IL-8 administered to non-granulocytopenic mice 
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shortly before intraperitoneal challenge with K. pneumoniae is not 
necessarily conflicting with the latter hypothesis. The administered IL-8 
may inhibit local neutrophil adhesion to endothelial cells activated by the 
bacterial challenge, thus limiting inflammatory damage from 
neutrophil-endothelial cell interaction (24). This might explain the lack 
of differences in leukocyte and bacterial counts we found, in spite of the 
protective effect of IL-8 in this model. Another possible explanaton is, 
that in these circumstances IL-8 initially attracts a sufficient number of 
neutrophils to the right place and the right time to be able to phagocytize 
and destroy the administered microorganisms to a certain extent. This 
initial event might suppress the initiation of the cascade of lethal 
cytokinemia. This hypothesis is not necessarily in conflict with the 
observed similar neutrophil and bacterial counts at later time points. 
Thus, the results in our animal models indicate that the effects of IL-1 
and IL-8 are partly opposite to each other. Especially in the case of 
granulocytopenic mice, this pleads against an important role of IL-8 as 
a mediator of the protective effect of IL-1 preexposition in infection. 
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GLUCOCORTICOSTEROIDS AND GLUCOSE 
ABSTRACT 
Preexposure to a low dose of interleukin-1 (IL-1) (3-30 μg/kg), 24 hours 
before a lethal Gram-negative bacterial infection prolongs survival in 
normal as well as in granulocytopenic mice. To examine whether this 
protective effect is mediated by glucocorticosteroids, we first measured 
corticosterone concentrations in mice after administration of 80 and 800 
ng of IL-1. IL-1 induced a dose-dependent increase in plasma 
corticosterone levels. Next, the corticosterone peak induced by a 
protective dose of IL-1 (800 ng) was simulated by administration of 
synthetic human adrenocorticotropic hormone [1-24] (ACTH ) in normal 
and in neutropenic mice. Although corticosterone levels induced by 
pretreatment with IL-1 or ACTH were virtually identical, the ACTH-
induced corticosterone peak was not associated with protection to 
Klebsiella pneumoniae infection in normal mice and to Pseudomonas 
aeruginosa infection in neutropenic mice. This indicates that the 
protective effect of IL-1 pretreatment to Gram-negative bacterial 
infection is not mediated by elevated levels of glucocorticosteroids. In 
addition, we found that plasma corticosterone concentrations during 
K. pneumoniae infection were significantly lower after pretreatment 
with IL-1 than after pretreatment with ACTH or vehicle, probably 
reflecting the better physical condition of IL-1 treated mice. 
INTRODUCTION 
Interleukin-1 (IL-1), a 17 kD protein produced by many different types of 
cell, has a variety of immunologic and inflammatory effects [9]. When 
injected into experimental animals, IL-1 is able to enhance nonspecific 
resistance to several Gram-positive and Gram-negative bacteria, fungi 
and plasmodia [30]. For example, we have shown that treatment with a 
single low dose (80-800 ng) of recombinant human IL-lß (rhIL-lß) 24 
hours before a lethal challenge with Gram-negative bacteria prolongs 
survival in normal and granulocytopenic mice [24,25]. The mechanism 
of the protective effect of IL-1 has not been elucidated. A direct 
antimicrobial effect of IL-1 has been excluded in vitro [25]. Whether IL-1 
induces enhanced clearance of microorganisms in vivo is controversial 
[13,14,24,25,27]. The presence of a protective effect of IL-1 to infectious 
challenges in granulocytopenic mice pleads against a major role of 
neutrophils [13,25,27,30]. The lack of effect of pretreatment with 
cyclooxygenase inhibitors or recombinant cytokines on survival of 
infection indicate that also the induction by IL-1 of cyclooxygenase 
metabolites or cytokines like IL-6, IL-8 or tumor necrosis factor-α 
(TNFa) is not likely to account for the IL-1 induced resistance [24-26,28-
30]. 
Injection of IL-1 into mice activates the pituitary-adrenal axis, as is 
manifested by increased plasma levels of adrenocorticotropic hormone 
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(ACTH) and cor t icosterone [5]. Since admin i s t r a t i on of 
glucocorticosteroids has been shown to increase survival of septic 
animals [17,21], the question was raised whether the protective effect of 
IL-1 might be due to IL-1 induced enhanced secretion of these 
hormones. To address this issue, we measured the corticosterone 
responses induced by different dosages of rhIL-lß. Furthermore, we 
simulated the IL-1 induced corticosterone peaks by administration of 
synthetic human АСТНм.24] (ACTH), and assessed the effect of 
administrat ion of ACTH on survival in infected normal and 
neutropenic mice. To find out whether protection was associated with 
changes in plasma corticosterone concentrations, we measured post­
infectious corticosterone concentrations in mice treated with IL-1 or 
ACTH as well. 
MATERIALS AND METHODS 
Abbreviations used: cfu (colony forming units), i.m. (intramuscular), 
i.p. (intraperitoneal), s.c. (subcutaneous), rhIL-1 
(recombinant human interleukin-1) ACTH (adrenocorticotropic 
hormone). 
Mice 
Female outbred Swiss mice (30-40 g, TNO, Rijswijk, The Netherlands) 
were kept under specific pathogen free conditions in an artificially 
lighted room with a light-dark cycle of 12 h (lights on at 7 a.m.- lights off 
at 7 p.m.). For experiments in which corticosterone levels were 
measured, the mice were housed individually for 4-5 days prior to 
initiation of the studies. Standard lab chow (RMH-TM; Hope Farms, 
Woerden, The Netherlands) and acidified water were available ad 
libitum. Granulocytopenic mice received irradiated food. 
Materials 
R h I L - l ß was kindly provided by Dr. P. Graber (Glaxo, Geneva, 
Switzerland) and by Dr. P. Ghiara (Sciavo, Siena, Italy). According to 
the specifications of the suppliers, endotoxin contamination was 
negligible (<1.53 ng/mg and <1.2 ng/mg respectively). IL-1 was stored 
undiluted at -70°C and was diluted immediately before use in pyrogen-
free isotonic phosphate buffered saline (pH 7.4). Inactivated IL-1 was 
prepared by heating at 95°C for 30 minutes. Human АСТНц.241 
(Synacthen, Ciba-Geigy, Arnhem, The Netherlands) was diluted in 
pyrogen-free saline. To all solutions, including control treatment 
(saline), normal mouse serum was added to an end volume of 2% (v/v). 
Gentamicin was purchased from Schering, Kenilworth, New Jersey, 
USA. Cyclophosphamide (ASTA Pharma, Frankfurt, Germany) was 
dissolved in sterile pyrogen-free distilled water. 
Bacterial challenges (Klebsiella pneumoniae, ATCC 43816 and 
Pseudomonas aeruginosa, ATCC 27853) were prepared by appropriate 
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dilution of overnight cultures and washed three times in saline. 
Experimental procedures 
All experiments started at 9.30 a.m. (t=0 h). 
(i) Corticosterone levels after treatment with IL-1 or ACTH. 
For single treatments, mice received 80 or 800 ng IL-1 intraperitoneally 
(i.p.), 50 μg ACTH subcutaneously (s.c.) or vehicle s.c. at time zero. In 
experiments in which 2 treatments with 50 μg ACTH s.c. were given, 
these injections were administered at time zero and 1.5 h. In these 
experiments, mice treated with IL-1 i.p. or vehicle s.c. at time zero 
received vehicle s.c. at 1.5 h. In case of 4 treatments with 50 μg ACTH 
the injections were given at 0, 1.5, 6, and 10 h. In these experiments 
mice treated with IL-1 or vehicle at time zero received vehicle at the 
other time points. At various time points after the first injection, mice 
were decapitated and blood was collected in EDTA coated tubes. Plasma 
was stored at -20°C until assayed. 
For corticosterone measurements in neutropenic mice, neutropenia 
( < 0 . 5 x l 0 ^ PMN/L) was induced by two s.c. injections of 
cyclophosphamide (150 mg/kg on day -3 and 100 mg/kg on day 0, before 
the treatments described above). 
(ii) Effect of IL-1 and ACTH pretreatment on survival. 
For survival experiments, some mice were rendered neutropenic as 
described above. Pretreatments with IL-1, ACTH (one, two or four 
administrations) or vehicle were given as described above. The 
infectious challenge was administered 24 h after the first injection. Non-
granulocytopenic mice received Klebsiella pneumoniae i.m. (1-5x10" 
cfu/mouse), whereas granulocytopenic mice received P. aeruginosa 
i.m. (0.5-1x10^ cfu/mouse). Six hours after the challenge, 120 mg/kg of 
gentamicin was given s.c. in order to postpone the time of death and 
thus accentuate differences between treatment groups. Mortality was 
recorded for a period of at least 48 h after challenge. 
(iii) Effect of IL-1 and ACTH pre treatment on corticosterone levels 
during infection. 
For corticosterone measurements during infection, non-neutropenic 
mice were pre treated 24 h before the challenge with either 800 ng of IL-1 
or 2 doses of 50 μg of ACTH or vehicle as described above. Klebsiella 
pneumoniae (1-5x10° cfu/mouse) was administered i.m., followed 6 
hours later by 120 mg/kg of gentamicin s.c. Plasma for corticosterone 
measurements was collected at various time points after the infectious 
challenge, and mortality and physical condition of the mice was 
observed. 
Assays 
Corticosterone concentrations in plasma were determined by a specific 
and sensitive radioimmunoassay as described by Sweep et al. [20]. 
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Statistical analysis 
Survival curves were analyzed with the log rank test [16]. Comparisons 
of medians of corticosterone levels between treatment groups were made 
by the Kruskal Wallis test at each time point [11]. P-values of < 0.05 were 
considered statistically significant. 
RESULTS 
Corticosterone levels after IL-1 treatment 
The corticosterone response (median values) in non-neutropenic mice to 
i.p. injection of 80 and 800 ng of IL-1 is shown in Figure I.A. Plasma 
corticosterone levels peaked (3.17 μπιοΙ/L) 2 hours after injection with 80 
ng of IL-1, and the concentration returned to control levels at 8 h. The 
differences with the vehicle-treated group reached stat ist ical 
significance at 1, 2 and 4 h after injection. Plasma corticosterone levels 
after 800 ng of IL-1 peaked 4 h after injection (3.48 μπιοΙ/L), and returned 
to control levels at 16 h. Significant differences with vehicle-treated mice 
are present at 0.5, 1, 2 and 4 h after IL-1 injection A significant 
difference between the groups treated with 80 and 800 ng of IL-1 is 
present at 4 hours after injection. 
In neutropenic mice, corticosterone levels after administration of 800 ng 
IL-1 peaked 2 h after injection (2.89 μπιοΙ/L), returning to values of 
control mice at 12 h. Significant differences with vehicle-treated 
neutropenic mice are present at 1, 1.5, 2 and 4 h after injection. The 
corticosterone levels induced by IL-1 or 4 injections of ACTH in 
neutropenic mice do not differ significantly at any time point (results not 
shown). 
The circadian rhythm of corticosterone levels observed in plasma of 
mice treated with vehicle is similar to that reported by others in 
untreated mice [10]. The low basal corticosterone levels in vehicle-
treated mice indicate that blood sampling took place under relatively 
stress-free circumstances. 
Simulation of IL-1 induced increased corticosterone levels by 
administration of ACTH 
Corticosterone concentrations (median values) in plasma after 
administration of 800 ng of IL-1 and after one, two or four consecutive 
injections of 50 mg of ACTH in normal mice are depicted in Fig. l.B. 
Plasma corticosterone levels after one injection of ACTH peaks at 1 h 
after injection (3.59 μηιοΙ/L), and reaches levels not significantly 
different from control mice at 8 h. 
The corticosterone levels after two injections of ACTH were not 
significantly different from the levels induced by IL-1, with the exception 
of the value 8 h after injection, at which time point levels after IL-1 are 
significantly higher. Four injections of ACTH produce a corticosterone 
peak which lasts longer than the IL-1 induced peak, the ACTH-induced 
level being significantly higher than the IL-1-induced level at 12 h after 
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Fig. l . A Median plasma corticosterone values in normal mice after 80 or 800 ng of 
rhIL-lß ι ρ at time zero (6 mice per datum point) Differences between the group treated 
with 80 ng IL-1 and the control t reatment group were significant at 1, 2 and 4 h after 
injection (p=0 007, 0 001 and 0 01 respectively) Differences between the group treated 
with 800 ng IL-1 and the control t reatment group were significant at 0 5, 1, 2 and 4 h 
after injection (p=0 05, 0 002, 0 03 and 0 0005 respectively) The difference between 
groups treated with 80 ng IL 1 and 800 ng IL-1 was significant a t 4 h after injection 
(p=0 0001) В Median plasma corticosterone levels after 800 ng of rhIL-lp ι ρ at time 
zero or one, two or four s с injections of 50 μg of АСТНц 241 o r control t reatment at 
time zero and 1 5, 6 and 10 h (6 mice per datum point) Differences between groups 
treated with 800 ng of IL-1 and one injection of ACTH were significant at 1, 4 and 8 h 
after injection (p=0 002, 0 004, and 0 006 respectively) The difference between groups 
treated with 800 ng IL-1 and two injections of ACTH was significant at 8 h (p=0 02) 
The difference between groups treated with 800 ng IL-1 and four injections of ACTH 
was significant at 12 h (p=0 002) 
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12 24 36 
time (h) 
F i g . 2 . A. Survival of normal mice infected l.m. at time zero with K. pneumoniae 
after pretreatment a t -24 h with 800 ngrhIL- lß i.p., 2 doses of ACTHi j.241 s.c. or vehicle 
s.c. at -24 and -22 5 h (36 mice per group). Differences between IL-1-treated and control 
mice were significant (χ =8.56, p<0.01) Differences between ACTH-treated and 
control mice were not significant В The same experiment as described for panel A in 
granulocytopenic mice infected l.m. with P. aeruginosa (24 mice pergroup) 
о 
Differences between IL-1 treated and control mice are significant (χ =9.94, p<0.005), 
whereas differences between ACTH-treated and control-treated mice are not 
significant. C. Survival of normal mice infected i.m. with K. pneumoniae at time 
zero after pretreatment at -24 h with 800 ng rhIL-lß i.p or 4 doses of АСТНц 24] o r 
control t r e a t m e n t s.c. at -24 , -22.5, -18 and -14 h (48 mice per group). Differences 
between IL-1-treated and control mice were significant (χ =4.30, p<0.05). Differences 
between ACTH-treated and control mice were not significant D . The same 
experiment as described for panel С in granulocytopenic mice infected 1 m. with Ρ 
aeruginosa (24 mice per group) Differences between IL-1 treated and control mice 
were significant (χ =10.34, p<0 005), whereas differences between ACTH-treated and 
vehicle-treated mice were not significant. 
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injection. When the same regimen of 800 ng of IL-1 or 4 ACTH injections 
was adminis tered to neutropenic mice, plasma corticosterone 
concentration curves did not differ significantly at any time point (data 
not shown). After intraperitoneal injection of 0.1 ml of IL-1 vehicle with 
800 ng heat-inactivated IL-1 and subcutaneous injection of 0.2 ml of 
saline, similar corticosterone levels were observed (data not shown). 
This indicates that differences in route of administration, injection 
volume and vehicles for treatment with IL-1 versus ACTH or control 
therapy did not induce different corticosterone responses. Since also 
additional s.c. vehicle injections did not significantly alter corticosterone 
levels, in Fig. l.B only the levels of the i.p. control group are presented. 
In infection experiments, two and four doses of ACTH were used to 
induce corticosterone responses. 
Effect of IL-1 and ACTH on survival 
Pretreatment of normal mice with 800 ng of IL-1 24 hours before an 
intramuscular infection with K. pneumoniae enhanced survival 
significantly (Fig. 2.A). To investigate whether this protective effect was 
mediated by the enhanced plasma corticosterone level induced by IL-1, 
the effect of 2 doses of ACTH on survival was assessed. Despite the 
similar corticosterone patterns after IL-1 and ACTH, the protective 
effect of IL-1 could not be reproduced by ACTH administration (Fig. 
2.A). When these treatments were given to granulocytopenic mice before 
an intramuscular P. aeruginosa infection, IL-1 enhanced survival 
significantly, while ACTH had no effect at all as compared to control 
therapy (Fig.2.B). 
When 4 doses of ACTH were administered, producing larger 
corticosterone peaks than IL-1, also no protection was observed in 
normal mice infected with K. pneumoniae (Fig. 2.C) and in 
granulocytopenic mice infected with P. aeruginosa (Fig. 2.D). 
Effect of IL-1 and ACTH pretreatment on corticosterone levels during 
infection 
Mice were infected with K. pneumoniae after pretreatment with either 
800 ng of IL-1, two doses of 50 μg of ACTH or vehicle injection. As 
expected, approximately 20% of control and ACTH treated mice died 
during the experiment, while all of the IL-1 treated mice survived for 48 
hours. Plasma corticosterone levels were increased at 6-12 hrs after 
infection in all treatment groups (Fig.3). 
Corticosterone concentrations of vehicle treated and ACTH treated mice 
did not differ significantly at any time point. In IL-1 treated mice, 
however, corticosterone levels were lower than in the control 
(significantly different at 36 and 48 hours) and in the ACTH treated 
group (significantly different at 12 and 36 hours) (Fig.3). Signs of 
discomfort of the infected animals (piloerection, decreased physical 
activity) were less pronounced in the IL-1 treated group. 
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Fig.3 Median corticosterone levels after ι m infection a t time zero of normal mice 
with К pneumoniae 24 h after pretreatment with 800 ng of rhIL-lß, 2 doses of 50 μg 
АСТНц.241, or control t reatment (6 mice per datum point) Corticosterone levels after 
IL-1 pretreatment were significantly lower than those in control treated mice at 36 and 
48 h (p=0 03 and p=0 02, respectively) and than those in ACTH-treated mice at 12 and 36 
h (p=0 04 and p=0 009, respectively) Differences between ACTH-treated and control-
treated groups were not significant 
DISCUSSION 
In the present study we examined the role of glucocorticosteroids in the 
IL-1 induced protection to a lethal bacterial challenge in mice. 
Preexposition with 800 ng of IL-1 24 h before a gram-negative challenge 
enhances survival in normal as well as in neutropenic mice [24,25]. 
Administration of a low (800 ng) dose of rhIL-lß to both normal or 
neutropenic mice resulted in an elevated plasma corticosterone level for 
8-12 h, which was similar to what others found in non-neutropenic mice 
[5]. Several authors have studied administration of glucocorticosteroids 
shortly before or after a challenge with endotoxin, microorganisms or 
other noxious substances and found a protective effect on survival 
[1,8,17]. Although plasma corticosterone in our study peaked 20 hours 
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before the infectious challenge and had returned to normal at the time of 
infection, a protective effect by the transiently increased level of 
corticosterone cannot be excluded a priori, since several effects of 
glucocorticosteroids are longlasting or are delayed for many hours 
[2,15,19,31]. Also our finding of a difference in corticosterone levels 
induced by a protective (800 ng) versus a non-protective (80 ng) dose of 
IL-1 might be in accordance with a role of glucocorticosteroids in the 
protective effect of IL-1. 
However, when we mimicked the plasma corticosterone concentration 
curve induced by 800 ng of IL-1 by administration of synthetic human 
ACTH in both normal and neutropenic mice, no protection against 
lethal bacterial infection was found. This indicates that protection by IL-
1 is not mediated by the elevated levels of glucocorticosteroids. 
During infection plasma levels of glucocorticoids are increased. The 
early presence of adequate concentrations of glucocorticosteroids is 
probably necessary for an effective control of overshooting of normal 
defense react ions occurring in infection and injury [3,15]. 
Glucocorticosteroids suppress production and effects of many of the 
mediators that play a role in tissue injury in severe infections [7]. 
Production of primary mediators like the cytokines IL-1, TNF, IL-6 and 
interferon-γ (IFNy), and of secondary mediators are inhibited by 
glucocorticosteroids [6,12,15,18,23]. In addition, glucocorticosteroids play 
a role in the induction of the secretion of acute phase proteins, of which 
many possess antiinflammatory and detoxifying effects [22]. A 
physiological role of these hormones during infection is further 
supported by the increased sensitivity of adrenalectomized rodents to the 
toxic effects of endotoxin, inflammatory cytokines and other 
inflammatory mediators, a sensitivity t h a t can be reversed by 
administration of glucocorticosteroids [3,4]. In various animal studies of 
gramnegative sepsis and endotoxin shock an increased survival after 
high-dose glucocorticosteroid pre t reatment has been documented 
[17,21]. Therefore, we also examined the impact of IL-1 pretreatment on 
the glucocorticoid response after an infectious challenge. Interestingly, 
we found lower corticosterone levels in IL-1 pretreated mice during 
infection. Since the IL-1-treated mice all survived the challenge, these 
relatively low corticosterone levels may reflect the better physical 
condition of these mice: the higher steroid levels in the vehicle and 
ACTH-treated mice might be a consequence of the lethal illness. 
In conclusion, the presented data suggest that the increase of resistance 
to infection induced by interleukin-1 is not due to the effect of this 
cytokine on glucocorticosteroid production. 
The improved outcome of infection in animals treated with IL-1 is 
associated with lower plasma corticosterone levels during the course of 
infection. 
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ACUTE PHASE PROTEINS AND IL-6 
ABSTRACT 
Treatment with a single low dose (80-800 ng) of interleukin-1 (IL-1), 24 h 
before a lethal bacterial challenge of granulocytopenic and of normal 
mice enhances nonspecific resistance. Since IL-1 induces secretion of 
acute phase proteins, liver proteins which possess several detoxifying 
effects, we investigated the role of these proteins in the IL-1-induced 
protection. Inhibition of liver protein synthesis using galactosamine 
(GALN) completely inhibited the IL-1-induced synthesis of acute phase 
proteins. GALN pretreatment abolished the protective effect of IL-1 on 
survival completely (neutropenic mice infected with Pseudomonas 
aeruginosa) or partially (nonneutropenic mice infected with Klebsiella 
pneumoniae). 
Pretreatment with IL-6, a cytokine induced by IL-1, did not reproduce the 
protection after IL-1 pretreatment, nor did it enhance or deteriorate the 
IL-1-enhanced resistance to infection. 
A protective effect of IL-1 via effects on glucose homeostasis during the 
acute phase response was investigated by comparing plasma glucose 
levels in IL-1-treated mice and control mice before and during infection. 
Although glucose levels in IL-1-pretreated mice were somewhat higher 
in the later stages of infection, no significant differences were present 
with levels in control mice, and the glucose levels in control-treated 
animals never fell to hypoglycemic values. 
We conclude that the IL-1-induced nonspecific resistance is neither 
mediated by induction of IL-6 nor by effects of IL-1 on glucose 
homeostasis. Acute phase proteins generated after IL-1 pretreatment, 
however, seem to play a critical role in the IL-1-induced protection to 
infection. 
INTRODUCTION 
Administration of the proinflammatory cytokine interleukin-1 (IL-1) has 
been shown to enhance nonspecific resistance in animals to several 
Gram-positive and Gram-negative bacteria, to fungi and plasmodia (33). 
The exact mechanism of this protection is still unclear. A direct 
antimicrobial effect of IL-1 has been excluded in vitro (30) and enhanced 
clearance of microorganisms induced by IL-1 in vivo has not been a 
constant finding (22,30). The protective effect of IL-1 to infectious 
challenges in granulocytopenic mice indicates tha t an effect on 
neutrophils does not mediate the IL-1-induced resistance (30,33). 
Additional studies have provided evidence against a major role of IL-1-
induced cyclo-oxygenase metabolites, glucocorticosteroids or cytokines 
like interleukin-8 or tumor necrosis factor in the IL-1-induced protection 
(30,33-35). 
In the present study, we have investigated whether the effects of IL-1 on 
the acute phase response could be responsible for the increased 
resistance induced by IL-1. 
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The acute phase response comprises a constellation of metabolic, 
endocrinologie, neurologic and immunologic alterations, which starts 
within hours of an initiating stimulus. These changes appear to be 
meant to balance or curtail the potential adverse consequences of the 
inflammatory process and restore homeostasis (15). Synthesis of acute 
phase proteins by the liver is a major component of the acute phase 
response and IL-1 appears to be an important inducer. We addressed the 
issue whether enhanced resistance to infection after IL-1 preexposition 
might be due to IL-1 induced enhanced secretion of acute phase proteins 
using galactosamine (GALN), a liver-specific blocker of RNA and protein 
synthesis which acts by depletion of UTP and thereby is able to block acute 
phase protein synthesis (5). We investigated to what extent GALN inhibits 
the IL-1 induced acute phase protein secretion by the liver. Next, we 
assessed whether GALN would also inhibit the IL-1 induced enhanced 
survival of normal and neutropenic mice after a lethal Gram-negative 
bacterial challenge. 
Since IL-1 has been shown to induce IL-6 production by endothelial cells, 
fibroblasts, macrophages and other cell types, it has been proposed that 
IL-6 is the direct mediator of a number of activities that were originally 
attributed to IL-1 (11,32). IL-6 induces a series of acute phase proteins and 
in addition possesses some other potentially protective effects in infection 
(12,32). Hence we studied the role of IL-6 in IL-1-induced protection. 
Another component of the acute-phase response to trauma and infection 
is carbohydrate dyshomeostasis. During severe infection, especially in 
rodents, an initial hyperglycemia may devolve into a profound 
hypoglycemia, the latter being a sign of decompensation (7). Since IL-1 
affects glucose metabolism in various ways (29), we addressed the 
question whether effects of IL-1 on glucose homeostasis resulted in 
enhanced survival. 
MATERIALS AND METHODS 
Mice 
Female outbred Swiss mice (20-25 g; TNO, Rijswijk, The Netherlands) 
were kept under specific-pathogen-free conditions with a light-dark cycle 
of 12 h (lights on at 7 a.m., lights off at 7 p.m.). Standard lab chow (RMH-
TM; Hope Farms, Woerden, The Netherlands) and acidified water were 
available ad libitum. Granulocytopenic mice received irradiated food. 
Matericds 
Recombinant human IL-lß (rhIL-lß) was kindly provided by Dr. P. 
Graber (Glaxo, Geneva, Switzerland) and Dr. P. Ghiara (Sciavo, Siena, 
Italy). According to the specifications of the suppliers, endotoxin 
contamination was negligible (<1.53 and <1.2 ng/mg, respectively). 
Recombinant human IL-6 (rhIL-6) was generously supplied by Dr. P. 
Stutz , Sandoz Research Inst i tute , Vienna, Austr ia . Endotoxin 
contamination was <0.4 U/mg in the Limulus assay. Recombinant 
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murine IL-6 (rmIL-6) was a kind gift from Dr. J.L. Renauld, Ludwig 
Institute for Cancer Research, Brussels, Belgium. Cytokines were stored 
undiluted at -70°C (rhIL-1 and rhIL-6) or 4°C (rmIL-6), and were diluted 
immediately before use in pyrogen-free isotonic phosphate-buffered saline 
(pH 7.4). Inactivated IL-1 was prepared by heating IL-1 at 95°C for 30 
min. To all these solutions, normal mouse serum was added to an end 
volume of 2% (vol/vol). D- Galactosamine (GALN) was purchased from 
Merck, Darmstadt , Germany) and dissolved in pyrogen-free saline 
shortly before injection. Endotoxin content was < 38 pg/g GALN. 
Gentamicin was purchased from Schering, Kenilworth, N.J . 
Cyclophosphamide (ASTA Pharma, Frankfurt, Germany) was dissolved 
in sterile pyrogen-free distilled water. Bacteria for infectious challenges 
{Klebsiella pneumoniae ATCC 43816 and Pseudomonas aeruginosa 
ATCC 27853) were cultured overnight, washed three times in saline, and 
appropriate dilutions were prepared. 
Experimental procedures 
All experiments started at 9.30 a.m. (time zero) 
(i) Liver enzymes, acute phase proteins, IL-6 and glucose levels after 
treatment with IL-1 and/or GALN. 
For assessment of liver injury by GALN, aspartate aminotransferase 
(ASAT) and alanine aminotransferase (ALAT) were determined in 
serum obtained from mice 24 h after intraperitoneal (i.p.) injection of 
different doses of GALN, 400 ng of IL-lß, or PBS. For determinations of 
acute phase proteins and IL-6 mice received two injections: GALN or 
vehicle (saline) was given i.p. at -30 min, IL-1 or control treatment (heat-
inactivated IL-1) was administered i.p. (0.1 ml) at time zero. At various 
time points blood was taken retro-orbitally from ether-anesthesized mice 
to prepare EDTA-plasma (fibrinogen measurements) or serum (serum 
amyloid A (SAA) and IL-6 measurements). IL-6 levels were also 
measured in serum obtained at different time points after a single i.p. 
treatment with 800 ng of rhIL-lß or 800 ng of rhIL-6. 
In the experiments in which glucose was measured, mice received a 
single i.p. injection of 800 ng of IL-1 or vehicle at time zero, an i.m. 
challenge with K. pneumoniae at 24 h and gentamicin (120 mg/kg 
subcutaneously (s.c.) 6 h later. Trunk blood of decapitated mice was 
collected at several time points in fluoride-coated tubes on melting ice. All 
plasma and serum samples were stored at -20°C until assay. 
When neutropenic mice were used, neutropenia (<0.5 χ 10^ granulocytes 
per liter) was induced by two s.c. injections of cyclophosphamide (150 and 
100 mg/kg, respectively) on day -3 and on day 0. 
(ii) Effects of cytokine and/or GALN pretreatment on survival. 
For survival experiments, some mice were rendered neutropenic as 
described above. IL-1 or control treatment (heat-inactivated IL-1) was 
administered i.p. (0.1 ml) at time zero. GALN (18 mg/mouse) or vehicle 
(saline) was given i.p. 30 minutes earlier. The infectious challenge was 
administered at 24 h. Neutropenic mice received P. aeruginosa 
intramuscularly (i.m.) (0.5 -1 χ 108 CFU per mouse). Because P. 
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aeruginosa does not kill non-neutropenic mice unless very high inocula 
are used, such mice received K. pneumoniae (1-5 χ 10° CFU per mouse). 
Six hours after the infectious challenge, 120 mg of gentamicin per kg of 
body weight was given s.c. in order to postpone the time of death and thus 
accentuate the differences between treatment groups. Mortality was 
recorded for a period of at least 48 h after challenge. 
In investigations on the protective effect of human and murine IL-6 on 
P. aeruginosa infection in neutropenic mice, the experimental protocol 
described above was used. The cytokines were given i.p. (0.1 ml) at time 
zero, and when both IL-1 and IL-6 were administered, a mixture of both 
cytokines was prepared immediately before injection. In all cases, heat-
inactivated IL-Iß was given as control treatment. 
Assays 
Serum ASAT and ALAT levels were assessed with routine procedures 
(BM/Hitachi 747, Boehringer Mannheim, Mannheim, Germany). 
Plasma glucose concentrations were determined with the hexokinase 
method (Cobas Bio, Hoffmann-Laroche B.V., Mijdrecht, The 
Netherlands). Serum IL-6 was quantitated as hybridoma growth factor 
(HGF) activity using the IL-6-dependent murine hybridoma 7TD1 (a kind 
gift from Dr. van Snick) as previously described (28). HGF activity 
resulting in half-maximal stimulation of the target cell growth was 
arbitrarily defined as 1 U. The reference standard in these experiments 
was rhIL-6 ( a kind gift from Immunex Corp., Seattle, WA; sp act, 10' 
U/ml). The detection limit of the assay was 50 U/ml. Serum amyloid A 
(SAA) was measured by a modification of the direct binding ELISA 
method for human plasma (27), using a mixture of rabbit polyclonal 
antisera to mouse SAA^ and SAA2 (kind gift from Dr. J. Sipe, Boston). 
Assays for fibrinogen in EDTA plasma were performed by measuring the 
rate of conversion of fibrinogen to fibrin in the presence of thrombin 
excess. Measurements of fibrin clot formation were performed on a 
coagulometer (KC-10, Salm & Kipp, Breukelen, The Netherlands). The 
results are expressed as milligrams of fibrinogen/L of plasma, the 
sensitivity of the assay is 1200 mg/L. Endotoxin levels were assessed 
using the limulus amebocyte lysate gelation test (LAL assay) which had a 
sensitivity of 6 pg/ml. 
Statistical analysis 
Survival curves were analyzed by the log rank test (24). Comparisons of 
medians of liver enzymes, acute phase proteins, IL-6 levels and glucose 
levels between treatment groups were made by the Kruskal Wallis test at 
each time point (13). Where 5 components were analyzed, the Bonferroni-
corrected α =0.05/5 = 0.01 was used. 
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RESULTS 
Hepatotoxicity of GALN 
Since galactosamine (GALN) is potentially hepatotoxic (5), we first 
assessed the effect in Swiss mice of different doses of this hexosamine on 
ASAT and ALAT in serum at 24 h after i.p. injection. At this time point, 
liver damage should have developed (5). After administration of 18 and 36 
mg of GALN/mouse (720 and 1440 mg/kg), doses which are commonly 
used by others (1,18,37), and which are reported to be effective in 
inhibition of protein synthesis (1,5), serum ASAT and ALAT levels in 
normal mice did not differ significantly from those in vehicle-treated 
mice; 90 and 180 mg GALN/mouse induced a significant increase of both 
enzymes as compared to vehicle-treated mice (Figure 1). In neutropenic 
mice, ASAT and ALAT levels after 18 mg GALN did not differ 
significantly from those in vehicle-treated mice; ASAT levels were 
elevated significantly from those in vehicle-treated mice after 180 mg of 
GALN (p<0.0005) and ALAT levels were significantly increased after 36 
and 180 mg GALN (p<0.01 and p<0.0001, respectively)(not shown). Also 
ASAT and ALAT in normal and neutropenic mice 24 h after treatment 
with two i.p. injections of 18 mg GALN or vehicle and 800 ng IL-1 or 
control t rea tment (the experimental setting to be used) were not 
significantly increased (not shown). In further experiments a dose of 
GALN of 18 mg/mouse was used. 
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Fig. 1. Median ASAT and ALAT concentrations in serum of normal mice 24 h after 
i.p. injection of PBS, 400 ng of IL-1 or different doses of GALN (6-8 mice/group). In 
comparison to PBS-treated mice, enzyme levels are significantly elevated after 90 mg 
GALN (ASAT: p=0.007, ALAT: p=0.0027) and after 180 mg GALN (p=0.009 for both 
ASAT and ALAT). 
ASAT ALAT 
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Inhibition ofIL-1-induced increase of acute phase protein production by 
pretreatment with GALN 
To verify the effect of GALN as an inhibitor of acute phase protein 
synthesis, serum concentrations of SAA and plasma concentrations of 
fibrinogen were chosen as markers of the acute phase response after IL-
1. 
Fig. 2. A. Median SAA serum levels in normal mice 8 h after i.p. injections with 
GALN (18 mg) or vehicle at t=-0.5 h, and IL-1 (800 ng) or control treatment at time zero 
(7 mice/group). B. Median fibrinogen plasma levels in normal mice 24 h after i.p. 
injections with GALN (18 mg) or vehicle at -0.5 h, and IL-1 (800 ng) or control 
treatment at time zero (6 mice/group).C. Median IL-6 serum levels in normal mice 2 h 
after i.p. injections with GALN (18 mg) or vehicle at -0.5 h, and IL-1 (800 ng) or control 
treatment at time zero (6 mice/group). 
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These acute phase proteins were measured in normal and neutropenic 
mice at the time point of their peak levels at 8 and 24 h, respectively, 
after IL-1 administration (3,9), with or without i.p. pretreatment with 
GALN 30 min before IL-1. As shown in Figure 2 for non-neutropenic 
mice, 800 ng of IL-1 i.p. induced SAA at 8 h and fibrinogen at 24 h. The 
induction by IL-1 of SAA in normal (Fig. 2A) and neutropenic mice 
(peak level 162 μg/L; 6 mice/group) is completely inhibited by GALN 
pretreatment (p<0.001), with no significant difference between SAA 
levels in mice treated with GALN + control treatment and with GALN + 
IL-1. Plasma fibrinogen in GALN-treated normal mice was lower than 
in vehicle-treated mice (p<0.01, Fig. 2B). The significant increase in 
plasma fibrinogen induced by 800 ng of IL-1 (p<0.005) was completely 
inhibited by 
pretreatment with GALN (p<0.01), and fibrinogen concentrations in mice 
treated with GALN plus IL-1 did not differ significantly from those in 
mice treated with GALN plus inactivated IL-1. 
In neutropenic mice, similar results were observed. Pretreatment of 
these mice with GALN before the IL-1 injection inhibited the plasma 
fibrinogen increase significantly in comparison to levels in mice that 
received vehicle before the IL-1 injection (median fibrinogen 3000 mg/L 
after IL-1 and 1425 mg/L after both GALN and IL-1, p<0.001). Median 
fibrinogen levels in mice after GALN plus IL-1 treatment did not differ 
significantly from those in mice treated with GALN plus inactivated IL-1 
treatment. Fibrinogen concentrations in GALN treated mice were 
somewhat lower than in vehicle-treated mice (1245 and 1725 mg/L, 
respectively) but the difference was not significant. 
Effects of pretreatment with IL-1 andJor GALN on survival 
Pretreatment of non-neutropenic mice with 800 ng of IL-1 24 h before an 
i.m. infection with K. pneumoniae significantly enhanced survival (χ 2 = 
25.93, p<0.0005)(Fig. ЗА). 
Administration of GALN 30 min before the IL-1 pretreatment partially 
inhibited the IL-1-induced protection, with significant differences of this 
group with both the IL-1-treated group and the group treated with GALN 
(χ2 = 5.69, p<0.01 and χ2 = 11.39, P<0.005, respectively). Survival of mice 
treated with GALN alone did not differ significantly from survival in 
mice treated with vehicle (χ 2 = 0.22). In neutropenic mice infected with 
P. aeruginosa, IL-1 pretreatment significantly enhanced survival ( χ 2 = 
13.10, p<0.0005)(Fig. 3B). GALN injection 30 min before the IL-1 injection 
completely inhibited the protective effect of IL-1 with no difference in 
survival between this group and mice treated with GALN followed by 
vehicle or with GALN followed by IL-1 (χ2 = 0.00). Mice treated with 
GALN survived somewhat better than mice treated with vehicle, but this 
difference was not significant. Normal and neutropenic mice treated 
with GALN without subsequent infection all survived. 
Role ofIL-6 in IL-1-induced protection to infection 
Serum IL-6 levels measured 2 h after administration of 800 ng of IL-1 
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were not reduced by pretreatment with GALN i.p. (18 mg/mouse) in 
normal (Fig. 2C) and neutropenic mice. On the contrary, IL-6 levels after 
GALN + IL-1 were enhanced in comparison to mice treated with IL-1, an 
enhancement which did not reach significance in normal (p=0.026) and 
neutropenic mice (p=0.34; median levels 58,300 and 47,350 U/ml, 
respectively; 7 mice/group). GALN administration alone does not elicit an 
100 
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Fig. 3. A. Survival of normal mice infected with K. pneumoniae at time zero, and 
pretreated with GALN (18 mg) or vehicle at -24 5 h, and IL-1 (800 ng) or control 
treatment at -24 h (85 mice/group). B. Survival of neutropenic mice infected with P. 
aeruginosa at time zero, and pretreated with GALN (18 mg) or vehicle at -24.5 h, and 
IL-1 (800 ng) or control treatment at -24 h (23-26 mice/group). Mice injected with GALN 
(18 mg) without subsequent infection all survived. 
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IL-6 response. In further investigation of a putative role of IL-6 as a 
mediator of the IL-1-induced protection to infection, serum IL-6 
concentrations were measured. IL-6 levels peaked at thirty min after an 
i.p. injection of 800 ng rhIL-6 (38900 U/ml) and at two hours after i.p. 
injection of 800 ng IL-1 (5020 U/ml) (6 mice/ datum point). However, no 
protective effect of pretreatment with 80, 400 or 800 ng of IL-6 was 
observed (Fig. 4A). To investigate whether some degree of species 
specificity of IL-6 (17,21) plays a role, we also assessed the effect of 
murine IL-6 (80, 400, 800 and 1600 ng) on survival of P. aeruginosa 
infection in neutropenic mice, but also this molecule did not influence 
survival (Fig. 4B). 
Since several studies report synergistic effects between IL-1 and IL-6 
(4,11), we assessed whether IL-6 would enhance IL-1-induced protection 
to a lethal P. aeruginosa infection. However, 80 or 800 ng of human or 
murine IL-6 did not affect protection induced by 80 or 800 ng of IL-1 
(shown for mIL-6, Fig. 4C). 
Deleterious effects of IL-6 in infections have also been suggested in 
several reports (31,36). We addressed this issue by administering higher 
doses of IL-6 prior to P. aeruginosa infection, but observed that survival 
of mice pretreated with doses of rhIL-6 of 1.6, 4 and 8 μg or with 1.6 μg 
rmIL-6 per mouse did not differ significantly from survival of control-
treated mice (Fig. 4D). Because of the complete absence of an effect of IL-
6, we did not perform similar studies in non-neutropenic mice. 
Effect of IL-1 treatment on plasma glucose before and after infection 
These experiments were limited to the Klebsiella infection, because 
fewer pretreatments, which could possibly influence glucose metabolism, 
are necessary in this model. The plasma glucose concentrations (median 
values) in mice after an i.p. injection of 800 ng of IL-1 at time -24 h and 
K. pneumoniae infection i.m. at time zero are depicted in Fig. 5. Plasma 
glucose showed a nadir at 4 h after i.p. injection in IL-1 treated mice but 
not in vehicle-treated mice (4.85 mmol/L and 8.5 mmol/L, respectively). 
The difference between IL-1 treated and vehicle-treated mice was 
significant at 4 and 12 h after IL-1, and also at 24 h after IL-1 injection, 
the time point of infectious challenge, the glucose level was significantly 
lower than in control mice. The glucose levels in IL-1 treated mice 
returned to control levels at 36 h after IL-1. 
Median plasma glucose levels after i.m. infection with K. pneumoniae 
did not differ significantly between the treatment groups, with the 
exception of 2 h, where values in the IL-1-treated group were still lower, 
and 48 h after infection, where values in the IL-1 treated group were 
higher. In late stages of the infection there is a tendency to higher 
glucose levels in mice pretreated with IL-1 as compared to control 
treatment. In this stage also signs of discomfort of the infected animals 
(piloerection, decreased physical activity) were less pronounced in the IL-
1 treated group. The IL-1 pretreated mice all survived for 48 h, whereas 
approximately 20% of the control-treated mice died during this period. 
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Fig. 4.A. Survival of neutropenic mice infected with P. aeruginosa at time zero, and 
pretreated at - 24 h with an i p. injection of 800 ng of IL-1, different doses of of human IL-
6 or control treatment. Each group consisted of at least 20 mice. Protection after IL-1 was 
significant (χ2 =11.27, p<0.001). Survival of the other t reatment groups did not differ 
significantly from the control group. B. Survival of neutropenic mice infected with Ρ 
aeruginosa at time zero, and pretreated at - 24 h with an i.p injection of 800 ng of IL-1, 
different doses of murine IL-6 or control treatment Each grcoip consisted of at least 20 
mice. Protection after IL-1 was significant (χ2 =9.97, p<0.005). Survival of the other 
t r e a t m e n t groups did not differ significantly from the control group C. Survival of 
neutropenic mice infected with Ρ aeruginosa at time zero, and pretreated at - 24 h with 
an i.p. injection of 80 ng of IL-1, mIL-6, combinations of mIL-6 and IL-1, or control 
t reatment. Each group consisted of at least 22 mice Survival in none of the t reatment 
groups differed significantly from survival in the control group D . Survival of 
neutropenic mice infected with P. aeruginosa at time zero, and pretreated at - 24 h with 
an i.p. injection of 800 ng of IL-1, different doses of human IL-6 or control treatment (20 
mice/group). Survival after IL-1 t r e a t m e n t was significantly enhanced (χ2 = 5 44, 
p<0 025). Survival of the other t r e a t m e n t groups did not differ significantly from 
survival in the control group 
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Fig. 5. Median values of glucose concentrations in mice a t different time points before 
and after K. pneumoniae infection at time zero and pretreatment with 800 ng of rhlL-
lß or vehicle a t t=-24 h (six mice per datum point). The difference between the two 
treatment groups was significant at 4, 12 and 24 h after IL-1 injection (p= 0.014, 0.005 
and 0 03 respectively), and at 2 and 48 h after K. pneumoniae injection (p= 0.03 and 
0 026, respectively). 
DISCUSSION 
We have previously reported that a single low dose of IL-1 administered 
24 h, but not 6 or 0.5 h, before a lethal gram-negative bacterial infection 
enhanced survival (30; Vogels, unpublished results). In the present 
study, we demonstrated that this enhanced survival is associated with an 
increased production of acute phase proteins. Acute phase proteins, 
synthesized by the liver during a variety of acute inflammatory processes 
(15) may operate as oxygen radical scavengers, protease inhibitors, 
coagulation factors and opsonins, and may therefore play a role in non-
specific defence of the host to infections. Most acute phase proteins are 
induced by IL-1 within a time course similar to that required for 
induction of protection in lethal infection. To investigate the role of acute 
phase proteins in the IL-1-induced enhanced resistance, we used 
galactosamine, a hepatocyte-specific inhibitor of RNA and protein 
synthesis (5). In normal and neutropenic mice, the IL-1-induced 
synthesis of acute phase proteins was completely blocked by GALN-
pretreatment. The protective effect of IL-1-pretreatment in infection was 
inhibited partially (non-neutropenic mice infected with K. pneumoniae) 
•°"" control 
• · — IL-1 
j L 
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or completely (neutropenic mice infected with P. aeruginosa) by a 
GALN dose that did not damage liver parenchymal cells. GALN did not 
inhibit production of IL-1-induced IL-6, confirming the expected 
specificity of GALN effects on hepatocytes (which do not produce IL-6), 
not affecting protein synthesis in IL-6-producing cells. IL-6 
concentrations in mice treated with GALN and IL-1 were even somewhat 
enhanced in comparison to mice treated with only IL-1 (factor 2.7 in 
normal mice, factor 1.2 in neutropenic mice). GALN per se did not 
increase IL-6 levels, arguing against an efffect of traces of contaminating 
endotoxin (less than 0.7 pg/mouse). GALN itself may have a slight 
priming effect on macrophage cytokine production, as observed by some 
investigators in vitro (16) and in vivo (19) after an endotoxin trigger. 
Others did not find such an effect (1). We do not believe that a GALN-
induced sensitizing effect of macrophages for IL-1, resulting in 
increased macrophage cytokine production, was responsible for the 
decrease of IL-1-induced protection to infection, since the IL-6 increase 
was relatively small, and even high doses of IL-6 with or without GALN 
were not toxic in mice (19). In addition, the sensitizing effect of GALN on 
endotoxin and TNF toxicity was shown to be mediated by inhibition of 
hepatic metabolism and not by activation of macrophages, since this 
sensitization can be completely reversed by restoring hepatic RNA and 
protein synthesis with uridine suppletion (1,8,18). 
The lack of effect on survival of infection by GALN pretreatment per se 
also argues against a detrimental effect of GALN via mechanisms 
independent of IL-1-induced protection, e.g., by an aspecific toxic effect of 
GALN or by GALN-induced sensitization for bacterial products or 
cytokines like TNF (8,37), and against a deleterious effect of the reduced 
serum fibrinogen levels observed in GALN-treated mice. Taken together, 
these results suggest a critical role of liver-induced proteins, most 
conceivably acute phase proteins, in the IL-1 induced nonspecific 
resistance to infection. 
A role of acute phase proteins in IL-1 induced enhanced survival of 
several challenges has also been suggested by other investigators. 
GALN abolished IL-1-induced protection to a subsequent lethal dose of 
IL-1 or TNF (37), and GALN inhibited enhanced survival of a lethal dose 
of LPS or TNF after a turpentine-induced acute phase response in mice 
(1). Libert and coworkers showed an inhibition by GALN of the protective 
effect IL-1 pretreatment to a lethal challenge of TNFa and GALN, an 
inhibition which could be restored by addition of uridine. These authors 
too suggested a role of acute phase proteins in the IL-1 induced protection 
(18). 
IL-1 induces IL-6, and several effects of IL-1 have been reported to be 
mediated by IL-6 (11,32). Apart from induction of acute phase proteins, 
IL-6 has other potentially beneficial effects (6,14,26,32). Nevertheless, our 
observations plead against a role of IL-6 in the IL-1 induced enhanced 
resistance to infection. Firstly, although GALN inhibits the IL-1 induced 
protection, it does not inhibit IL-1-induced IL-6 production. Secondly, 
doses of 80-800 ng of human IL-6 did not enhance survival of a lethal P. 
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aeruginosa challenge, in spite of the larger IL-6 peak in mice after rhlL-
6 than after IL-1. Higher doses (1.6 - 8 μg) neither protected nor showed 
deleterious effects, in accordance with earlier reports by us and others 
(4,32). Since there is some species specificity for IL-6 (17,21) we tested the 
protective effect of pretreatment with different doses of murine IL-6, but 
no effect on survival was observed. Some studies describe synergy 
between IL-1 and IL-6 effects (4,11), and IL-1 and IL-6 are likely to be 
present simultaneously after IL-1 injection. However, we found that 
coadministration of different doses of human or murine IL-6 did not 
enhance the IL-1 induced enhanced survival of infection. 
Other investigators reported protection by IL-6 pretreatment against a 
lethal combination of LPS and GALN provided that the induced TNF was 
partially neutralized (2). Using very high doses mIL-6 (20-50 μg) another 
group found enhanced bacterial clearance of Listeria monocytogenes 
(20). However, in accordance with our results, pretreatment with 0.2-5 
μg mIL-6 did not protect against a lethal combination of rmTNF and 
GALN, whereas IL-1 did, according to the authors by induction of acute 
phase proteins (18). In addition, our results of high IL-6 levels associated 
with lack of protection to infection in mice pretreated with GALN and IL-
1 are similar to the high serum IL-6 levels reported by Havell et al. in 
anti-TNFa treated mice that succumbed to experimental listeriosis (10). 
The fact that IL-6 as an inducer of acute phase proteins is not capable of 
enhancing nonspecific resistance, whereas acute phase proteins 
themselves seem to do so, is not necessarily contradictory. IL-6 and IL-1 
are known to induce a different spectrum of acute phase proteins (25), 
and it is conceivable that the IL-1-induced spectrum is protective and the 
IL-6-induced spectrum is not. Furthermore, IL-1 is a more potent 
inducer than IL-6 for several proteins that can be induced by both 
(21,23,25). 
We also investigated the role of IL-1 induced changes in blood glucose. 
IL-1 affects glucose homeostasis in different ways (7,29). Whereas 
insulin-inducing and insulin-like effects would lead to hypoglycemia, the 
toxic effects of higher doses of IL-1 on pancreatic ß cells and the induction 
by IL-1 of glucagon and stress hormones would elevate plasma glucose 
levels. These effects may result in a reduction of hypoglycemia during the 
terminal phase of sepsis. Although the fall in blood glucose induced by 
IL-1 was not completely restored at the time of infection in our mice, the 
plasma glucose levels measured in infected mice after IL-1 treatment did 
not differ significantly from those in controls at most time points. 
Moreover, in both treatment groups glucose levels never fell to 
hypoglycemic values. Therefore, we feel that effects on blood glucose does 
not seem to play a major role. 
In conclusion, the data presented here suggest that the increase in 
resistance induced by IL-1 is at least partially mediated by GALN-
inhibitible liver proteins, most likely acute phase proteins. IL-6 does not 
seem to be an intermediate for this IL-1 effect. Finally, the improved 
outcome of infection in IL-1-treated mice is not associated with 
physiologically significant changes in blood glucose levels during 
75 
CHAPTER 5 
infection. 
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TNF. GM-CSF AND EICOSANOIDS 
ABSTRACT 
Treatment with a single low dose (80-800 ng) of interleukin-1 (IL-1), 24 h 
before a lethal bacterial challenge in granulocytopenic and in normal 
mice enhances nonspecific resistance. The mechanism behind this 
protection has only partially been elucidated. Since IL-1 induces 
production of tumor necrosis factor α (TNFa), granulocyte-macrophage 
colony- stimulating factor (GM-CSF), platelet-activating factor (PAF) 
and arachidonic acid metabolites, we investigated the potential role of 
these substances in the IL-1-induced protection. Low doses of murine 
T N F a but not of human TNFa enhanced survival, suggesting an effect 
via the type II TNF receptor rather than the type I TNF receptor. 
Pretreatment with a high dose of a rat anti-murine TNFa monoclonal 
antibody showed a dose-related protective effect, which could be further 
enhanced by IL-1. Combination of optimal doses of anti-TNFa and IL-1 
produced no further increase in survival as compared to separate 
pretreatment, suggesting similar pathways of protection. Pretreatment 
with a low, unprotective dose of the anti-TNFa antibody partially 
inhibited the IL-1-induced protection. 
P r e t r e a t m e n t with different doses of GM-CSF before a lethal 
Pseudomonas aeruginosa challenge in neutropenic mice did not 
enhance survival. Different doses of WEB 2170, a selective PAF receptor 
antagonist, MK-886, a selective inhibitor of leukotriene biosynthesis, or 
several cyclooxygenase inhibitors did not reduce the protective effect of 
IL-1 pretreatment. We conclude that the IL-1-induced nonspecific 
resistance is partially mediated by induction of TNFa, and not by GM-
CSF, PAF and arachidonic acid metabolites. The mechanism of action of 
IL-1 seems to be similar to that of anti-TNFa. 
INTRODUCTION 
Interleukin-1 (IL-1), two 17-kDa proteins (IL-la and IL-lß) produced by 
many different types of cells, possesses a wide spectrum of biological 
properties (6). In animals administration of IL-1 has been shown to 
enhance nonspecific resistance to Gram-positive and Gram-negative 
bacteria, fungi and plasmodia (36). For instance, treatment of both 
neutropenic and normal mice with a single low dose (3-30 μg/kg) of 
recombinant human IL-lß (rhIL-lß) 24 h before a lethal infection with 
Gram-negative bacteria enhances survival (34, 35). The exact 
mechanism of this protective effect is still unclear. A direct 
antimicrobial effect of IL-1 has been excluded in vitro (34). Whether IL-1 
enhances the clearance of microorganisms in vivo is controversial (18, 
21, 34, 35). The protective effect of IL-1 to infectious challenges in 
granulocytopenic mice indicates that neutrophils do not play a major 
role (18, 34, 36). Also glucocorticosteroids or cytokines like interleukin-6 
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and interleukin-8 do not mediate the IL-1-induced enhanced resistance 
(34-39). Recently, we could show that the protective effect of IL-1 in 
normal as well as in neutropenic mice is mediated to some extent by 
hepatic acute phase proteins (39). 
In the present study, the mechanisms of the IL-1-induced non-specific 
resistance have been further investigated, with special attention to other 
inflammatory mediators induced by IL-1. 
IL-1 generates production of tumor necrosis factor α (TNFa) and 
granulocyte-macrophage stimulating factor (GM-CSF) in vitro as well 
as in vivo (25, 28). TNFa possesses several potentially protective effects 
in the host resistance to pathogens, many of which are shared with IL-1 
(4, 32, 36). GM-CSF has, in addition to its effects on hematopoiesis, 
potent stimulating effects on macrophage and neutrophil functions, and 
it induces several inflammatory mediators (41). An in-vivo role in 
antimicrobial host resistance has been shown for both TNFa and GM-
CSF (30, 31, 36). 
In addition to these cytokines, IL-1 administration induces production of 
eicosanoids like platelet-activating factor (PAF) (2) and arachidonic acid 
(8), the latter resulting in production of a variety of lipoxygenase and 
cyclooxygenase metabolites. Several effects of these mediators might be 
beneficial to the host in the enhancement of non-specific resistance to 
infection (2, 8, 13, 36). 
In this paper we have investigated the role of TNFa, GM-CSF, PAF, 
lipoxygenase and cyclooxygenase products in IL-1-induced enhanced 
resistance of neutropenic mice to lethal Gram-negative infection. 
MATERIALS AND METHODS 
Mice 
Female outbred Swiss mice (20-25 g; TNO, Rijswijk, The Netherlands) 
were kept under specific-pathogen-free conditions in an artificially 
lighted room with a light-dark cycle of 12 h (lights on at 7 a.m., lights off 
at 7 p.m.). Standard irradiated lab chow (RMH-TM; Hope Farms, 
Woerden, The Netherlands) and acidified water were available ad 
libitum. 
Materials 
Recombinant human IL-lß (rhIL-lß) was kindly provided by Dr. P. 
Graber (Glaxo, Geneva, Switzerland) and Dr. P. Ghiara (Sciavo, Siena, 
Italy). According to the specifications of the suppliers, endotoxin 
contamination in the limulus amoebocyte lysate (LAL) assay was 
negligible (<1.53 and <1.2 ng/mg, respectively). Human and murine 
r T N F a were generously donated by Dr. G. Adolf, Ernst-Boehringer 
Insti tut , Vienna, Austria. Specific activities were 6x107 U/mg and 
1.2x107 U/mg in murine LM cells, and endotoxin contents were < 100 
pg/mg and < 51 pg/mg, respectively. Murine rGM-CSF (a kind gift of Dr. 
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I. Lindley, Sandoz, Vienna, Austria) had a specific activity of 6x107 U/mg 
in the murine bone marrow cell proliferation assay, and endotoxin 
content was 23 pg/mg. Cytokines were stored undiluted at -70 °C, and 
were diluted immediately before use in pyrogen-free isotonic phosphate-
buffered saline (pH 7.4). Inactivated IL-1 was prepared by heating IL-1 at 
95 °C for 30 min. To all these solutions, normal mouse serum was added 
to an end volume of 2% (vol/vol). WEB 2170, a specific competitive PAF 
receptor antagonist (14), was donated by Dr. F. Pistel, Boehringer 
Ingelheim, Ingelheim, FRG. MK-886, a 5-lipoxygenase translocation 
inhibitor (12), was provided by Dr. J.W. Gillard, Merck Frosst Canada 
Ine, Quebec, Canada. WEB 2170 and MK-886 were dissolved in 0.5% 
Tylose solution, freshly prepared by dissolving carboxymethylcellulose 
(Tylose, Hoechst, Frankfurt, FRG) in pyrogen-free distilled water. 
Indomethacin (Holland Pharmaceutical Supply, Alphen aan de Rijn, 
The Netherlands), Acetylsalicylic acid (Genpharma, Maarssen, The 
Netherlands) and Ibuprofen (Boots pharmaceuticals, Nottingham, U.K.) 
were dissolved in pyrogen-free saline. Gentamicin was purchased from 
Schering, Kenilworth, N.J. Cyclophosphamide (ASTA P h a r m a , 
Frankfurt, Germany) was dissolved in sterile pyrogen-free distilled 
water. Rat IgG, containing 35 pg/mg endotoxin, and lipopolysacharide 
(LPS, from Escherichia coli serotype 055:B5) were from Sigma Chemical 
Co, St. Louis, MO, USA. 
The hybridoma producing the neutralizing rat anti-murine TNFa mAb 
(Vlq) (7) was kindly provided by Dr. P. Krammer, German Cancer 
Research Center, Heidelberg, FRG. The rat mAb (IgG2a, к) was purified 
from ascites by 45% ammonium sulphate precipitation followed by 
dialysis against pyrogen-free destilled water, protein G chromatography 
and another dialysis step. LPS content (LAL assay) was less than 8.2 
pg/mg protein. In the L929 bioassay (1), the rmTNFcc neutralizing activity 
was 175 U/ μg. Bacteria for infectious challenges (Pseudomonas 
aeruginosa, ATCC 27853) were cultured overnight, washed three times 
in saline, and appropriate dilutions were prepared. 
L929 TNF Bioassay 
The assay was performed as previously described (1). Briefly, 100,000 L929 
cells were added to serial twofold dilutions of rmTNF. The test was 
performed in the presence of 4 μg/ml emetine (Sigma GmbH, München, 
FRG). After 20 h at 37 °C and 5% C02 in air at 90% relative humidity, 
TNF-mediated cytopathic effects on L929 cells were evaluated with crystal 
violet at 540 nm (Sigma Chemical Co, St. Louis, MO, USA). The detection 
limit of the assay was 80 pg/ml. 
Experimental protocols 
For survival experiments, mice were rendered neutropenic (<0.5 χ IO" 
granulocytes per liter) by two s.c. injections of cyclophosphamide (150 and 
100 mg/kg, respectively) on day -4 and on day -1. IL-1, rmGM-CSF, 
rhTNFct, rmTNFa or control treatment (heat-inactivated IL-1) were 
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administered i.p. (0.1 ml) 24 h before a lethal i.m. challenge with P. 
aeruginosa a t time zero. Six hours after the bacterial challenge, 120 mg 
of gentamicin per kg of body weight was given s.c. in order to postpone the 
time of death and thus accentuate the differences between treatment 
groups. Mortality was recorded for a period of at least 48 h after 
challenge. For investigations of the respective roles of TNFa, PAF and 
arachidonic acid metabolites in the IL-1 induced enhanced survival, Vlq, 
a neutralizing anti murine TNFa mAb, was given i.v. 3 h before the i.p. 
IL-1 injection, and WEB 2170 and MK-886 were administered orally by 
gavage 1 h before the IL-1 injection. The cyclooxygenase inhibitors 
ibuprofen, acetylsalicylic acid and indomethacin were administered 
orally (gavage) or intraperitoneally 45 min before the IL-1 injection. 
In experiments for confirming the in vivo activity of the anti-TNFa 
monoclonal antibody, serum TNF bioactivity at 2 h after i.p. LPS was 
measured in mice pretreated i.v. with anti-TNFa or saline 3 h before the 
LPS challenge. In addition, survival was compared in groups of mice 
pretreated i.v. with anti-TNFa or the same amount of rat IgG 3 h before a 
lethal i.p. LPS challenge. 
Statistical analysis 
Survival data were analyzed with the log rank test (27). Ρ values of less 
than 0.05 were considered significant. 
RESULTS 
Effect of TNF a compared to LL-1-induced protection to infection 
We first investigated the role of TNFa in the IL-1-induced protection to 
infection. Different doses of h T N F a , m T N F a or hIL-lß were 
administered intraperitoneally to neutropenic mice 24 h before a lethal 
i.m. P. aeruginosa challenge. As shown in Fig. 1A and IB, both 80 and 
800 ng of rhIL-ip produced significant protection in comparison to control 
mice. Survival was not significantly enhanced by 80 or 800 ng rhTNFa 
and 80 ng rmTNFa. However, 800 ng rmTNFa enhanced survival 
significantly; this protection was not significantly different from 
protection induced by 80 ng rhIL-lß (Fig. IB). 
Effects of anti-TNFa immunoglobulin G 
To investigate the role of TNFa in the IL-1-induced protection to infection 
further, we assessed the effect of Vlq , a neutralizing rat-anti murine 
TNFa monoclonal antibody. In experiments by Echtenacher et al. (7) and 
in our own experiments, intravenous pretreatment with 5 χ 10 4 
neutralizing units of anti-TNFa completely neutralized LPS-induced 
serum TNFa bioactivity. In addition, the same dose of anti-TNFa i.v. 
protected significantly against a lethal i.p. LPS challenge (2.5 mg/mouse) 
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administered 3 h later (anti-TNFa pretreated mice vs IgG pretreated 
mice: χ2 = 5.44, p< 0.025; 10 mice/group; not shown). 
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Figure 1. A. Survival of neutropenic mice pretreated i.p. with different doses of rhIL-lß 
or rhTNFct 24 h before a lethal ι m. P. aeruginosa infection a t time zero. Significant 
protection occurs in the groups pretreated with 80 or 800 ng IL-lß (χ^= 7.74 and 10.01, ρ < 
0.01 and p< 0.05, respectively; 29-31 mice/group) B . Survival of neutropenic mice 
pretreated i.p. with different doses of r m T N F a 24 h before a lethal i.m. P. aeruginosa 
infection. Significant protection occurs in the groups pretreated with 80 or 800 ng IL-lß 
( χ 2 as in panel B) and with 800 ng of rmTNFa ( χ 2 = 4.81, ρ < 0 05). С. Survival of 
neutropenic mice pretreated ι p. with different doses of rmGM-CSF or 800 ng of rhIL-lß 
24 h before a lethal i.m. Ρ aeruginosa infection. The difference in survival between 
the IL-1 treated and the control treated group is significant (χ = 6.29, ρ < 0.025). 
Differences between groups pretreated with rmGM-CSF or control t reatment are not 
significant (28 mice/group). 
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Administration of anti-TNFa (15, 60 or 400 μg/mouse i.v.) 27 h before а 
lethal P. aeruginosa challenge enhanced survival in a dose-dependent 
fashion (in comparison with the same amount of IgG: χ 2 =2.0 (η.s.), χ 2 
=4.95, ρ<0.05 and χ 2 = 7.97, ρ< 0.005, respectively; at least 11 mice/group; 
not shown). Survival after administration of 400 μg of anti-TNFa at t=-27 
h before the infectious challenge did not differ significantly from the 
same dose of anti-TNFa given at t=-3 h ( χ 2 = 1.46), and anti-TNFa 
administered at t = -27 h protected to almost the same extent as the same 
dose administered at - 3 h (both compared to the same dose of IgG 
simultaneously: χ 2 = 2.85, p=0.08 and χ 2 = 4.33, p<0.05, respectively; 30-31 
mice/group; not shown). Combined treatment of the lower doses of anti-
T N F a at t=-27 h with a suboptimal dose (400 ng) of IL-1 at t=-24 h 
enhanced survival as compared to anti-TNFa or IL-1 separately (Fig. 
2A, shown for 15 μg/mouse). Anti-TNFa (400 μg) administered i.v. at 27 
h before infection induced similar protection as 800 ng of IL-1 
administered i.p. at t=-24 h, and combination of the two treatments could 
not further enhance survival (Fig. 2B). 
Pretreatment at - 27 h with a low, non-protective dose of anti-TNFa ( 5 μg 
i.v.) reduced the protective effect induced by 800 ng IL-1 i.p. at -24 h (Fig. 
2C). 
Effect ofGM-CSF compared to ÏL-1-induced protection to infection 
Next, we investigated whether GM-CSF might be a mediator of the IL-1-
induced protection to infection. A dose range of GM-CSF expected to be 
physiologically relevant was investigated; GM-CSF was administered i.p. 
to neutropenic mice 24 h before a lethal i.m. challenge with P. 
aeruginosa. Survival was not affected by 0.5, 1, 2, 5 or 10 μg of GM-CSF 
in comparison to survival in control mice (Fig. 1С). 
Effect of pretreatment with inhibitors of PAF, lipooxygenase and 
cyclooxygenase on IL-l-induced enhanced survival of infection 
To assess the role of PAF in the IL-1 induced protection, we administered 
WEB 2170, a PAF receptor antagonist in different oral doses (10, 30 and 
150 mg/kg), 1 h before 800 ng of IL-1. Such dosage schedules, reported to 
be effective in inhibition of PAF effects (14, 15), did not significantly 
influence the IL-1 induced protection in comparison to pretreatment with 
vehicle (shown for 30 mg/kg, Fig. ЗА). The same doses of WEB 2170 per 
se did not affect survival in comparison to vehicle treatment (not shown). 
Next, we investigated the role of leukotrienes in the IL-1 induced 
protection to infection by administration of MK-886, an inhibitor of 
lipoxygenase translocation. MK-886 (10, 30 or 150 mg/kg)was 
administered orally 1 h before i.p. injection of 800 ng IL-1. Such dosage 
schedules (reported to be effective in inhibition of leukotriene effects (44)) 
did not reduce survival of P. aeruginosa infection in comparison to mice 
pretreated with vehicle. Survival of mice treated with different doses of 
86 
TNF. GM-CSFANDEICOSANOIDS 
о ' • ' ' • ' • "-
О 12 IA Ъ I» 
t i m i I h ! 
Figure 2. 
A. Survival of neutropenic mice pretreated i.v. with 15 μβ of anti-TNFot or the same 
amount of control IgG at t=-27 h and/or treated i.p. with 400 ng of rhIL-lß or control 
t rea tment a t t=-24 h before a lethal i.m. P. aeruginosa infection a t time zero. 
Significant differences in survival are present between mice treated with IgG plus 
control t reatment versus mice treated with IgG plus IL-1 (χ2 = 5.68, p<0.025) and versus 
mice treated with anti-TNFa plus IL-1 (χ2 = 8.79, p<0.005; 10 mice/group). B. Survival 
of neutropenic mice pretreated i.v. with 400 \ig of anti-TNFa or the same amount of 
control IgG at t=-27 h and/or treated i.p. with 800 ng of rhIL-lß or control t reatment at 
t=-24 h before a lethal i.m. P. aeruginosa infection. Significant differences in 
survival are present between mice treated with IgG plus control t reatment versus mice 
treated with IgG plus IL-1 (χ2 = 12.09, p<0.01), versus mice treated with anti-TNFa 
( χ 2 = 4 . 8 5 , p<0.05), and versus mice treated with ant i-TNFa plus IL-1 (χ2 = 8.72, 
p<0.005) (29-31 mice/gTOup). C. Survival of neutropenic mice pretreated i.v. with 5 μg 
of anti-TNFa or the same amount of control IgG at t=-27 h and/or treated i.p. with 800 
ng of rh IL- lß or control t rea tment a t t=-24 h before a lethal i.m. P. aeruginosa 
infection. Survival between mice treated with IgG plus control treatment does not differ 
significantly from tha t in mice treated with ant i-TNFa plus control t reatment . The 
difference in survival between mice treated with IgG plus control t rea tment versus 
mice treated with IgG plus IL-1 is significant (χ2 = 12.09, p<0.001), whereas no 
significant difference in survival is present between mice treated with ant i-TNFa 
plus control t r e a t m e n t versus mice t r e a t e d with a n t i - T N F a plus IL-1 (18-20 
mice/group) 
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MK-886 did not differ significantly from that in mice treated with vehicle 
(shown for 30 mg/kg, Fig. 3B). 
Pre t reatment with indomethacin, Ibuprofen or acetylsalicylic acid 
administered orally or intraperitoneally in doses reported to completely 
inhibit cyclooxygenase effects (5, 45 and 220 mg/kg, respectively) (42) did 
not affect the IL-1 induced enhanced survival of infection. Survival after 
administration of these cyclooxygenase inhibitors per se did not differ 
from survival after pretreatment with vehicle (20 mice/group; not 
shown). 
Ü 12 ¿A X> W 
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Figure 3. 
A. Survival of neutropenic mice treated orally with 30 mg/kg WEB 2170 or vehicle at 
t=-25 h, and injected i.p. with 800 ng of rhIL-lß or control treatment at t=-24 h before a 
lethal i.m. P. aeruginosa infection a t time zero. Survival in IL-1 treated mice 
pretreated with WEB 2170 or vehicle is significantly enhanced in comparison to 
survival in mice that received vehicle at both occasions (χ -7.43 and 14 88, p<0.01 and 
p<0.0005 respecively). Survival in IL-1 treated mice after pretreatment with WEB 2170 
does not differ significantly from that in vehicle-pretreated mice (χ -1.44, p>0.2) 
B. Survival of neutropenic mice treated orally with 30 mg/kg MK-886 or vehicle at t=-25 
h, and i.p. with 800 ng of rhIL-lß or control treatment at t=-24 h before a lethal ι m. Ρ 
aeruginosa infection Survival in IL-1 treated mice pretreated with MK-886 or vehicle 
is significantly enhanced in comparison to survival in mice that received vehicle a t 
both occasions (χ 2 =7.72 and 13.27, p<0 01 and p<0 0005, respectively) Survival in IL-1 
treated mice after pretreatment with MK-886 does not differ significantly from that in 
vehicle-pretreated mice (χ -1.44, p>0.2, 23 mice/group) 
88 
TNF. GM-CSF AND EICOSANOIDS 
DISCUSSION 
In the present study, we investigated the potential role of TNFa, GM-CSF, 
platelet activating factor and arachidonic acid metabolites in IL-1-
induced enhanced resistance to infection. These mediators are induced 
by IL-1 (2, 3, 8, 25, 28), and potentially increase the host resistance to 
infection. In the experiments presented here we found that only murine 
T N F a protected and that GM-GSF, inhibitors of PAF, inhibitors of 
lipooxygenase and of cyclooxygenase did not influence survival. 
Although TNF pretreatment has been shown to enhance resistance to 
bacterial, fungal,viral and protozoal infections (7, 24, 30), administration 
of human TNFa in our infection model in doses expected to be effective in 
vivo (24) did not mimiek the protective effect of IL-1. Since many effects of 
TNFa have been shown to be species specific (20), we assessed the effect of 
murine rTNFa. Pretreatment with 800 ng of murine TNFa was found to 
protect to about the same degree as 80 ng of rhIL-1. The difference in 
protection between human and murine TNFa in mice could indicate that 
the protective effects are predominantly mediated via the murine type II 
TNF receptor, since this receptor has a much stronger specificity for 
murine TNFa than the type I TNF receptor (20). 
Not only murine TNFa pretreatment, but also pretreatment with a high 
dose of anti-TNFa immunoglobulin was shown to induce a dose-related 
protection to a lethal P. aeruginosa infection. This protection could be 
enhanced by coadministration of a suboptimal dose of IL-1. A higher dose 
of anti-TNFa (400 μg) induced a similar protection as 800 ng of IL-1, and 
combined treatment did not further increase survival. This suggests, that 
IL-1 and anti-TNFa exert their protective effect through a similar 
pathway, and that this pathway is already maximally affected by 400 μg of 
anti-TNFa or 800 ng of IL-1. Since protection induced by this high dose of 
anti-TNFa was similar when it was administered at 27 or 3 hrs before 
infection, it is likely that the mode of action is interference with TNFa 
during the lethal cytokinemic phase of the infection (33). In fact, in 
neutropenic rats a protective effect of an anti-TNFA monoclonal antibody 
has been shown to infection with P. aeruginosa (26). The low amount of 
endotoxin contamination of our anti-TNFa preparation could not explain 
its protective effect, but the serum half-life of the antibody of about 24 h (7) 
is sufficient to obtain such an effect in the experimental model used. The 
way IL-1 treatment could interfere with the lethal cytokinemic phase of 
infection is by decreased cytokine production, or by downregulation of 
cytokine receptors resulting in reduced effects of the cytokine overshoot 
(40, 43). Studies on such IL-1 effects are currently in progress. The 
paradox that mouse TNFa as well as anti-TNFa given at - 24 h protect 
should probably be explained in a similar fashion. TNF pretreatment 
may enhance host defence mechanisms like phagocyte activation and 
induction of acute phase proteins (30, 32). It may also, like anti-TNFa and 
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IL-1, protect the host by interference with the lethal cytokinemia during 
infection, either by desensitization of target cells to the toxic effects of 
cytokines, by inducing refractoriness of cytokine-producing cells 
resulting in reduced production after infection, or by induction of TNF 
binding proteins (9, 16, 19, 40). Administration of a low dose of anti-TNFa, 
which by itself did not enhance survival, diminished the IL-1 induced 
protection. This result, combined with the observation of a moderate 
protective effect of p r e t r e a t m e n t with m r T N F a , suggests t h a t 
endogenously produced TNFa contributes to the protective effect of IL-1. 
GM-CSF would be a good candidate as a mediator of the IL-1-induced 
protection (5). Reports on enhancement of antimicrobial resistance by 
GM-CSF in vitro are numerous (11). In vivo protective effects of 
p r e t r e a t m e n t with low doses of GM-CSF have been shown in 
experimental models of bacterial as well as viral infections (10, 17), but 
this is not a universal finding (22). In addition to stimulation of 
hematopoiesis, GM-CSF is able to activate mature phagocytes and it 
induces several secondary mediators (11, 23, 29, 31). IL-1 might protect, 
via GM-CSF or directly, by activating macrophages, since 24 h after a 
single dose of GM-CSF (1 μg) macrophages are still activated (23). 
However, no protective effect of GM-CSF was observed, arguing against a 
role of GM-CSF as a mediator of the IL-1-induced enhanced resistance. 
A role of PAF and leukotrienes in this infection model was assessed by 
administration of WEB 2170, a competitive PAF receptor antagonist (14), 
and MK-886, a leukotriene synthesis inhibitor (12), prior to a protective 
injection of IL-1. These substances did not abolish the protective effect of 
IL-1. These results argue against a major role of PAF and leukotrienes in 
the IL-1-induced enhanced resistance. 
In extension of previous experiments (35), inhibition of induction of 
prostaglandins and tromboxanes by IL-1 by pretreatment with several 
cyclooxygenase inhibitors did not affect the IL-1-induced resistance to 
infection, providing additional evidence against a role of cyclooxygenase 
products. 
We conclude that the protective effect of pretreatment of neutropenic mice 
with a low dose of IL-1 in a lethal P. aeruginosa infection are not 
mediated by induction of GM-CSF, PAF, leukotrienes or cyclooxygenase 
products, but that TNFa seems to contribute to the IL-1-induced 
protection. 
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MODULATION OF CYTOKINE OVERSHOOT AND ITS EFFECTS 
ABSTRACT 
Pretreatment with a low dose of interleukin-1 (IL-1) 24 h before lethal 
bacterial infection prolongs survival in normal and in neutropenic mice. 
We investigated whether this protection occurs by interference with the 
deleterious effects of cytokines. The effect of IL-1 pretreatment on 
concentrations of cytokines (IL-la, IL-Iß, IL-6, TNFa) circulating in 
vivo and capacity of macrophages to produce these cytokines ex vivo 
was assessed in uninfected, non-neutropenic and neutropenic Swiss 
mice, in Swiss mice infected with Klebsiella pneumoniae (non-
neutropenic mice) or Pseudomonas aeruginosa (neutropenic mice) and 
in neutropenic СЗН/HeN and СЗН/HeJ mice infected with P. 
aeruginosa. In Swiss and СЗН/HeN mice, IL-1 pretreatment enhanced 
survival and reduced circulating tumor necrosis factor α (TNFa) and IL-
6 concentrations as well as LPS-stimulated production of IL-la and 
T N F a ex vivo. In СЗН/HeJ mice, a lack of an IL-1-induced protective 
effect on survival in lethal infection was associated with low cytokine 
concentrations in vivo and production ex vivo. These results suggest 
that a reduction of cytokine production by IL-1 pretreatment plays a role 
in the enhanced resistance to infection. In contrast with the decrease of 
cytokine production, upregulation of mRNA for the IL-1 receptor 
antagonist (IL-IRa) was observed in several organs of IL-1 pretreated 
mice, suggesting an attenuating role for IL-IRa of IL-1 effects during the 
lethal cytokinemia. In addition, we found that IL-1 pretreatment 
downregulated steady state mRNA for the type I IL-1 receptor (IL-1RI) 
and the type I TNF receptor (TNFRI) in several organs at time of 
infection, suggesting desensitization of target cells to be an additional 
mechanism of IL-1 induced protection. We conclude that the IL-1 
induced nonspecific resistance is at least partially mediated by 
downregulation of cytokine production, and that the induction of IL-IRa 
and desensitization of target cells by receptor down-modulation may also 
contribute to this phenomenon. 
INTRODUCTION 
Interleukin-1 (IL-1), two 17-kDa proteins (IL-la and IL-lß) produced by a 
variety of cell types, possesses a wide spectrum of biological effects (1). In 
animals, administration of IL-1 has been shown to enhance non-specific 
resistance to bacteria, fungi and plasmodia (2,3). For example, 
pretreatment with a low dose (3-30 μg/kg) of recombinant human IL-lß 
( rhIL- lß) 24 h before a lethal Gram-negative infectious challenge 
enhances survival of normal and neutropenic mice (4,5). The 
mechanism for this protection has only partially been clarified. A direct 
antimicrobial effect of IL-1 has been excluded in vitro (4), and whether 
IL-1 induces enhanced clearance of microorganisms in vivo is 
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controversial (4,6). The protective effect of IL-1 in granulocytopenic mice 
argues against a major role of neutrophils (2,4,7). Glucocorticosteroids, 
eicosanoids or cytokines like IL-6, IL-8 and GM-CSF do not mediate the 
IL-1 induced resistance to infection (8-11). However, IL-1 induced TNFa 
and IL-1 induced acute phase proteins play some role as mediators of the 
IL-1 effect (10,11). 
In severe Gram-negative infection, excessive production of several 
cytokines including TNFa, IL-1, IL-8 and IFNy , sometimes referred to 
as lethal cytokinemia", has been implicated in morbidity and lethality 
(12-14). To limit these deleterious effects, several counterregulatory 
mechanisms seem to exist: cytokine production may be inhibited (15), 
and host sensitivity to proinflammatory cytokines may be reduced by 
production of endogenous inhibitors (16,17) or tolerance of target cells, for 
example by down-regulation of receptors (18,19). IL-1 might enhance 
host resistance to lethal infection by one or more of these mechanisms. 
IL-1 has been shown to induce its specific inhibitor, the competitive 
receptor antagonist (IL-IRa) in vivo in humans and in vitro (20-22). IL-
1 is also capable of desensitizing to a lethal dose of LPS, TNFa and IL-1 
(18) in vivo, and to reduce mRNA and protein levels for the type I IL-1 
receptor (IL-1RI) and the TNF receptor (TNFR) in several types of cells 
in vitro (23,24). In the present study, we have investigated whether these 
mechanisms play a role in the IL-1 induced protection to infection by 
assessing the effect of IL-1 pretreatment on in vivo and in vitro cytokine 
production and on organ mRNA levels of IL-1RI, TNFRI and IL-IRa in 
infected animals. 
MATERIALS AND METHODS 
Mice 
Female outbred Swiss mice (weight, 20-25 g; TNO, Rijswijk, The 
Netherlands), female inbred СЗН/HeJ and СЗН/HeN mice (weight, 18-25 
g; Bomholt Gard, Ry, Denmark) and New Zealand white rabbits (from a 
local colony) were kept under specific-pathogen-free conditions. 
Materials 
Recombinant murine and human IL-lß (rmIL-lß and rhIL-lß) and 
polyclonal rabbit anti-murine IL-la and IL-lß antisera were generously 
provided by Dr. P. Graber (Glaxo, Geneva, Switzerland); rmlL-la and 
rhIL- la were a kind gift of P. Lomedico, Hoffmann-Laroche, Nutley, NJ, 
USA and rmTNFa and rhTNFa were kindly donated by Dr. G. Adolf, 
Ernst-Boehringer Insti tut , Vienna, Austria. Inactivated IL-lß was 
prepared by heat ing rh IL- lß at 95°C for 30 min. For in-vivo 
administration, rhIL-lß or inactivated rhIL-lß (control treatment) was 
dissolved in pyrogen-free phosphate-buffered saline, pH 7.4 (PBS) with 2% 
(vol/vol) mouse serum. Kind donations were received of cDNA for mlL-
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1RI (Dr. Ueli Gubler, Hoffmann-Laroche Inc.), mTNFRI (Dr. D. 
Wallach, Weizmann Institute, Rehovot, Israel), mIL-IRa (Prof. A.S. 
Whitehead, University of Dublin, Dublin, Ireland) and chicken ß-actin 
(Dr. Brigitte Huber, Tufts University, Boston, Mass.). 
Radioimmunoassays for IL-lex, IL-lß and TNFa 
RIAs for the murine cytokines were performed essentially as described 
previously (25). To optimize this RIA for murine plasma and cell culture 
samples, several modifications were necessary. Because standard curves 
in assay buffer and sample medium did not superimpose, the medium of 
the standards was chosen to be identical to that of the samples. To 
improve sensitivity, the RIA was performed at 4°C, and the assay buffer 
in which the radiolabeled cytokines and second antibody were dissolved 
was changed to 6.25 mM sodium phosphate (pH 7.4), 12.75 raM EDTA, 
0.25% bovine serum albumine (ORHD21/22 grade, Sigma), 0.02% sodium 
azide with addition of 0.1% (v/v) Triton-X and 10,000 kallikrein-
inactivating units/ml of aprotinin, and with omission of NRS. 
The mean of triplicate standards was calculated, the value for 
nonspecific binding (without rabbit antiserum) was subtracted, and 
standard curves were fitted by weighted (26) non-linear regression using 
a four-parameter logistic model (27). 
IL-6 bioassay 
IL-6 levels in serum were quantitated as hybridoma growth factor activity 
by using the IL-6 dependent murine hybridoma 7TD1 (a kind gift from J. 
van Snick) as described previously (28). Hybridoma growth factor activity 
resulting in half-maximal stimulation was arbitrarily defined as 1 U. 
The detection limit of the assay was 50 U/ml. 
Experimental protocols 
(i) Survival experiments. 
To ascertain the effectivity of rhIL-lß pretreatments, enhancement of 
survival of P. aeruginosa infection was assessed simultaneously with 
the preparation of samples for RIA and mRNA determinations. Since P. 
aeruginosa (ATCC 27853) does not kill normal mice, mice were rendered 
neutropenic (<0.5 χ 10° granulocytes per liter) by two subcutaneous (s.c.) 
injections of cyclophosphamide (ASTA Pharma, Frankfurt, Germany) 
on day -4 and on day -1 (150 and 100 mg/kg, respectively). On day -1, 800 ng 
of hIL-lß or control treatment was injected intraperitoneally (i.p.) (0.1 
ml), and 24 h later, time zero, a lethal challenge with 0.5-1x107 CFU of 
P. aeruginosa was given intramuscularly (i.m.) in the left thigh muscle. 
Six hours after the infection, gentamicin (120 mg/kg; Schering, 
Kenilworth, N.J.) was administered s.c. in order to postpone the time of 
death, and thus accentuate the differences between treatment groups. 
Mortality was recorded for at least 48 h. 
(ii) Preparation of samples for cytokine protein measurements. 
Mice were pretreated i.p. with 800 ng of rhIL-lß or control treatment 24 h 
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before an i.m. infectious challenge with P. aeruginosa (neutropenic 
mice) or with 1-5x106 CFU K. pneumoniae ATCC 43816 (non-neutropenic 
mice). All bacterial challenges (0.1 ml per mouse) were prepared by 
appropriate dilution of overnight cultures washed three times in saline. 
For assessments of circulating cytokines, blood was collected individually 
in EDTA-coated tubes on ice at several time points after infection. Plasma 
was prepared within 1 h by 10 min centrifugation at 400 g at 4°C and 
stored at -70 °C. For assessment oí ex vivo cytokine production, resident 
peritoneal macrophages were harvested by rinsing the peritoneal cavity 
aseptically with cold PBS with 0.38% (wt/vol) sodium citrate. After 
centrifugation at 400 χ g at 4°C, cells were resuspended in RPMI 1640 
(Dutch modification; Flow Laboratories, Irvine, UK), containing 1 mM 
pyruvate, 2 mM L-glutamine and 100 μg/ml gentamicin. After culture of 
peritoneal macrophages (1x10° cells/ml for 24 h) in 96-well microtiter 
plates in RPMI medium with or without lipopolysacharide (LPS, from 
Escherichia coli serotype 055:B5; Sigma Chemical Co, St. Louis, MO, 
USA) at a final concentration of 100 ng/ml, the culture supernatants 
were harvested, replaced by RPMI medium, and cells and supernatants 
were frozen at -70°C. Two more freeze-thaw cycles were done before assay 
of cell-associated cytokines to accomplish lysis, 
(iii) Preparation of tissues for mRNA assessments. 
Since surface protein expression of murine IL-1 and TNF receptors are 
below detection limit for proper statistical analysis, and the murine IL-
lRa protein and corresponding antibodies were not yet available to 
produce an assay, in vivo receptor expression and IL-IRa regulation were 
studied using gene expression. At 4, 12 or 24 h after i.p. administration of 
800 ng of rhIL-lß or control injection i.p., Swiss mice were bled, killed by 
cervical dislocation and liver, spleen, kidneys, lungs, thymus and brain 
were frozen immediately in liquid nitrogen and stored at -70°C. Total 
RNA was extracted using the guanidine-isothiocyanate-CsCl method 
(29). For Northern hybridization, performed to verify integrity of RNA 
isolates, 20 μg of total RNA was subjected to electrophoresis in a 1.2 % 
agarose-formaldehyde gel and transferred by capillary action to Hybond 
N+ membrane (Amersham, Buckinghamshire, England). RNA was 
fixed to the membrane with UV light as suggested by the manufacturer. 
Since all cDNA probes to be used were specific for the respective mRNA, 
and analysis of both Northern and dot blots reveal a direct quantitative 
relationship (23), gene expression was analyzed using dot blots. Dot blots 
(50 μg and four two-fold dilutions) for quantification of RNA also 
employed nylon membranes, and were sequentially probed with cDNA for 
mIL-lRI (2.2 kilobase (kb)), mlL-lRa (1.7 kb), mTNFRI (1.5 kb), and ß-
Actin. cDNA were labeled with ^ 2 P using a random primed DNA 
labelling kit (Pharmacia). Membranes were exposed at -70°C to Kodak 
XAR5 films with Dupont Cronex intensifying screens. Autoradiograms 
were scanned by laser densitometry (Ultroscan XL, Pharmacia LKB, 
Bromma, Sweden). Ratio's of densities of mIL-lRI, mIL-IRa, mTNFRI 
mRNA's after IL-1 versus control pretreatment (inactivated IL-lß) were 
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calculated and related to ß-Actin by dividing by the ratio's of ß-Actin 
expression after IL-1 versus control pretreatment. 
Statistical analysis 
Survival data were analyzed by use of the log rank test (30). Comparisons 
of cytokine concentrations between treatment groups were made by the 
Kruskal Wallis test (31). Ρ values of less than 0.05 were considered 
significant. When η components were analyzed, the Bonferroni-corrected 
α = 0.05/n was used. 
RESULTS 
Specificity and validation of RIAs for murine cytokines 
Specificity of the three antisera was confirmed by assessing lack of 
displacement of tracer from the respective antibody by mrIL-la, mrIL-lß, 
mrTNFa, hrIL-la, hrIL-lß and hrTNFcc, all tested in concentrations up 
to 5 μg/ml. Sensitivities of the RIAs for mIL-la, mIL-lß and mTNFcc with 
freshly prepared tracers ranged from 50-80, 20-70 and 80-140 pg/ml, 
respectively. The intraassay coefficient of variation (CV) was less than 
15% from the detection limit to typically 1800 pg/ml (IL-la and IL-lß) and 
6000 pg/ml (TNFa). Interassay precision, expressed as CV, was 
estimated by measuring two different plasma concentrations of IL-la, 
IL- lß , and TNFa (320 and 625 pg/ml) in duplicate on 10 different 
occasions, and was 15.0% and 12.9% for IL-la, 3.8% and 7.1% for IL-lß 
and 15.4% and 11.0% for TNFa. Recovery in these occasions was 91% and 
98% for IL-la, 87% and 94% for IL-lß and 91% and 112% for TNFa, with 
SEM always < 6.3%. When supernatant from unstimulated peritoneal 
macrophages was spiked with 160 or 320 pg/ml mrIL-la, mrIL-lß and 
mrTNFa, and measured on 10 occasions, recovery was 111% and 94% for 
IL-la, 110% and 89% for IL-lß and 120% and 112% for TNFa, with sem 
always < 16%. 
Effect ofrhIL-1 β pretreatment on survival in different strains of mice 
The LPS-hyporesponsive СЗН/HeJ mice (32) were compared to the closely 
related LPS-sensitive СЗН/HeN mice and to Swiss mice. The responses 
of the mice were verified by the lack of rise in plasma TNFa levels 2 h 
after i.p. LPS (50 μg) in СЗН/HeJ mice, and a rise in СЗН/HeN mice (33) 
(not shown). We examined survival and cytokine production in СЗН/HeJ 
and СЗН/HeN mice infected with P. aeruginosa. 
As shown in Fig. 1, pretreatment with 800 ng rhIL-lß 24 h before lethal 
P. aeruginosa infection enhanced survival significantly in neutropenic 
СЗН/HeN and Swiss mice (χ2= 4.33 and 8.03, p<0.05 and p<0.005, 
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Fig. 1. Survival of neutropenic Swiss, СЗН/HeN and СЗН/HeJ mice of a lethal i.m. 
challenge with P. aeruginosa administered at time zero after i p. pretreatment at -24 h 
with 800 ng of IL-lß or control pretreatment (inactivated IL-lß) Survival is 
significantly enhanced by IL-1 pretreatment in Swiss and in СЗН/HeN mice (χ2=4 22 
and 8.03, p<0.05 and p<0.005, respectively), but not in СЗН/HeJ mice (23-28 mice/group) 
8000 
time (h) 
Fig. 2. Median plasma TNFoc concentrations in Swiss mice after i.m К pneumoniae 
infection in normal mice (squares) or Ρ aeruginosa infection in neutropenic mice 
(circles) (five mice per datum point) 
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Fig. 3. Plasma TNFa concentrations in Swiss mice pretreated at -24 h with 800 ng of IL-
lß (right) or control pretreatment (inactivated IL-lß)(left), and infected attime zero with 
K. pneumoniae (normal mice; panel A) or P. aeruginosa (neutropenic mice; panel B). 
Differences with control mice are significant at 5 and 8 h after P. aeruginosa infection 
(p=0.009 and p=0.0043, respectively; 6-10 mice/group). 
respectively), but only slightly in neutropenic СЗН/HeJ mice (χ2=1.67, 
η.s.). Survival of infected mice not treated with IL-1 was somewhat better 
in СЗН/HeJ mice as compared to untreated СЗН/HeN mice (χ2=2.78, 
p=0.09). Survival of IL-1-pretreated СЗН/HeN mice did not differ 
significantly from that in СЗН/HeJ mice not treated with IL-1. 
Measurement ofin-vivo cytokine production 
Plasma concentrations of IL-la and IL-lß were at or below the detection 
limit at each time point after an i.m. challenge with K. pneumoniae 
(non-neutropenic mice) or P. aeruginosa (neutropenic mice). 
As shown in Fig. 2, plasma TNFa concentrations rose in Swiss mice at 
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different time points in both types of infection. TNFa concentrations 
peaked at 1 h after K. pneumoniae inoculation, and then declined to the 
detection limit at 15-20 h. After P. aeruginosa injection, TNFa levels 
were lower than after the K. pneumoniae challenge and peaked later 
(1900 pg/ml at 5 h). 
The effect of rhIL-lß pretreatment on plasma TNFa levels in Swiss mice 
after infection is shown in Fig. 3. After a K. pneumoniae challenge, 
TNFa plasma levels in IL-1 pretreated normal mice were lower, albeit 
not statistically significant. In neutropenic P. aeruginosa-iniecteà Swiss 
mice, TNFa levels in the IL-1-pretreated group were reduced at each time 
point (significant at 5 and 8 h, p=0.009 and p=0.0043, respectively). 
In neutropenic СЗН/HeJ mice pretreated with rhIL-lß or control 
injections, plasma TNFa 5 h after a P. aeruginosa challenge was 
undetectable. In СЗН/HeN mice, IL-lß pretreatment caused a significant 
reduction of TNFa levels at this time point (p=0.04); also in Swiss mice 
examined in the same experiment this difference was highly significant 
(p=0.0015) (Fig. 4). In each strain of mice and in both pretreatment 
groups, TNFa levels were undetectable at 24 h. 
IL-6 serum levels, measured 3 h and 8 h after P. aeruginosa infection in 
neutropenic Swiss mice, were reduced by IL-1 pre treatment (t=3 h: from 
6826 to 1736 U/ml, p=0.004; t=8 h: from 2746 to 1463 U/ml, n.s.; 6-7 
mice/group). 
1 
tu 
ft 
a 
СЗН/HeJ СЗН/HeN Swiss 
mice 
Pig. 4. Effect of i.p. pretreatment at -24 h with 800 ng of IL-lß (right) or control 
pretreatment (inactivated IL-lß) (left) on plasma TNFa concentrations at 5 h after i.m. 
P. aeruginosa infection administered at time zero in neutropenic Swiss, C3H/HEN 
and СЗН/HeJ mice. The reduction of TNFa is significant in СЗН/HeN mice (p=0.04) 
and in Swiss mice (p=0.0015), but not in СЗН/HeJ mice (8-10 mice/group). 
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Measurement of cytokine production ex vivo 
Since macrophages are principal sources of IL-1 and TNFa, the effect of 
IL-1 pretreatment on cytokine production capacity was studied with 
peritoneal macrophages from uninfected or infected non-neutropenic or 
neutropenic mice (Fig. 5). These cells were removed from the mice and 
cultured for 24 h with or without LPS. No cytokine production was 
detectable in cells or supernatants of cells from uninfected mice 
incubated without LPS, indicating the absence of significant endotoxin 
contamination during cell isolation and culture (data not shown). In 
uninfected non-neutropenic Swiss mice, secreted T N F a of LPS-
stimulated peritoneal macrophages obtained 24 h after IL-1 or control 
pretreatment was significantly reduced in the group pretreated with IL-1 
(p=0.01), whereas cell-associated IL-la after culture with LPS was non-
significantly reduced (Panel A). 
In similar experiments with noninfected neutropenic Swiss mice, the 
same pattern was observed (Panel B). 
In peritoneal cells isolated from non-neutropenic Swiss mice 5 h after a 
K. pneumoniae challenge and cultured with LPS, cell-associated IL-la 
and secreted T N F a were significantly reduced when mice were 
pretreated with IL-1 (p=0.01, and p=0.017, respectively; Panel C). Basal 
T N F a secretion was present in unstimulated cells, which was also 
reduced by pretreatment with IL-1 (from 320 to 170 pg/ml, p=0.067) (not 
shown). 
In unstimulated and LPS-stimulated macrophages collected 5 h after P. 
aeruginosa injection from neutropenic СЗН/HeJ mice pretreated in vivo 
with rhIL-lß or vehicle treatment, cytokines were low or undetectable in 
cellular fractions and supernatants (Panel D). In IL-1 pretreated 
СЗН/HeN mice, peritoneal cells isolated 5 h after P. aeruginosa infection 
contained less intracellular IL-la (p=0.014) and secreted less TNFa 
(p=0.019) in comparison to cells from control mice (Panel E). Five hours 
after P. aeruginosa infection in neutropenic Swiss mice, cell-associated 
IL-la, and IL-lß and TNFa in supernatants after LPS-stimulation were 
significantly reduced by in vivo IL-1 pretreatment (p=0.0048, p=0.0076 
and p=0.024, respectively; Panel F). In supernatants from unstimulated 
cells, low levels of spontaneous TNFa were present; however these were 
still significantly reduced in IL-1 pretreated cells (190 versus 140 pg/ml, 
p=0.0059)(data not shown). 
Twenty four hours after P. aeruginosa infection in control or IL-1 
pretreated СЗН/HeJ mice, cytokine concentrations in cellular fractions or 
supernatants of unstimulated or stimulated macrophage cultures were 
negligible (Panel G). Macrophages from neutropenic СЗН/HeN mice 
obtained 24 h after P. aeruginosa infection and cultured with LPS 
contained cell-associated IL-la concentrations of 1570 and 850 pg/ml in 
control and IL-1 treated mice, respectively (n.s.); TNFa secreted by these 
cells was only slightly reduced (Panel H). In LPS stimulated peritoneal 
macrophages from neutropenic Swiss mice 24 h after P. aeruginosa 
105 
CHAPTER 7 
|m/8d цп/íd 
i 8 
im/Sd 
1 § § 
\m/9à |m/8d 
Іш/Bd 
О 
S 
2 
i § 
Іш/Sd im/Bd 
MODULATION OF CYTOKINE OVERSHOOT ANT) ITS EFFECTS 
Fig. 5. Ex vivo measurements of cytokine concentrations in cultured LPS-stimulated 
supernatants (s) and cells (c) isolated from mice pretreated in DIDO with IL-Iß (right) or 
control pretreatment (inactivated IL-lß) (left) without infection, or after infection with 
К pneumoniae (normal mice) or Ρ aeruginosa (neutropenic mice) (4-8 mice/group) 
A. Macrophages isolated from non-neutropenic uninfected Swiss mice 24 h after in 
vivo pretreatments Secreted TNFa is significantly reduced after IL-1 pretreatment 
(p=0 01) B. Macrophages isolated from neutropenic uninfected Swiss mice 24 h after m 
vivo pretreatments Secreted TNFa is significantly reduced after IL-1 pretreatment 
(p=0 009) С Macrophages isolated from non-neutropenic IL-1 or control pretreated 
Swiss mice 5 h after infection with К pneumoniae Cell-associated IL-la and secreted 
TNFa from LPS-stimulated cells are significantly reduced after IL-1 pretreatment 
(p=0 01 and p=0 017, respectively) D. Macrophages isolated from neutropenic IL-1 or 
control pretreated СЗН/HeJ mice 5 h after infection with Ρ aeruginosa E. Macrophages 
isolated from neutropenic IL-1 or control pretreated СЗН/HeN mice 5 h after infection 
with Ρ aeruginosa Cell-associated IL-la and secreted TNFa from LPS-stimulated 
cells are significantly reduced after IL-1 pretreatment (p=0 014 and p=0 019, 
respectively) F. Macrophages isolated from neutropenic IL-1 or control pretreated Swiss 
mice 5 h after infection with Ρ aeruginosa Cell associated IL-la and secreted IL-lß 
and TNFa from LPS-stimulated cells are significantly reduced after IL-1 pretreatment 
(p=0 0048, p=0 0076 and p=0 024, respectively G. Macrophages isolated from neutropenic 
IL-1 or control pretreated СЗН/HeJ mice 24 h after infection with Ρ aeruginosa 
H. Macrophages isolated from neutropenic IL-1 or control pretreated СЗН/HeN mice 24 h 
after infection with Ρ aeruginosa I Macrophages isolated from neutropenic IL-1 or 
control pretreated Swiss mice 24 h after infection with Ρ aeruginosa Secreted TNFa 
from LPS-stimulated cells is significantly reduced after IL-1 pretreatment (p=0 04) 
infection, IL-1 pretreatment reduced cell-associated IL- la by 65% 
(p=0.04), and secreted TNFa by 30% (n.s.) (Panel I). 
Effect of IL·! pretreatment on IL-lfta gene expression in organs 
The steady state mRNA expression of the IL-IRa was not influenced by 
IL-1 pretreatment in any organ at early time points, but at 24 h a 1.8 and 
9-fold upregulation was present in spleen and liver, respectively (Table 1 
and Fig. 6) . 
Effect of IL-1 pretreatment on IL-1RI and TNFRIgene expression 
As shown in the dot blot (Fig 6) a 60% and 54% downregulation of steady 
state levels of mRNA for the IL-1RI and TNFRI, respectively, was found 
in the spleen 24 hours after IL-1 pretreatment in comparison to control 
treatment. In Table 1 the results of steady state mRNA levels 12 and 24 h 
after IL-1 pre t r e a t m e n t are shown for the various organs. A 
downregulation (±30%) of steady state levels of mRNA for the type I IL-1 
receptor and for the type I TNF receptor were present in spleen, thymus, 
and lung at 12 and 24 h after IL-1 pre treatment in comparison to control 
treatment, and no effect occurred in the brain. A clear upregulation of 
IL-1RI and TNFRI mRNA was present in the liver at 24 h after IL-1 
pretreatment, following a downregulation at 12 h. In the kidney, after 12h 
pretreatment there was no IL-1 effect; at 24 h an upregulation was 
observed for the TNFRI but not for the IL-1RI. 
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Spleen 
control EL-1 
IL-IRa 
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Fig. 6. Effect of IL-1 t reatment on steady state levels of IL-IRa, IL-1RI and TNFRI 
mRNA isolated from the spleen at 24 h. Equivalent loading of the lanes was monitored 
by the constitutive expression of the ß-Actin housekeeping gene. 
DISCUSSION 
In the present study, we have shown that IL-1 induced enhancement of 
survival of lethal Gram-negative infections in normal and neutropenic 
mice is associated with decreased circulating concentrations of TNFa 
and IL-6 and reduced ex vivo production of IL- la and TNFa by 
macrophages. In these same animals there was an upregulation of IL-
IRa mRNA in the liver and spleen. In parallel, a down-regulation of type 
I IL-1 receptor and TNFa receptor mRNA occurs. These results support 
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the concept that reduction of cytokine production or cytokine effects is 
beneficial in serious infections (12,34-37). 
The role of IL-1-induced downregulation of cytokine production in IL-1-
induced enhanced survival was further examined in СЗН/HeJ mice, 
which do not produce cytokines after a challenge such as LPS. In 
СЗН/HeJ mice, cytokine concentrations after a Gram-negative bacterial 
challenge are expected to be low. Therefore, if reduction of cytokine 
production would be the principal mechanism of IL-1-induced protection 
to infection, IL-1-induced enhanced survival should not occur in these 
mice. Our results are in accordance with this assumption. We observed a 
stepwise increase in survival to P. aeruginosa infection by IL-1 
p r e t r e a t m e n t in СЗН/HeJ mice (nonsignificant), СЗН/HeN mice 
(significant) and Swiss mice (highly significant). In plasma of 
neutropenic СЗН/HeJ mice, five hours after the P. aeruginosa challenge 
cytokines were not detectable; in СЗН/HeN mice, TNFa plasma 
concentrations were elevated, and significantly reduced by IL-1 
pretreatment; in Swiss mice, these effects of IL-1 pretreatment were even 
more pronounced. The increasing protective effect of IL-1 in СЗН/HeJ, 
СЗН/HeN and Swiss mice, respectively, is also parallelled by an 
increasing downregulation of cytokine production ex vivo. 
The downregulation of proinflammatory cytokines by pretreatment with 
IL-1 appears to be associated with upregulation of IL-IRa mRNA at the 
time of infection. IL-IRa inhibits many effects of IL-1 by blocking the IL-1 
receptor (38). Attenuation of IL-1 effects by IL-IRa during severe 
infections has been demonstrated (35,39), and two recent studies 
demonstrate that administering neutralizing antibodies to IL-IRa 
enhances the severity of disease (40,41). Induction of IL-IRa synthesis in 
vitro by IL-1 has recently been reported (20-22,42). Our finding of 
enhanced gene expression of IL-IRa in spleen and liver after IL-1 
pretreatment could imply that IL-IRa induction plays a role in IL-1 
induced protection. Interestingly, a similar pattern, i.e. downregulation 
of proinflammatory cytokines with upregulation of IL-IRa occurs once 
infections such as meningococcal infection and typhoid fever have been 
established (43,44). It is likely that in natural overwhelming infections 
(such as meningococcal sepsis in humans) the protective downregulation 
of cytokine production upregulation of anti-inflammatory cytokines 
occurs too late. 
In addition to the modulation of pro- and anti-inflammatory cytokine 
production, we also investigated whether a desensitization of target cells 
by down-regulation of receptors plays a role in the IL-1-induced enhanced 
survival of infection. This possibility has been suggested by several in 
vitro studies (23,24), although this does not apply to all types of cells (45). 
Because of the low numbers of cytokine surface receptors, we assessed 
steady state gene expression of the type I IL-1R and the type I TNFR in 
organs of Swiss mice 24 h after IL-1 or control injection, which is the time 
of the infectious challenge. 
IL-1 pretreatment induced a downregulation in spleen, thymus and lung 
levels of both IL-1RI and TNFRI mRNA. These results suggest that IL-1-
induced protection to infection is partially mediated by downregulation of 
110 
MODULATION OF CYTOKINE OVERSHOOT AND ITS EFFECTS 
these receptors for IL-1 and TNF. 
We have not been able to evaluate the effect of IL-1 on the IL-1RII. 
However, it is likely that this receptor is of lesser biological relevance, 
since it has been recently reported that IL-1 signalling occurs exclusively 
via the type I receptor (46). Also the type I TNFR seems to be of greater 
biological relevance than the TNFRII, since TNFRI-dependent signalling 
cascades have been proposed important in the effects of TNFa as a 
proinflammatory factor (47), and since mice deficient for the TNFRI are 
resistant to septic shock (48). 
In the liver, IL-1RI and TNFRI mRNA steady state levels were 
upregulated at 24 h. The role of this upregulation is unclear for the IL-1 
induced protection. On the other hand, it could be argued that this 
upregulation at the level of the hepatocyte is beneficial by augmenting 
acute phase proteins (11). In addition, since IL-1 pre t rea tment 
ameliorates the biochemical and histological signs of liver damage 
(Vogels et al, manuscript in preparation), increased IL-1R on hepatocytes 
may augment this effect. Receptor upregulation may also enhance 
clearance of IL-1 and TNFa and thus add to the reduction of plasma 
cytokine levels (49,50). The observed TNFR upregulation in the kidney 
could also contribute to clearance of TNFa (51). 
Wallach et al. (18) also reported a protective effect of IL-1 pretreatment in 
galactosamine-sensitized mice to lethal effects of IL-1, TNF and LPS. 
Similar to our observations, these investigators suggested that IL-1 
induced protection is mediated by decreased cytokine production after 
LPS, and demonstrated decreased cytokine sensitivity of target cells. In 
contrast, Libert et al. (52), who studied the desensitization by IL-1 
pretreatment to TNF and LPS in galactosamine-treated mice, did not 
observe reduced TNFa plasma concentrations or modulated surface 
TNFa receptors in the liver 12 h after IL-1 pretreatment. Because of the 
differences in the models used (especially the galactosamine 
sensitization), it is difficult to compare these results with ours. 
Sheppard et al. (52) reported protection by IL-1 pretreatment to a lethal 
TNFa challenge, and also suggested desensitization of target cells as a 
mechanism. Contel et al. (53) observed decreased TNFa levels after LPS 
administration in IL-1 pretreated mice. In ex vivo studies with 
macrophages, desensitization for LPS was observed for only 2 hrs; these 
authors suggest a role of in ini>o-induced corticosterone in the TNFa 
d o w n r e g u l a t i o n . In our mode ls , however , IL-1- induced 
glucocorticosteroids do not play a role (9). 
Although numerous studies report a deleterious role of overproduced 
cytokines during infection, physiological quantities of TNF, IL-1 and IL-6 
during infection may be protective (39). Further studies employing 
specific antibodies could ulteriorly confirm a causal role of reduction of 
these cytokines in our model of IL-1-induced protection. 
In addition to modulation of inflammatory and anti-inflammatory 
cytokines and cytokine receptors, other mechanisms of IL-1 induced 
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protection could be operative. Induction of soluble TNF receptors by IL-1, 
which neutralized TNFa, has been reported in vivo (21). We have 
previously reported the role of IL-1 induced protective acute phase 
proteins (11). These proteins may be responsible for the slight protection 
induced by IL-1 which we observed in C3HHeJ mice. The mechanisms 
put forward in our studies might well be responsible for other IL-1 
induced beneficial effects induced by IL-1 such as radiation protection, 
prevention of IL-2 toxicity, prevention of cytosine arabinoside induced 
alopecia and prevention of acetaminophen-induced liver damage (55-58). 
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ROLE OF MACROPHAGES AND sTNF-RECEPTORS 
ABSTRACT 
Pretreatment with a low intraperitoneal (1 p.) dose of recombinant 
human interleukin-lß (IL-1) 24 h before a lethal intramuscular (1 m ) 
Pseudomonas aeruginosa infection prolongs survival in neutropenic 
mice The role of macrophages in this protective effect was investigated by 
selectively depleting these cells with dichloromethylene diphosphonate 
containing liposomes (DMDPL) DMDPL administered ι ρ , which deplete 
peritoneal, liver and spleen macrophages, abolished the IL-1 induced 
protection, whereas DMDPL administered intravenously, which deplete 
only liver and spleen macrophages, had no influence on this IL-1 effect 
These results suggest that macrophages present at the site of the IL-1 
injection play a major role in the protective effect of ι ρ administered IL-
1 The IL-1-induced protection was associated with enhanced secretion of 
nitrite (NO2") but not of superoxide anion (O2") by ex vivo stimulated 
peritoneal macrophages 
In IL-1 treated mice, serum concentrations of soluble TNF receptors 
(sTNFRs) were slightly enhanced at early time points after infection, but 
reduced at 8 h after infection This reduction was significant for the 
sTNFR-p55 Whether this reflects reduced production of membrane 
TNFR or a lesser compromised renal function after IL-1 pretreatment 
remains to be established 
We conclude that the IL-1 induced nonspecific resistance to infection is 
mediated by peritoneal macrophages and is associated with enhanced 
nitrite production capacity of these cells and with reduced serum p55 
soluble TNF receptors 
INTRODUCTION 
Administration of the proinflammatory cytokine interleukin-1 (IL-1) 
leads to enhanced nonspecific resistance to Gram-positive and Gram-
negative bacteria, fungi and plasmodia (1,2) For example, we have 
shown that pretreatment with a single low dose (3-30 μg/kg) of 
recombinant human IL-Iß (rhIL-lß) 24 h before a lethal gram-negative 
infectious challenge with Klebsiella pneumoniae or Pseudomonas 
aeruginosa enhances survival of normal and neutropenic mice, 
respectively (3,4) The mechanism of this protection has only partially 
been clarified A direct antimicrobial effect of IL-1 has been excluded in 
vitro (3) Glucocorticosteroids, eicosanoids or cytokines like IL-6, IL-8 
and GM-CSF do not mediate the IL-1-induced resistance to infection (5-8) 
However, IL-1-induced TNFa and IL-1-induced acute phase proteins play 
some role as mediators (7,8) The protective effect of IL-1 to infectious 
challenges in granulocytopenic mice indicates that neutrophils do not 
play a major role (2,3,9) 
Activated macrophages represent major effectors in host defense against 
many microbial pathogens Among the numerous secretory products of 
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macrophages (10) are two independent groups of inorganic compounds 
with a high degree of chemical activity: reactive oxygen intermediates 
(ROD, including superoxide and hydrogen peroxide, and reactive 
nitrogen intermediates (RNI), e.g. nitric oxide (NO) (11). Secretion of 
oxygen-derived metabolites by macrophages has been related to 
antimicrobial activity (12,13). NO is derived from the terminal guanido 
nitrogen of L-arginine (14,15) through a reaction catalysed by nitric oxide 
synthase (NOS). NOS comprises at least two different enzymes (16). One 
type is constitutive, and plays a role in blood pressure homeostasis. An 
inducible NOS is produced in macrophages and other cells after 
activation by LPS or cytokines (11,17), and this enzyme causes prolonged 
production of large amounts of NO (11,14). In mice, RNI play an 
important role in resistance to various pathogens, such as helminths 
(18,19), protozoa (20), fungi (15) and bacteria (21). In the present study, we 
have investigated the role of macrophages in the IL-1-induced protection 
to infection in neutropenic mice by selective depletion of these cells with 
dichlorodimethylene diphosphonate containig liposomes (DMDPL) (22). 
We also measured the effect of IL-1 pretreatment on ex vivo production 
by peritoneal macrophages of the superoxide anion, and of nitrite, a 
stable end product of NO (23). 
During serious infection, an overshoot of production of proinflammatory 
cytokines are held responsible for morbidity and lethality (24-27). Among 
these cytokines, especially TNF has received much attention. TNF effects 
may be counteracted by soluble TNF receptors, which represent shedded 
p55 and p75 membrane receptors (28,29). IL-1 induces sTNFR in vivo(30). 
To investigate whether an additional protective mechanism of IL-1 may 
be an enhanced shedding of sTNFR, we have assessed serum 
concentrations of TNF binding proteins during infection. 
MATERIALS AND METHODS 
Mice 
Female outbred Swiss mice (weight, 20-25 g; TNO, Rijswijk, The 
Netherlands) were kept under specific-pathogen-free conditions. 
Acidified water and irradiated lab chow (RMH, Hope Farms, Woerden, 
The Netherlands) were available at libitum. 
Materials 
Recombinant human IL-lß (rhIL-lß) was generously provided by Dr. P. 
Graber (Glaxo, Geneva, Switzerland). Inactivated hrIL-lß (control 
pretreatment) was prepared by heating at 95°C for 30 min. For in vivo 
adminis t ra t ion, rhIL- lß and the control protein were dissolved in 
pyrogen-free phosphate-buffered saline, pH 7.4 (PBS) with 2% (vol/vol) 
mouse serum. Dichloromethylene diphosphonate containing liposomes 
(DMDPL) were prepared as described previously (31). 
Survival experiments 
Since Pseudomonas aeruginosa does not kill normal mice, mice were 
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rendered neutropenic (<0.5 χ 10^ granulocytes per liter) by two 
subcutaneous (s.c.) injections of cyclophosphamide ASTA Pharma, 
Frankfurt, Germany) on day -4 and day -1 (150 and 100 mg/kg, 
respectively). On day -1, 800 ng of hIL-lß or control pretreatment was 
injected intraperitoneally (i.p.; 0.1 ml); 24 h later, time zero, a lethal 
chal lenge wi th 0 .5-1x10 ' CFU of P. aeruginosa was given 
intramuscularly (i.m.) in the left thigh muscle. Six hours after the 
infection, gentamicin (120 mg/kg; Schering, Kenilwoth, N.J.) was 
administered s.c. in order to postpone the time of death, and thus 
accentuate the differences between treatment groups. Mortality was 
recorded for at least 48 h. 
For elimination of macrophages, 0.2 ml of DMDPL was administered i.p. 
or i.v. via the tail vein at 60 h before infection. Elimination of 
macrophages by DMDPL is complete after 24 h and has been shown to 
last at least 7 days (31). Control treatments for DMDPL consisted of either 
0.2 ml phosphate-buffered saline (PBS) i.p. or no treatment. The efficacy 
of macrophage depletion by these administration routes have been 
checked previously (22,31). 
Bacterial challenges (P. aeruginosa ATCC 27853) were prepared by 
appropriate dilution of overnight cultures, and cultures were washed 
three times in saline. 
Peritoneal macrophage collection and assays for superoxide and nitrite 
To ascertain the effectivity of the IL-1 pretreatments, enhancement of 
survival of P. aeruginosa infection was always assessed in parallel to 
the isolation of the peritoneal cells. Resident peritoneal macrophages 
were harvested 24 h after i.p. injection of 800 ng of IL-1 or heat-inactivated 
IL-1 (control pretreatment) by rinsing the peritoneal cavity aseptically 
with cold PBS with 0.38% (wt/vol) sodium citrate. Samples visually 
contaminated with erythrocytes were discarded. After 10 min. 
centrifugation at 400 χ g at 4°C, cells were resuspended, pooled per 2 
mice within each treatment group and plated in 96-well flat-bottom 
microtiter plates at 2x10^ cells /ml (nitrite determinations) or 5x10^ cells 
/ml (superoxide determinations) in 0.1 ml of phenol red-free RPMI 1640 
(Dutch modification; Flow Laboratories, Irvine, UK), containing 1 raM 
pyruvate, 2 mM L-glutamine and 100 ug/ml gentamicin. For superoxide 
radical measurements, RPMI was supplemented with 10% FBS. After 2 
h adherence at 37°C in 5%C02, 95% air, nonadherent cells were removed 
by washing twice with warm medium. After this procedure, adherent 
cells were 99% macrophages in both treatment groups, as judged by 
Giemsa staining. Cell viability was > 95% in both treatment groups, as 
assessed by trypan blue dye exclusion. 
The generation of superoxide by peritoneal macrophages was measured 
colorimetrically by the superoxide dismutase-inhibitable reduction of 
cytochrome С (Sigma Chemical Co, St. Louis, MO, USA) as described 
(32). Adherent macrophages were incubated for 20, 40, 60 or 90 min. with 
100 μΐ of reaction solution containing 160 μΜ ferricytochrome С and 200 
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ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma) in phenol red-free 
Hank's balanced salt solution with 1% glucose at pH 7.3. The absorbance 
at 550 nm was determined in a Biotek microplate reader. Blank wells 
containing macrophages and medium with ferricytochrome С were used 
as controls, and subtracted. The amount of O2" produced per well was 
calculated as reported by Pick (32) from the following formula: 
riMol O2" per well = (absorbance at 550 nm) χ 100 / 6.3 
Prelimimary experiments showed that O2- production was completely 
abolished by the presence of superoxide dismutase (300 U/ml). 
For nitrite (NO2") determinations, after culture of macrophages for 24 h 
with or without lipopolysacharide (LPS, from Escherichia coli serotype 
055:B5; Sigma) at a final concentration of 100 ng/ml, the culture 
supernatants were harvested, replaced by RPMI medium, and cells and 
supernatants were frozen at -70°C. Two more freeze-thaw cycles of the 
cells were done before assay of NO2" to accomplish cell lysis. The 
concentration of NO2" , which serves as a measure for RNI generation 
(14), was measured using the diazotization technique (33). Briefly, 100 μΐ 
aliquots were removed from conditioned medium and incubated with an 
equal volume of Griess reagent (1% sulfanilamide/0.1% naphtylethylene 
diamine dihydrochloride/2.5% H 3 P O 4 ; all from Sigma) at room 
temperature for 10 min. The absorbance at 550 nm was determined as 
described above. NO2" was quantified by using sodium nitrite as a 
standard. The background nitrite values of each media were determined 
and subtracted from experimental values. 
Serum levels of TNF binding proteins 
Murine sTNFR-p55 and p75 were determined by ELISA as described 
previously (34). The detection limit in serum for sTNFR-p55 was 5 pg/ml 
and for sTNFR-p75 50 pg/ml. 
Statistical analysis 
Survival data were analyzed by use of the log rank test (35). Comparisons 
of medians of concentrations of nitrite, superoxide and soluble TNFa 
receptors between treatment groups were made by the Kruskal Wallis test 
(36). Ρ values of less than 0.05 were considered significant. 
RESULTS 
Effect of IL·! on survival after macrophage depletion 
The effect of pretreatments with IL-1 and/or DMDPL in neutropenic mice 
on survival of a lethal i.m. challenge with P. aeruginosa is shown in 
Fig. 1. Pretreatment with 800 ng of IL-1 i.p. at 24 h before infection at 
time zero significantly enhanced survival in comparison to pretreatment 
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with 800 ng of heat-inactivated IL-1 i.p. (control pretreatment) (χ2=4.47, 
P< 0.05). When 0.2 ml of DMDPL was injected intraperitoneally 60 h 
before the i.p. IL-1 or control injection, the protective effect of IL-1 on 
survival was completely abolished. I n constras t , in t ravenous 
administration of 0.2 ml of DMDPL, which does not affect peritoneal 
macrophages (22) at 60 h before i.p. IL-1 or control injections did not 
reduce the IL-1-induced protection to infection (IL-1 vs control-treated 
mice: χ2=5.42, P<0.025). 
In previous experiments, ingestion by macrophages of empty liposomes 
containing only PBS, which would be expected to produce some 
activation, did not produce effects compatible with DMDPL (22). To 
exclude any activation, in our experiments PBS or no treatment were 
given as control treatment for DMDPL. As expected, a similar protective 
effect of IL-1 was observed, whether no treatment or 0.2 ml of PBS was 
given as a control treatment for the DMDPL. Also DMDPL per se had no 
effect, since the survival of mice that received inactivated IL-1 was not 
significantly influenced by the type of pretreatment at -60 h (no treatment, 
PBS i.p. or DMDPL i.p. or i.V.; not shown). 
hours 
Fig. 1 Survival in neutropenic Swiss mice of a lethal ι m challenge with Ρ 
aeruginosa at time zero after ι ρ pretreatment at -24 h with 800 ng of rhIL-lß or control 
treatment (inactivated IL-1), and pretreatment at -60 h with DMDPL ι ρ or ι ν or PBS 
ip Survival of IL-1 pretreated mice is enhanced in comparison to control-treated mice 
after pretreatment with PBS ι ρ or DMDPL ι ν (χ2=4 47, and 5 42, p< 0 05 and 0.025, 
respectively) After DMDPL ι ρ , IL-1 confers no significant protection, and survival in 
IL-1-treated mice is significantly reduced after ι ρ DMDPL versus i.p PBS at -60 h 
(χ2
=
4 47p p<o 05) In mice that received heat-inactivated IL-1, survival after i.p or l.v 
DMDPL or i ρ PBS at -60 h was not significantly different from survival after no 
treatment at-60 h (10 mice/group) 
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Effect ofIL-1 on ex vivo macrophage superoxide production 
Peritoneal macrophages from neutropenic mice were harvested 24 h after 
intraperitoneal administration of 800 ng IL-1 or control treatment, the 
time point of infection. Macrophage yields were similar in both treatment 
groups. After 20, 40, 60 and 90 minutes of stimulation with PMA, the 
amount of superoxide did not differ significantly between macrophage 
supernatants isolated from IL-1-treated and control mice (results not 
shown). 
Effect of IL-1 on ex vivo macrophage nitrite production 
24 h after i.p. pretreatment with 800 ng of IL-1 or control pretreatment, 
peritoneal macrophages were harvested and cultured for 24 h with or 
without LPS. NC"2" levels were negligible in cells with or without LPS 
stimulation, and in supernatants from unstimulated cells (data not 
shown). The latter result indicates the absence of significant endotoxin 
contamination during cell isolation and culture. In supernatants from 
LPS stimulated cells, IL-1 pretreatment caused a doubling of NO2" 
production (Fig.2), which is on the margin of significance (P=0.057). The 
results are expressed as micromoles of NO2" per 24 h. per 10^ cells 
originally plated, and represent means for triplicates from one of two 
experiments. 
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F i g . 2. Median concentration of N02- in s u p e r n a t a n t s from adherent peritoneal 
macrophages isolated from neutropenic mice pretreated i.p. at -24 h with 800 ng of heat-
inactivated IL-1 (control treatment) or 800 ng of IL-1, and cultured for 24 h with LPS 
(p=0.057; 7-8 mice/group). 
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Effect of IL-1 on serum levels ofsTNFR after infection 
Serum concentrations of soluble p55 and p75 TNFa receptors were 
measured at 1, 2 and 8 h after infection in mice pretreated i.p. with 800 ng 
IL-1 or control pretreatment (heat-inactivated IL-1) (Fig.3). sTNFR-p55 
and sTNFR-p75 were measured simultaneously in serum from each 
mouse, and each mouse was used only once. Both sTNFR-p55 and 
sTNFR-p75 gradually increased after 2 and 8 hours. At 1 h after infection, 
no significant differences between the two treatment groups were 
present. 
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Fig. 3. Median serum concentrations of sTNFR-p55 (panel A) and sTNFR-p75 (panel 
B) in neutropenic mice pretreated at -24 h with 800 ng of rhIL- lß or control-
treatment(heat-inactivated rhIL-lß) and infected at time zero with P. aeruginosa i.m. 
The difference between IL-1-pretreated and control mice is significant for sTNFR p55 
at 8 h after infection (p=0.02; 5 mice/group). 
At 2 h after infection, both sTNFR-p55 and sTNFR-p75 increased to a 
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nonsignificant extent in the IL-1 group as compared to the control group. 
However, at 8 h after infection, sTNFR-p55 concentrations were 
significantly lower in the group pretreated with IL-1 (P=0.02), whereas 
sTNFR p75 did not differ from the control. 
DISCUSSION 
In the present study, we report that macrophages play a role in the 
protection to lethal Gram-negative infection of neutropenic mice induced 
by pretreatment with a low intraperitoneal dose of IL-1. Intraperitoneal 
injection of DMDP-liposomes (DMDPL), which eliminates peritoneal, 
liver and spleen macrophages (22), virtually completely abolished the 
protective effect of i.p. IL-1 to an intramuscular challenge with P. 
aeruginosa. Intravenous administration of DMDPL, however, which 
depletes liver and spleen macrophages but not peritoneal macrophages 
(22), did not reduce the IL-1-induced protection to infection. These results 
indicate that IL-1 induced protection occurs by an effect on adjacent 
macrophages, and not by effects on macrophages after systemic 
diffusion. These local macrophages could protect the IL-1 treated 
animals either via augmented microbicidal mechanisms or via secretion 
of secondary mediators. 
Therefore we have measured the effect of IL-1 administration on ex vivo 
production of two major classes of inorganic antimicrobial systems, 
reactive oxygen intermediates (ROI) (37,38) and reactive nitrogen 
intermediates (RNI) (16,18) by peritoneal macrophages 24 hrs after IL-1 
administration, the time point of infection. IL-1 pretreatment did not 
affect production of superoxide, a ROI, but more than doubled production 
of nitrite, a stable metabolite of nitric oxide (NO) and a measure of RNI 
generation (14). 
RNI, in particular NO, have recently been proposed important in 
macrophage antimicrobial effects to several int racel lular and 
extracellular pathogens (15,16,18-21). Thus, enhanced NO production by 
macrophages after IL-1 pretreatment may play a role in the IL-1 induced 
protection by enhancing microbial clearance. Such IL-1-induced 
enhanced micobial clearance has been shown in experimental fungal, 
Listeria and E. coli infection, but in some of these models neutrophils 
seem to be the important effector cells (9,39-41). Enhanced in vivo 
clearance of bacteria after IL-1 pretreatment does not play a role in 
thelethal P. aeruginosa infection studied here (3), and this finding led 
us to the hypothesis that the mechanism of protection could be 
interference with lethal cytokinemia or other deleterious metabolic events 
(2,24). In this respect, NO could play a role in IL-1 induced protection, 
since this mediator has a number of other biologic functions, e.g., 
prolonged inhibition of platelet activation and aggregation and vascular 
effects (42). Our finding of involvement of TNFcc in IL-1 induced 
protection is in accordance with this assumption (43). Since presently 
available NOS inhibitors like Nß-monomethyl-L-arginine do not 
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discriminate sufficiently between inducible NOS and the constitutive 
form of this enzyme (44), more selective inhibitors should be awaited for 
obtaining definitive evidence for a role of NO in IL-1 induced protection to 
infection. 
In addition to RNI, other macrophage products may play a role in IL-1 
induced enhanced survival. We have previously excuded a role for 
secondary cytokines like IL-6, IL-8, GM-CSF and inflammatory 
mediators like cyclooxygenase products, leukotrienes and platelet-
activating factor has already been excluded (5-8), whereas IL-1 induced 
TNFa has been shown to play some role. Induction of hepatic acute phase 
proteins (APP) by hepatocytes were found important in IL-1-induced 
enhanced resistance (7). IL-6, which also induces a spectrum of APP, did 
not enhance survival of infection (7). This may be due to the difference in 
spectrum of IL-6-induced APP or to differences in APP-inducing potency 
between IL-1 and IL-6 (7). The possibility that the acute phase proteins 
are under the control of leukemia inhibiting factor produced by peritoneal 
macrophages stimulated by IL-1 deserves further study. Another 
mechanism behind IL-1 induced enhanced resistance to infection is the 
reduced proinflammatory cytokine production capacity of macrophages 
exposed to IL-1, which is accompanied by an upregulated production of 
the an t i in f l ammatory IL-1 receptor an tagon i s t (43). This 
counterregulatory mechanism in severe infection, which is also observed 
in infection in humans (45,46) could well be mediated by macrophage 
products like IL-4 and IL-10 induced by IL-1. Thus we investigated 
whether IL-1 induced protection is also associated with increased serum 
concentrations of soluble TNF receptors p55 and p75 after infection. The 
increased circulating concentrations of sTNFR during severe infections 
also seem to represent a mechanism which is beneficial for the host, 
since these binding proteins antagonize the deleterious effects of TNF at 
least to some extent, whereas on the other hand the loss of cell surface 
receptors can lead to a transiently decreased responsiveness to TNFa. 
Contrary to our expectations, we found an impressive reduction of sTNFR 
p55 in the IL-1 treated mice as compared to controls at 8 h after infection, 
and a slight reduction of sTNFR-p75. It is very unlikely that this finding 
explains protection against lethality. The question is how this effect on 
sTNFR is being produced. The great difference between sTNFR-p55 and 
p75 concentrations at this time point precludes that this effect is due to 
differences in renal clearance (47) between the two groups of mice. The 
lower serum sTNFR-p55 levels in IL-1-pretreated infected mice may be 
due to the significantly lower concentrations of TNFa we have found at 5 
and 8 hours after P. aeruginosa infection in IL-1 pretreated mice 
(34,43,48). Alternatively, the reduced sTNFR concentrations may reflect a 
reduced production of TNF membrane receptors, resulting in lower 
quantities of receptors available for shedding after inflammatory stimuli 
like TNF, IL-1 and LPS. In accordance with this hypothesis, we have 
recently found that the mRNA for TNFR-p55 is reduced in several organs 
24 hours after IL-1 injection into mice (43). 
In conclusion, peritoneal macrophages seem to play an essential role in 
127 
CHAPTER 8 
the enhanced nonspecific resistance to infection in neutropenic mice 
induced by i.p. pretreatment with IL-1. This protection is associated with 
enhanced RNI production capacity of these cells, and with reduced 
serum sTNFR-p55 after infection. 
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ABSTRACT 
Pretreatment with a low dose of rhIL-lß (IL-1; 3 to 30 μg/kg) 24 h before a 
lethal Pseudomonas aeruginosa infection prolongs survival in 
neutropenic mice. We investigated the role of the type I IL-1 receptor (IL-
1RI) and the IL-1RII in this IL-1 induced protection using a specific IL-1 
receptor antagonist (IL-1-Ra), which mainly blocks effects via the IL-1RI. 
Pretreatment with the IL-IRa before IL-1 partially blocked the IL-1 
induced enhanced survival. 
Pretreatment with a specific neutralizing monoclonal antibody to the IL-
1RI (35F5), however, annihilated the IL-1 induced protection, whereas 
pretreatment with ALVA-42, a blocking anti-IL-lRII antibody, did not 
diminish the IL-1 induced protection. 
The nonapeptide fragment 163-171 of rhIL-lß, which possesses the 
immunoadjuvant but not the inflammatory effect of the entire molecule 
via a non-receptor-mediated signal transduction process, did not 
reproduce the IL-1 induced protection. 
Histopathologic evaluation of organs from IL-1 or control- pretreated 
mice that had succumbed from the P. aeruginosa infection showed some 
amelioration of morphology in several crucial organs, and significant 
amelioration of hepatic histopathology. The latter was associated with 
reduced serum aspar ta te aminotransferase (ASAT) and alanine 
aminotransferase (ALAT) concentrations. This amelioration of IL-1 
dependent histologic and biochemical changes may reflect the previously 
reported induction of protective hepatic acute phase protein secretion as 
well as reduced cytokine production and cytokine sensitivity of target 
cellls after infection. 
We conclude that the IL-1 induced nonspecific resistance to infection is 
mediated by cells bearing typel IL-1 receptors, and is associated with a 
reduction of histopathologic changes in organs, especially the liver. 
INTRODUCTION 
Administration of the proinflammatory cytokine interleukin-1 (IL-1) 
leads to enhanced nonspecific resistance to Gram-positive and Gram-
negative bacteria, fungi and plasmodia (24, 44). For example, we have 
shown that pretreatment with a single low dose (3-30 μg/kg) of 
recombinant human IL-lß (rhIL-lß) 24 h before a lethal gram-negative 
infectious challenge with Klebsiella pneumoniae or Pseudomonas 
aeruginosa enhances survival of normal and neutropenic mice, 
respectively (42, 43). The mechanism of this protection has only partially 
been clarified. A direct antimicrobial effect of IL-1 has been excluded in 
vitro (42), and whether IL-1 induces enhanced clearance of 
microorganisms in vivo is controversial (32, 42). The protective effect of 
IL-1 to infectious challenges in granulocytopenic mice indicates that 
neutrophils do not play a major role (23, 42, 44). Glucocorticosteroids, 
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eicosanoids or cytokines like IL-6, IL-8 and GM-CSF do not mediate the 
IL-1-induced resistance to infection (45-48). However, IL-1-induced TNFa 
and IL-1-induced acute phase proteins play some role as mediators of the 
IL-1 effect (47,48). 
Two receptors For IL-1, which differ in both size and tissue distribution 
have been fully characterized (31, 39). The type I IL-1 receptor (IL-1RI) is 
a 80 kDa protein present on T-lymphocytes, endothelial cells, fibroblasts, 
and hepatocytes, and the type II IL-1 receptor (IL-1RII) is a 68 kDa 
protein found on B-lymphocytes, monocytes and neutrophils (6, 11, 21, 29). 
In the present study, we have investigated the role of the IL-1RI and the 
IL-1RII in the IL-lß-induced protection to infection in mice using 
neutralizing monoclonal antibodies to the murine type I and type II 
receptors, respectively (11, 17). We also used the IL-1 receptor antagonist 
(IL-IRa), a naturally occurring 25-kDa glycoprotein belonging to the IL-1 
gene family, which blocks IL-1 effects by specifically binding to mainly 
the type I receptor without agonist activity (4, 13, 18). To further elucidate 
the role of IL-1 receptors , we inves t iga ted whether the 
immunostimulatory 163-171 nonapeptide fragment of hIL-lß, which acts 
via a non-receptor signal transducing pathway, (7, 8), exerts protective 
activity. 
Excessive production of proinflammatory cytokines such as TNFa, IL-lß, 
IL-8 and IFNy has been implicated in morbidity and lethality, as occurs 
in severe Gram-negative infection (12). Recently, we demonstrated that 
the IL-1 induced protection to infection is associated with reduced plasma 
concentrations of TNFa and IL-6 during infection together with an 
increase of mRNA for the antiinflammatory IL-IRa, and decreased IL-1 
and TNF receptor mRNA (49). In the present study, we have investigated 
whether this IL-1-induced modulation of cytokine responses is also 
reflected in ameliorated histopathology of IL-1-pretreated infected 
neutropenic mice. 
MATERIALS AND METHODS 
Mice 
Female outbred Swiss mice (weight, 20-25 g; TNO, Rijswijk, The 
Netherlands) were kept under specific-pathogen-free conditions. 
Standard irradiated lab chow (RMH-TM; Hope Farms, Woerden, The 
Netherlands) and acidified water were available ad libitum. 
Materials 
Recombinant human IL-lß (rhIL-lß) was generously provided by Dr. P. 
Graber (Glaxo, Geneva, Switzerland). The human IL-1 receptor 
antagonist (IL-IRa) (3) was donated by Dr. J . Vannice, Synergen, 
Boulder, Co, USA. Inactivated hrIL-lß and IL-IRa (control treatments) 
were prepared by heating at 95°C for 30 min. For in vivo administration, 
rhIL-lß, IL-IRa and the control proteins were dissolved in pyrogen-free 
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phosphate-buffered saline, pH 7.4 (PBS) with 2% (vol/vol) mouse serum. 
35F5, a rat IgGl anti-mouse IL-1 Rt l monoclonal antibody (11), was a 
kind gift from Dr. R. Chizzonite, Hoffmann-La Roche, Nutley, New 
Jersey, USA. As a control antibody, a purified rat IgG was obtained from 
Sigma (#1-4131; Sigma Immunochemicals, St. Louis, MO, USA). ALVA 
42, a murine IgGl monoclonal antibody blocking the murine IL-1RII (17), 
and the IL-lß peptide 163-171 (2) were donated by Dr. P. Ghiara, Sciavo, 
Siena, Italy. Purified mouse IgG, used as control antibody for ALVA-42, 
was obtained from Sigma (#1-5381). 
Survival experiments 
Since P. aeruginosa (ATCC 27853) does not kill normal mice, mice were 
rendered neutropenic (<0.5 χ IO" granulocytes per liter) by two 
subcutaneous (s.c.) injections of cyclophosphamide ASTA Pharma, 
Frankfurt, Germany) on day -4 and day -1 (150 and 100 mg/kg, 
respectively). On day -1, 800 ng of hIL-lß or control t reatment was 
injected intraperitoneally (i.p.; 0.1 ml); 24 h later, time zero, a lethal 
chal lenge wi th 0 .5-1x10 ' CFU of P. aeruginosa was given 
intramuscularly (i.m.) in the left thigh muscle. Six hours after the 
infection, gentamicin (120 mg/kg; Schering, Kenilwoth, N.J.) was 
administered s.c. in order to postpone the time of death, and thus 
accentuate the differences between treatment groups. Mortality was 
recorded for at least 48 h. 
Histopathologic studies 
Observer-masked histopathology was performed on IL-1 pretreated or 
control neutropenic mice that died of P. aeruginosa infection; surviving 
mice were sacrificed 10 days after infection. From all mice, brain, lung, 
heart, liver, kidney and spleen were collected into buffered formaldehyde 
and processed for histopathologic evaluation according to routine 
histological procedures. Sections were stained with hematoxylin and 
eosin, with periodic acid Schiff or by the modified Masson-Trichrome 
(Goldner) s ta ining technique. The intensi ty and extension of 
histopathological changes were graded semiquantitatively. 
Liver enzymes 
For assessment of the effect of IL-1 on liver enzymes, aspartate 
aminotransferase (ASAT) levels and alanine aminotransferase (ALAT) 
levels were measured in non-hemolytic EDTA-plasma from IL-1 
pretreated and control neutropenic mice 24 h after i.m. P. aeruginosa 
infection. ASAT and ALAT levels were assessed by routine procedures 
(BM/Hitachi 747; Boehringer Mannheim, Mannheim, Germany). 
Statistical analysis 
Survival data were analyzed by use of the log rank test (37). Comparisons 
of biochemical and histopathologic data between treatment groups were 
made by the Kruskal Wallis test (20). Ρ values of less than 0.05 were 
137 
CHAPTER 9 
considered significant. 
RESULTS 
Effect oflL-IRa and type I and type IIIL-1 receptor antibodies on IL-1 
induced protection to infection 
To investigate the involvement of the type I and type II IL-1 receptors in 
the IL-1 induced enhanced resistance to infection, IL-IRa, which inhibits 
mainly IL-1 effects via the type I receptor (18, 30), was administered in a 
100-1,000-fold molar excess over IL-1. 
Doses of IL-IRa varying from 40 to 250 μg administered i.p. 15 min. before 
800 ng IL-1 i.p., analogous to the regimen found effective by others (30, 
34), did not significantly reduce the IL-1 induced protection of 
neutropenic mice to a lethal P. aeruginosa challenge (not shown). After 
800 μg of IL-IRa, a 1,000 fold molar excess over IL-1, there was a trend to 
reduction of the IL-1 induced protection, although the difference between 
the IL-1-treated groups pretreated with control versus IL-IRa 
pretreatment did not reach significance (Fig. 1A). 
Fig. 1.A Survival of neutropenic mice infected ι τη with Ρ aeruginosa at t=0, and 
pretreated at -24 25 h with 800 μg of IL IRa or inactivated IL IRa ( = control treatment C) 
ι ρ , and at -24 h with Θ00 ng of rhIL-lß or inactivated IL-Iß (= control treatment C) ι ρ 
Mice pretreated with inactivated IL-IRa and 800 ng of IL-1 were protected significantly 
in comparison to mice receiving control injection at both occasions (χ2 = 9 79, p<0 005), 
whereas mice pretreated with Θ00 ng of IL-IRa followed by 800 ng of IL-1 were protected to 
a nonsignificant extent The difference between IL 1-treated mice pretreated with either 
IL-IRa or inactivated IL-IRa is not significant Also the difference between mice 
receiving either IL-IRa or inactivated IL-IRa followed by inactivated IL-1 is not 
significant (22 mice/group) B. Survival of neutropenic mice infected ι m with Ρ 
aeruginosa at t=0, and pretreated ι ρ at -42 h with 200 μς of the neutralizing anti-IL-lRI 
antibody 35F5 or control IgG, and at -24 h with 800 ng ofrhIL-lß or inactivated rhIL-lß (= 
control treatment Ο ι ρ Mice receiving control IgG followed by IL-1 were protected 
significantly in comparison to mice receiving control IgG followed by inactivated IL-1 
(χ2=6 13, p<0 025) The survival of IL-1 treated mice pretreated with 35F5 is not 
significantly different from that in control treated mice pretreated with 35F5 Also the 
difference between mice receiving either control IgG or 35F5 followed by inactivated IL-
1 is not significant (20 mice/group) C. Survival of neutropenic mice infected ι m with 
Ρ aeruginosa at t=0, and pretreated ι ρ at -42 h with 200 μg of 35F5, ALVA-42, or control 
IgG, and at -24 h with 800 ng of rhIL-lß or inactivated rhIL-lß (= control treatment Ο ι ρ 
Mice receiving IgG followed by IL-1 were protected significantly in comparison to mice 
receiving IgG followed by inactivated IL-1 (χ2=6 63, p=0 01) 
Mice receiving ALVA-42 followed by IL 1 were protected significantly in comparison to 
mice receiving ALVA 42 following inactivated IL 1 (χ2=3 86, p=0 05) The difference in 
survival between IL 1 treated mice pretreated with ALVA 42 or control IgG is not 
significant The survival of IL 1 treated mice pretreated with 35F5 does not differ 
significantly from that in mice pretreated with inactivated IL-1 and pretreated with 
either 35F5 or control IgG (10-11 mice/group) 
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These results suggest a potential role for the type I receptor in the IL-1 
induced protection to infection. The IL-IRa, however, is not completely 
specific for the type I IL-1R, since it also binds to the murine IL-1RII, be 
it with a much lower affinity (18, 30, 31). Therefore, complete inhibition of 
the IL-1 effect using even higher doses of IL-IRa would not allow to 
distinguish between a complete effect via the type I receptor due to more 
effective blockade and an additional IL-1 effect via the type II receptor. 
In an alternative approach to establish the possible role of the type I or 
type II IL-1 receptor, we performed experiments with 35F5, a specific 
neutralizing rat anti-murine IL-1RI mAb (11), and ALVA-42, a mAb 
directed against the murine IL-1RII (5, 17). 
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Pretreatment with 35F5 (200 μg i.p.), 4 h before IL-1 was almost fully 
effective, reducing significantly the IL-1 induced enhanced survival 
(χ2=5.92, p<0.025) to nonsignificant protection (χ2=2.53, p=0.12; 12 
mice/group; not shown). 
When the same i.p. dose of 35F5 was administered 18 h before IL-1 it 
abrogated the IL-1 induced protection, corroborating the data obtained 
with the IL-IRa (Fig. IB). Survival after pretreatment of control-treated 
infected mice with either 200 μg r a t IgG or 35F5 did not differ 
significantly from survival after pretreatment with saline, and therefore 
only the saline-pretreated group is presented in Fig. IB. 
When pretreatment with either 35F5 or ALVA-42 was performed within 
one experiment, the complete inhibition of the IL-1 effect by 200 μg 35F5 
administered 18 h before IL-1 was confirmed, whereas no effect was 
observed with 200 μg of ALVA-42, a dose reported to be effective in 
reduction of LPS lethality (5, 17) (Fig.lC) 
Survival of mice which received heat-inactivated IL-1 and pretreatment 
with either rat IgG, 35F5 or ALVA-42 dit not differ from that of mice 
treated with inactivated IL-1 and pretreated with murine IgG; therefore 
in Fig.lC only the latter group is shown. Since survival of IL-1 treated 
mice pretreated with rat IgG did not differ significantly from that in mice 
pretreated with murine IgG, only the latter group is presented. 
Effect of163-171 peptide pretreatment on survival of infection 
Next, we investigated the effect of the nonapeptide fragment (163-171) of 
human IL- Iß, which lacks a series of the inflammatory and acute phase 
effects of the entire molecule, but possesses a range of immuno-
stimulating effects via non-IL-lR-mediated pathways (2, 7, 8). 
Whereas significant protection was produced by i.p. injection of 800 ng 
IL-1 into neutropenic mice 24 h before a lethal P. aeruginosa infection, 
i.p. pretreatment with nonapeptide doses varying from 1 to 320 μg (a 21 to 
6,800 -fold molar excess over IL-1), which have been found effective by 
others (7, 36, 41), did not enhance survival (not shown). Combined i.p. 
administration of the same doses of the nonapeptide and 800 ng of IL-1 
i.p. did not affect the IL-1 -induced protection to infection (not shown). 
Effect of IL·! pretreatment on liver enzymes after infection 
For as ses sment of liver injury in infected mice, a s p a r t a t e 
aminotransferase (ASAT) and alanine aminotransferase (ALAT) levels 
were determined in sera obtained from IL-1 pretreated and control-
treated neutropenic mice 24 h after a lethal i.m. P. aeruginosa 
challenge, a time point at which no mice had yet succumbed. As shown 
in Fig. 2, serum ALAT concentrations are significantly reduced in the 
IL-1 pretreated group as compared to the control group. 
Histopathology 
Neutropenic mice received IL-1 or control pretreatment 24 h before 
infection with P. aeruginosa at time zero. Survival, scored for 48 h, was 
significantly enhanced in IL-1 pretreated mice, confirming the 
140 
MEDIATING RECEPTOR AND PATHOLOGY 
2000Γ 
J 
Ρ 
1000 
• ASAT 
0 ALAT 
control IL-1 
pre treatment 
Fig. 2. Median serum ASAT and ALAT concentrations measured 24 h after a lethal 
i.m. P. aeruginosa challenge at time zero in mice pretreated at t=-24 h with 800 ng i.p. 
or inactivated IL-1. The difference in ASAT concentrations between the two 
pretreatment groups is not significant, whereas the difference in ALAT concentrations 
is significant (p=0.0095) (7-9 mice/group). 
effectiveness of the IL-1 pretreatment (χ2=6.88, p<0.01; 15 mice/group; 
survival curve not shown). After 48 h post infection no further deaths 
occurred. After death, organs were removed, processed for histology as 
described in the Materials and Methods section and examined 
histopathologically. Since the mice died in a time span of only 18 h, and 
no difference in severity or frequency of lesions was found between these 
mice within each pretreatment group, the time point of demise of mice 
was not considered in the statistical evaluation of the histopathological 
results. The mice that survived the infection (2 in the control group and 8 
in the IL-1 group) were sacrificed 10 days after infection for evaluation of 
histopathology. Histopathologic data from mice that succumbed within 48 
hours after infection and from surviving mice sacrificed 10 days after 
infection are summarized in table 1. In general, despite the profound 
neutropenia, in both pretreatment groups neutrophil accumulations 
could be observed in all organs. Organs most seriously affected in mice 
that had died from the infection were the lungs and liver. In the 
surviving mice sacrificed after 10 days, most pathological changes were 
found in the lungs, brains and kidneys. 
In the liver of mice that died within 48 hours after infection, the overall 
difference in morphologic changes between the IL-1 treated group and 
the control group was significant (p=0.02); these differences included 
glycogen depletion, fatty degeneration of parenchymal cells and 
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hepatocyte necrosis, which all were less frequent in the IL-1 pretreated 
group. In surviving mice sacrificed after 10 days, glycogen depletion and 
fatty degeneration of parenchymal cells were rarely observed. 
Extramedul lary erythropoiesis was found independent of IL-1 
pretreatment in mice that survived for 10 days. Occasionally petecchiae 
were seen in the liver of the control mice. 
The lungs of mice that died within 48 hours after infection exhibited an 
emphysema-like picture, with a simplification and loss of the acinar 
s t ructure of the alveolar duct. Parenchymal infil tration with 
inflammatory cells, particularly PMN, were frequently observed and 
caused enlargement of the parenchymal area. Infectious lesions with 
bacteria and tissue necrosis were sometimes seen. As a result of tissue 
necrosis and petecchiae, enhanced phagocytosis with hemozoin 
containing macrophages were found. The pathological changes exhibited 
a lobular distribution. Inflammatory reactions were still present in mice 
that survived for 10 days after infection and were independent of IL-1 or 
control treatment. 
Spleens of both IL-1-treated and control mice dying from infection often 
displayed depletion of the red pulp in the cortical area, and involution of 
the white pulp. In spleens from surviving mice sacrificed 10 days after 
infection, however, erythropoiesis was usually increased. Probably in 
relat ion to the presence of petecchiae, occasionally enhanced 
phagocytosis with macrophages containing hemozoin was found. 
In the kidney, in mice dying within 48 hours after infection as well as in 
mice sacrificed on day 10 after infection the most frequent observation 
was glomerular infiltration with predominantly neutrophils. In both 
pretreatment groups, tubular necrosis occurred in about half of the mice, 
also in the mice that had survived, and petecchiae were occasionally 
found. The only type of lesion observed in the brain were petecchiae, both 
in mice dying of the infection and, less severely, in surviving mice 
sacrificed after 10 days. In the heart, no histopathological changes were 
observed in mice dying within 48 hours or in mice sacrificed after 10 days 
in both treatment groups. 
Representative histological sections of livers and lungs of mice that died 
within 48 hours after infection from both experimental groups are shown 
in Fig. 3. 
Fig. 3. A. (p.143, 144). Liver after demise of infection after control pretreatment 
(periodic acid Schiff staining; 350x). Nuclear pyknosis and strong fatty degeneration of 
parenchymal cells are present. B. Liver after demise of infection after IL-1 
pretreatment (periodic acid Schiff staining; 450x). Both normal areas and areas with 
fatty degeneration of parenchymal cells can be seen. No nuclear pyknosis is present. 
C. Lung after demise of infection after control pretreatment (periodic acid Schiff 
staining; 250x). Strong infiltration and simplification of alveolar structure are present. 
D. Lung after demise of infection after IL-1 pretreatment (periodic acid Schiff staining; 
160x). A much lesser degree of infiltration is present, and the structure of the alveolar 
ducts is more or less intact. 
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Table 1. (p. 145). Histopathologic data from neutropenic mice receiving i.p. IL-1 or 
control treatment 24 h before i.m. infection with P.aeruginosa (time zero). The effect of 
IL-1 treatment was analyzed in mice succumbing within 48 hours after infection as well 
as in surviving mice sacrificed 10 days after infection. Statistical analysis was 
performed in the group that died within 48 hours after infection and in the total group. 
DISCUSSION 
In this study, we found that the type I and not the type II IL-1 receptor 
mediates the protective effect of rhIL-lß in lethal P. aeruginosa infection 
in neutropenic mice. 
The role of the IL-1RI was first investigated using the IL-IRa, a 
competitive inhibitor of IL-la and IL-Iß binding to mainly the IL-1RI (3, 
18). A 1,000-fold molar excess of IL-IRa over IL-1 partially blocked the IL-
1 induced protection. Since high doses of the IL-IRa may also block IL-1 
effects via the type II IL-1 receptor (4, 30), which has much less affinity 
for the IL-IRa, studies with higher doses of the IL-IRa would not 
differentiate between more effective blockade of IL-1 effects via type I 
receptors or a partial effect of IL-1 via the type II receptor. Therefore, we 
used 35F5, a specific neutralizing antibody directed against the murine 
IL-1RI (11). Pret reatment with 35F5 annihilated the IL-1 induced 
protection to infection, suggesting that this IL-1 effect is mediated via 
cells bearing the type I receptor. The complete lack of reduction of the IL-
1-induced enhanced survival by pretreatment with ALVA-42, which is 
reported to block the type IIIL-1R, (5, 17) underscores the role of the type I 
receptor. However, a recent report (16) suggests that this antibody does 
not bind to the type II receptor, which may be another explanation of the 
lack of effect. Neta et al (33) also found that radi opro tection induced by IL-
1 pretreatment could be blocked by the 35F5 antibody, suggesting that the 
type I IL-1R was mediating this response. The key role of the IL-1RI is 
corroborated by the recent study of Sims et al (40) reporting that the IL-1 
induced signal transduction is mediated exclusively via this receptor. 
Which type of IL-lRI-bearing cells play a role in the IL-1-induced 
protection remains to be clarified. Our previous report (47) on a role of 
acute phase proteins, produced by hepatocytes, which bear the IL-1RI 
(30), is in accordance with the findings of this study. The same holds for 
induction by IL-1 of TNFct, which may be produced by endothelial cells, 
fibroblasts and by monocytes via small quantities of type I IL-IRs (40), and 
which has been shown to play some role in our protection studies (48). It 
is of interest tha t neither IL-IRa nor 35F5 alone were able to affect 
survival, as has been found in other studies (1, 30). However, this may 
largely be explained by the single administration and the short half life of 
these reagents. 
The IL-1 induced enhanced survival of infection could not be mimicked by 
the nonapeptide fragment (161-173) of rhIL-lß. This immunostimulatory 
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domain of rhIL-lß lacks inflammatory effects like pyrogenicity, induction 
of prostaglandins, IL-6, glucocorticosteroids, and acute phase proteins (2, 
7). Boraschi et al. recently reported that the nonapeptide enters the cell 
through a receptor-independent mechanism, possibly by passive diffusion 
through the cell membrane (8). This would be in accordance with the role 
of IL-lRI-mediated signal transduction pathway of the IL-1 effect in our 
studies. 
Histopathologic evaluation of organs of the neutropenic mice that had 
died from P. aeruginosa infection showed that the lungs and the liver 
were most severely affected. IL-1 pretreatment significantly reduced liver 
lesions, and the pathologic alterations of the spleen were prevented to an 
extent on the margin of significance. In the present study the protective 
effect of IL-1 on pathological changes in organs is probably 
underestimated, since only IL-1 pretreated mice that had died from the 
infection, and most likely had more severe pathology, were considered, 
whereas the large proportion of IL-1 treated mice that survived the 
infection, and probably had less severe lesions, were not taken into 
account. Thus, in previous studies where a somewhat lower infectious 
challenge, we found a clear reduction of frequency of hemorrhages in all 
organs but the brain in the IL-1 treated group, when IL-1 and control-
treated mice were all sacrificed 30 h after infection (46). 
The finding of IL-1-induced protection against liver damage after 
infection (i.e., less glycogen depletion, fatty degeneration and cell 
necrosis) fits with the finding of lower serum concentrations of ASAT 
and ALAT, markers of hepatocyte necrosis. Such protection is 
reminiscent of the IL-1-induced protection against acetaminophen-
induced hepatotoxicity (38). 
The mechanism of the IL-1 induced protection of liver hepatocytes and 
cells in other organs remains to be elucidated. An excess of cytokines and 
more distal inflammatory mediators like leukotrienes, platelet-activating 
factor, nitric oxide and superoxide radicals produced during lethal 
infection may be responsible for many pathologic phenomena (12, 28). 
Recently, we were able to show that IL-1 pretreatment reduces cytokine 
production (49), and a role of this mechanism in the ameliorated 
pathological changes is likely. On the other hand, antagonists of 
leukotrienes, prostaglandins and platelet activating factor were found not 
to affect IL-1-induced protection (48). In addition, IL-1 pretreatment 
might induce protection via desensitisation of the host to the overshoot of 
cytokines and inflammatory mediators (9, 10, 50). Such desensitization 
may occur either by induction of protective substances like acute phase 
proteins, soluble cytokine receptors or receptor antagonists (27, 47, 50), by 
downregulation of cytokine receptors or by induction of intracellular 
protective proteins like MnSOD, heat shock proteins or other protective 
proteins in target cells (22, 26, 35). 
Since the liver has a crucial role in production of acute phase proteins, in 
detoxification of substances like leukotrienes (19) and in clearance of 
cytokines (14), the protective effect of IL-1 on hepatocytes that we found is 
likely to be physiologically relevant in the enhanced survival of mice. Also 
the observations that hepatectomized animals are much more sensitive to 
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lethal effects of LPS-conditioned sera (15), and that pretreatment with D-
galactosamine, a hepatospecific RNA synthesis inhibitor sensitizes to 
TNF-induced lethality (25) corroborate this assumption. 
In conclusion, the IL-1 induced protection to P. aeruginosa infection in 
neutropenic mice seems to be mediated via the type I IL-1 receptor. The 
nonapeptide fragment of rhIL-lß is not protective. The IL-1-induced 
protection is associated with significant reduction of histopathologic and 
biochemical signs of hepatocyte damage, possibly reflecting the IL-1 
induced reduction of cytokine overshoot during infection. 
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SUMMARY AND CONCLUSIONS 
SUMMARY AND CONCLUSIONS. 
In spite of the availability of a large armator ium of powerful 
antimicrobial drugs, the treatment of serious infections, such as Gram-
negat ive s e p t i c a e m i a , r e m a i n s a problem, especia l ly in 
immunocompromised patients. Therefore, an alternative approach, 
namely efforts to strengthen host defense is at tract ing ever more 
attention. Since the beginning of the century, researchers have tried to 
enhance nonspecific resistance of the host to a variety of micro­
organisms. Administration of killed microorganisms like mycobacteria 
and Candida albicans, or of bacterial products like endotoxin 
(lipopolysaccharide, LPS), muramyl peptides and protodyne could 
augment non-specific resistance to infection. However, the toxicity of 
these substances precluded use in human medicine. It was shown that 
these microbial immunostimulants are able to induce cytokines, small 
peptides which function as autocrine and intercellular messengers, such 
as interleukin-1 (IL-1), tumor necrosis factor (TNF), and interferon-γ 
(IFNy). Subsequenly, it was shown that these substances were able to 
induce increased nonspecific resistance to infection. The finding that IL-
1 could enhance resistance to infection in mice was the starting point of 
this thesis. 
Interleukin-1 is the collective name for two 17-kDa polypeptides, IL-la 
and IL-ip, which are coded for by different genes. Despite their limited 
amino-acid homology (26%), they bind to the same cellular receptors and 
the biological effects of IL-la and IL-lß are virtually the same. IL-1 is a 
key mediator of inflammation, tissue injury and immunological 
reactions, and has multiple biological effects, including several 
haematologic and metabolic changes typical of host responses to infection 
(fever, neutrophilia, hypoferremia, synthesis of hepatic acute phase 
proteins and of glucocorticosteroids). In mice, pre t rea tment with 
nanogram quantities of IL-1 has been shown to protect to a variety of 
micro-organisms, including Gram-positive and Gram-negative bacteria, 
fungi, protozoa and viruses. Therefore, IL-1 would be an excellent 
candidate treatment modality for enhancement of nonspecific resistance 
in humans. However, in humans also administration of IL-1 has met 
with side effects, such as fever, chills, anorexia, myalgia and 
hypotension. Despite these side effects, IL-1 is currently being 
investigated as a drug in cancer treatment, e.g. as a stimulant for 
megakaryopioesis. 
For application of IL-1 in treatment or prevention we should understand 
the mechanism of the IL-1-induced enhanced nonspecific resistance. 
Knowledge of the mechanisms behind these effects of IL-1 would possibly 
enable us to design other, less toxic treatment modalities. Therefore, the 
investigations in this thesis were designed to elucidate mechanisms of 
IL-1 induced enhanced resistance to Gram-negative infection. Previously 
established models were used, namely the enhancement of survival after 
pretreatment with 30 μg/kg of human recombinant IL-lß administered 
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intraperitoneally (i.p.) 24 h before a lethal intramuscular (i.m.) challenge 
with Klebsiella pneumoniae (in normal mice) or Pseudomonas 
aeruginosa (in severely neutropenic mice, which possess very low 
numbers of neutrophils). 
Chapter 2 presents an overview of immune modulators which enhance 
nonspecific resistance to infection. Immunostimulatory effects are 
discussed of bacterial products and of several cytokines which mediate 
their effects, including IL-1, IL-2, TNFa, interferons, and colony 
stimulating factors. 
Some mechanisms of IL-1-induced resistance had already been excluded. 
IL-1 does not possess a direct antimicrobial effect. It is not likely that IL-1 
exerts its effect by activation or enhanced accumulation (Chemotaxis) of 
neutrophils, cells important for bacterial clearance (phagocytosis and 
killing of pathogens). Arguments against this mechanism are the 
effectiveness of IL-1 in neutropenic mice, and, according to the majority 
of publications, the similar neutrophil counts as well as bacterial counts 
in organs from IL-1 treated and control mice. IL-1 does not induce 
protection by acceleration of bone marrow restoration in neutropenic 
mice either. Also, IL-1-induced fever does not play a role. Although LPS 
protects to some extent via reduction of serum iron, necessary for the 
growth of many bacteria, IL-1 treatment was not associated with 
hypoferremia. 
Chapter 3 discusses the possible role of interleukin-8 (IL-8), a cytokine 
which is produced by macrophages and other cells shortly after IL-1 
injection, in the IL-1-induced protection of normal and neutropenic mice 
against infection with Gram-negative bacteria. IL-8 induces neutrophil 
Chemotaxis and activation, including an oxidative burs t and 
degranulat ion. Administration of IL-8 24 h before a lethal K. 
pneumoniae challenge of non-neutropenic mice or a lethal P. 
aeruginosa challenge in neutropenic mice did not reproduce the IL-1 -
induced enhanced survival. These findings argue against a role of IL-8 in 
this IL-1 effect, and represent another argument against a role of 
neutrophils in the IL-1-induced enhanced survival. 
However, a protective effect of IL-8 was observed in non-neutropenic mice 
when IL-8 and bacteria were simultaneously present at the same site. No 
differences in leukocyte and bacterial counts were found. The 
administered IL-8 may inhibit local neutrophil adhesion to endothelial 
cells activated as a consequence of the bacterial challenge, thus reducing 
inflammatory damage from a neutrophil-endothelial cell interaction. 
An unexpected detrimental effect of IL-8 was observed when IL-8 was 
administered i.p. shortly before (neutropenic mice) or 6 h after (all mice) 
i.p. bacterial challenge. In these cases, similar bacterial counts were 
found in vitro as well as in vivo after IL-8 exposition, arguing against a 
role of IL-8 as a bacterial growth factor. Similar neutrophil counts and a 
more pronounced harmful effect of IL-8 in severely neutropenic mice 
than in normal mice suggest that a chemotactic and neutrophil-
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activating effect resulting in excessive release of toxic neutrophil 
secretory products is probably not responsible. The most likely 
explanation for the IL-8-induced reduced survival is participation of IL-8 
in "lethal cytokinemia", i.e., an overshoot of production of cytokines and 
secondary inflammatory mediators like leukotrienes and oxygen 
radicals, which is thought to cause morbidity and demise. The 
observation of more pronounced brain hemorrhages in IL-8-treated 
animals is in agreement with this hypothesis. 
In conclusion, although deleterious as well as beneficial effects of IL-8 on 
survival are possible, depending on time and place of injection and 
numbers of neutrophils, the lack of effect of IL-8 administration in our 
mouse model pleads against a role of IL-8 in IL-1-induced protection. 
Chapter 4 evaluates the role of glucocorticosteroids in IL-1-induced 
enhanced resistance to lethal K. pneumoniae and P. aeruginosa 
infections of normal and neutropenic mice, respectively. IL-1 activates 
the pituitary-adrenal axis, resulting in increased plasma levels of 
adrenocort icotrope hormone (ACTH) and cort icosterone, a 
glucocorticosteroid. Glucocorticosteroids, hormones produced after 
many forms of stress, possess several potentially protective effects, e.g. 
they control the overshoot of normal defense reactions after infection and 
injury, inhibiting production of cytokines and other inflammatory 
mediators. In fact, high doses of glucocorticosteroids have been shown to 
increase survival of septic animals. IL-1-induced corticosterone patterns 
were assessed in both normal and neutropenic mice at 24 hrs after IL-1 
administration, the time of inoculation of the bacteria. When these 
corticosterone peaks were subsequently simulated by injection of 
synthetic human ACTH 1-24, however, the ILl-induced enhanced 
survival was not reproduced, a rgu ing a g a i n s t a role of 
glucocorticosteroids in this IL-1 effect. Corticosterone concentrations 
were also assessed during the course of infection. These were 
significantly lower in IL-1 pretreated mice, probably reflecting the better 
physical condition of these mice. 
The role of acute phase proteins, IL-6 and of glucose homeostasis in IL-1-
induced protection to Gram-negative infection is described in Chapter 5. 
Sets of acute phase proteins (APP) are produced by hepatocytes after 
stimuli like IL-1, IL-6 and TNFa within a time course similar to that 
required for the induction of protection to a lethal infection elicited by IL-
1. APP possess several anti-inflammatory and detoxifying effects. For 
example, they may act as oxygen radical scavengers, protease inhibitors, 
coagulation factors and opsonins, and hence play a role in the nonspecific 
defense of the host to infections. IL-1-induced enhanced survival was 
associated with increased production of acute phase proteins, as assessed 
by production of serum amyloid A (SAA) and fibrinogen. D-
galactosamine (GALN), a specific inhibitor of liver protein synthesis, 
inhibited production of SAA and fibrinogen, and virtually completely (P. 
aeruginosa) or partially (K. pneumoniae) inhibited the IL-l-induced 
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enhanced survival, whereas GALN injection per se did not affect 
survival. Therefore, acute phase proteins seem to play a critical role in 
the IL-1 induced protection to infection. 
IL-1 induces IL-6 in many types of cell, and several effects of IL-1 have 
been reported to be mediated by IL-6. IL-6 exerts potentially protective 
effects, including induction of a series of acute phase proteins. However, 
several observations plead against a role of IL-6 in the IL-1-induced 
enhanced resistance to infection. First, although GALN inhibited IL-1-
induced protection, it did not inhibit IL-1-induced IL-6 production. 
Second, pretreatment of infected mice with a broad range of doses of 
human as well as murine IL-6 did not reproduce the IL-1-induced 
protection, despite the larger IL-6 peak in mice after IL-6 treatment than 
after IL-1. Also a synergistic effect between IL-1 and IL-6 did not occur. 
IL-1 exerts effects on glucose homeostasis on several levels and in 
different ways. On one hand, insulin-inducing and insulin-like effects 
would lead to hypoglycemia, on the other hand toxic effects of higher 
doses of IL-1 on pancreatic ß-cells and the induction by IL-1 of glucagon 
and stress hormones would increase plasma glucose levels. Glucose 
concentrations after infection were somewhat lower in control mice, but 
they never fell to hypoglycemic values. These data suggest that in IL-1-
induced enhanced resistance to infection IL-1 effects on glucose 
homeostasis and on IL-6 production are not involved, but that this IL-1 
effect is at least partially mediated by GALN-inhibitable proteins, most 
conceivably hepatic acute phase proteins. 
In C h a p t e r 6 the role of several inflammatory mediators induced by IL-1 
has been investigated, i.e. tumor necrosis factor α (TNFa), granulocyte-
macrophage colony-stimulating factor (GM-CSF), platelet-activating 
factor (PAF) and arachidonic acid metabolites (prostaglandins and 
leukotriene B4). These mediators have several potentially protective 
effects. GM-CSF stimulates hematopoiesis, activates macrophages and 
neutrophils and induces several other inflammatory mediators. 
Eicosanoids possess cytoprotective effects, and regulate numerous 
aspects of macrophage cell function, including cytokine gene expression 
and differentiation. Also PAF influences cytokine production, and 
enhances cytotoxicity of several types of cell. TNFa possesses many effects 
similar to IL-1, including induction of acute phase proteins, induction of 
several secondary inflammatory mediators, and reduction of effects of 
overshoot of inflammatory mediators during the lethal phase of infection. 
Administration of a dose range of GM-CSF expected to be physiologically 
relevant did not reproduce the IL-1 -induced protection to infection. When 
IL-1-treated mice were pretreated with neutralizing doses of a selective 
PAF receptor antagonist, selective inhibitors of leukotriene biosynthesis 
or of several cyclooxygenase inhibitors, the enhanced survival induced by 
IL-1 was not diminished, arguing against a role of these mediators in IL-
1-induced protection. Pretreatment with a low dose of murine TNFa 
enhanced survival of infection, whereas the same dose of human TNFa 
produced no effect. Pretreatment with a low dose of a rat-anti-murine 
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TNFa monoclonal antibody at 3 h before IL-1 tended to inhibit the IL-1-
induced protection. These results suggest tha t the IL-1-induced 
nonspecific resistance is partially mediated by induction of TNFct. 
Paradoxically, pretreatment with a higher dose of this antibody showed a 
dose-related protective effect per se, which could be further enhanced by 
a suboptimal dose of IL-1. A combination of optimal doses of anti-TNFct 
and IL-1 did not further enhance survival, indicating a similar 
mechanism of protection. The protection induced by this high dose of 
anti-TNFct was similar when it was administered at 3 h before IL-1 (27 h 
before infection) and at 3 h before infection, suggesting an effect in the 
phase of infection. The most likely explanation of these findings is that 
the mechanism of protection of IL-1 as well as of anti-TNFct involves an 
attenuation of deleterious effects of overproduced inflammatory cytokines 
like TNFa ("lethal cytokinemia") during lethal infection. 
In Chapter 7, it was investigated whether the IL-1-induced protection to 
infection occurs by interference with the detrimental effects of excessive 
production of cytokines during infection, referred to as "lethal 
cytokinemia". Counterrregulatory mechanisms against deleterious 
effects of cytokines are theoretically possible at several levels. Cytokine 
production may be inhibited, and host sensitivity for cytokine effects may 
be reduced by production of endogenous inhibitors, or by tolerance of 
target cells, for example by down-regulation of cytokine receptors. For 
studies on these mechanisms, sensitive and specific radioimmunoassays 
were developed for murine IL-la, IL-lß and TNFa. Also an additional 
animal model was used, i.e., СЗН/HeJ mice; these mice produce only 
very low amounts of cytokines after administration of lipopolysaccharide, 
the most important cytokine-inducing part of Gram-negative bacteria, as 
compared to СЗН/HeN mice, their normal littermates. In Swiss and 
СЗН/HeN mice, IL-1-induced enhanced survival was associated with 
reduced circulating TNFa and IL-6 concentrations after infection, as well 
as with reduced LPS-stimulated production of IL-1 and TNFa by 
macrophages ex vivo. If reduction of endogenous cytokine production 
would be the principal mechanism of IL-1-induced protection, IL-1-
induced enhanced survival should not occur in СЗН/HeJ mice. The 
findings in СЗН/HeJ mice are in accordance with this assumption: in 
these mice, a lack of an IL-1-induced protective effect was associated with 
low cytokine concentrations in vivo and low production capacity ex vivo. 
In addition, both IL-1-induced enhanced survival of infection and IL-1-
induced reduction of in vivo and ex vivo cytokine production showed a 
step-wise increase for СЗН/HeJ, СЗН/HeN and Swiss mice. These results 
indicate that a reduction of cytokine production by IL-1 pretreatment 
plays a role in the enhanced resistance to infection. 
In several organs of IL-1 treated mice, an upregulation of mRNA for the 
IL-1 receptor antagonist (IL-IRa) was observed at the time of infection. 
This molecule functions as a competitive inhibitor of IL-1 effects, and 
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hence this upregulation may represent another possible mechanism of 
IL-1-induced protection to infection. 
Two forms of both IL-1 receptors and TNF receptors have been fully 
characterized. At the time of infection, steady state mRNA for the type I 
IL-1 receptor (IL-1RI) and the type I TNF receptor (TNFRI), which, 
according to the literature, represent the principle biologically relevant 
receptors for IL-1 and TNFct, respectively, were downregulated, 
suggesting desensitisation of target cells to be an additional mechanism 
of IL-1-induced protection. In the liver, however, a clear upregulation of 
IL-1RI and TNFRI mRNA was present at 24 h after IL-1 treatment, and 
in the kidney an upregulation was observed for the TNFRI. Since the liver 
and kidneys are important clearance organs for TNFa and IL-1, the 
observed upregulation may be involved in IL-1-induced enhanced 
survival. The upregulated IL-1R1 in the liver may also be advantageous 
by augmenting acute phase protein induction. In addition, since IL-1 
ameliorates the biochemical and histological signs of liver damage 
(Chapter 9), increased IL-1R on hepatocytes may be related to this 
beneficial effect. 
In Chapter 8, a possible role of macrophages in the protection induced by 
i.p. IL-1-pretreatment was investigated by selectively depleting these cells 
using diphosphonate containing liposomes (DMDPL). Intraperitoneal 
injection of DMDPL, which eliminate peritoneal, liver and spleen 
macrophages, abolished the IL-1-induced protection, whereas 
intravenously administered DMDPL, which deplete liver and spleen 
macrophages but not peritoneal macrophages, did not reduce this IL-1 
effect. These results indicate that macrophages present at the site of IL-1 
injection play a major role in the protective effect. Two important groups 
of macrophage products are reactive oxygen intermediates (ROI), e.g. 
superoxide, and reactive nitrogen intermediates (RNI), e.g. nitric oxide 
(NO) and its metabolite, nitrite. These substances possess antimicrobial 
effects, but overproduction is deleterious. The IL-1-induced protection 
was associated with somewhat enhanced secretion of nitrite but no effect 
on superoxide anion production by ex vivo s t imulated peritoneal 
macrophages from mice pretreated with IL-1. It is not likely, however, 
t ha t the role of macrophages in protection involves enhanced 
antimicrobial activity, in view of the similar bacterial counts in IL-1 
treated and control mice (Ch. 2). NO possesses some other potentially 
protective effects, e.g. inhibition of platelet activation and aggregation. 
Both the role of TNFa, a macrophage product (Ch. 6) and the IL-1-
induced reduction of cytokine production potential of peritoneal 
macrophages (Ch. 7), are in accordance with the observed role of 
peritoneal macrophages in IL-1-induced protection. 
Extending the research on cytokine inhibitors in Chapter 7, serum 
concentrations of soluble TNF receptors (sTNFRs) after infection were 
assessed. At early time points, sTNFRs were slightly enhanced in IL-1-
pretreated mice. At later time points, however, in these mice sTNFRs 
were reduced, and this finding is difficult to reconcile with a protection 
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against death. Whether this reflects a reduction of sTNFR-inducing 
inflammatory stimuli or reduced production of membrane TNFR (Ch.7) 
remains to be established. 
In Chapter 9, the role of the type 1 receptor (IL-1RI) and the IL-1RII in 
IL-1-induced protective activity is investigated. When a 1,000-fold molar 
excess of IL-IRa over IL-1 was administered, which mainly blocks IL-1 
effects via the IL-1RI, a partial inhibition of IL-1-induced enhanced 
survival was observed. Since high doses of the IL-IRa may also block IL-1 
effects via the IL-lRII, which has much lower affinity for the IL-IRa, 
higher doses of IL-IRa were not tested. 
Pretreatment with a specific neutralizing antibody to the IL-1RI, 
completely blocked the IL-1 effect. A nonapeptide fragment of IL-Iß, 
which possesses the immunostimulatory but not the inflammatory effect 
of the entire molecule and acts via a non-receptor-mediated signal 
transduction process, did not mimiek the IL-1-induced enhanced 
survival. These results suggest a principal role of the IL-1RI in IL-1-
induced enhanced resistance to infection. These results are in 
accordance with the observed role of APP (Ch. 5), which are produced by 
IL-1-bearing hepatocytes, and with a role of TNFa (Ch. 6), which is 
produced by many cell types, including IL-lRI-bearing endothelial cells 
and fibroblasts, and by monocytes and macrophages via small quantities 
of IL-1RI. The key role of the IL-1RI is corroborated by recent studies 
reporting that IL-1 signal transduction is mediated exclusively via this 
receptor. 
Histopathological evaluation of organs from IL-1-pretreated mice that 
had succumbed from infection showed some amelioration of morphology 
in several crucial organs, and significant amelioration of hepatic 
histology. This was associated with amelioration of biochemical indices of 
liver damage. These findings may reflect the induction of protective acute 
phase protein secretion reported in Ch. 5, as well as reduction of cytokine 
production and cytokine sensitivity and induction of cytokine inhibitors 
after infection by IL-1 pretreatment (Ch. 7). Preservation of liver function 
may also be important in clearance of cytokines and LPS and in 
detoxification of leukotrienes during infection. 
In conclusion, the research described in this thesis has identified several 
mechanisms of IL-1-induced protection to infection, and excluded others. 
Previous research had already excluded a direct antimicrobial effect of 
IL-1, and a role of neutrophils, fever, hypoferremia and enhanced bone 
marrow restoration after I L I pretreatment. The results presented in this 
thesis show that also IL-1-induced IL-6, IL-8, GM-CSF, PAF, LTB4, 
prostaglandins, superoxide, glucocorticosteroids, and effects on glucose 
homeostasis and on soluble TNFR do not play a role. 
Figure 1 shows a schematic representation of the pathways (upper part of 
the scheme) identified in this thesis of IL-1-induced protection to lethal 
infection (lower part of the scheme, represented in bold). 
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IL-1-induced protection is mediated via the type 1 IL-1 receptor. 
Macrophages present at the site of IL-1 injection are crucial for the effect. 
TNFa and acute phase proteins play a role in the IL-1 effect. The 
enhanced survival after IL-1 injection is associated with reduced plasma 
cytokine levels and with reduced cytokine production capacity of 
peritoneal macrophages. In addition, increased gene expression for the 
IL-IRa and reduced gene expression of the type 1 receptors for IL-1 and 
TNF are likely to play a role. 
A view on the observed mechanisms of IL-1 protection shows that the IL-
1-induced enhanced resistance to infection to the host in our model of 
Gram-negative infection is multifactorial, and not effected by strictly 
enhancing one aspect of host defense. All observed mechanisms can be 
reconciled with the concept that pathology and death are caused not 
merely by microorganisms themselves, but also by an overshoot of host 
defense reactions culminating in "lethal cytokinemia", on which IL-1 
pretreatment exerts a dampening effect. 
A role of IL-1-induced NO production should be further investigated. It is 
possible that, in addition to reduction of cytokines, also ROI and other 
inflammatory mediated are reduced in IL-1-pretreated infected mice. 
Also measurement of plasma and tissue concentrations of the murine 
IL-IRa protein should be performed. In line with recent developments, it 
would be of interest to include other regulators, e.g. IL-4, IL-10, IL-13 and 
leukemia-inhibiting factor in future studies. It would also be interesting 
to further study whether IL-1-induced intracel lular manganous 
superoxide dismutase and heat shock proteins, which are cytoprotective, 
play a role. 
In view of the toxicity of IL-1 in humans and the neccessity of 
administration before infection, despite the clear enhancing effect on 
nonspecific resistance to infection, the future will have to learn whether 
treatment with this cytokine as a supplementation to antimicrobial 
therapy will find its way to clinical medicine. 
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Nonostante la disponibilità di una grande quantità di potenti antibiotici, 
la terapia per alcune tipologie di gravi infezioni, quali per esempio la 
sepsi Gram-negativa, rimane problematica, specie con quei pazienti che 
presentano un defecit del proprio sistema immunitario. Perciò una 
strategia terapeutica alternativa richiama sempre più attenzione, quella 
di rinforzare le difese immunitarie del soggetto. Già dall'inizio di questo 
secolo, ricercatori hanno provato a rinforzare la resistenza aspecifica, 
cioè la resistenza immediata del corpo verso una grande varietà di 
microorganismi. La somministrazione di microorganismi uccisi, per 
esempio micobatteri e Candida albicans, e anche di diversi prodotti 
batterici come endotossine (lipopolysacharide, LPS), murarmi peptidi e 
protodyne, potevano aumentare la resistenza aspecifica verso infezioni. 
Tuttavia, la tossicità di queste sostanze ne precludeva l'impiego nella 
medicina umana. Veniva dimostrato che la somministrazione di questi 
immunostimulanti di origine microbica poteva indurre la produzione di 
citokine, cioè piccoli peptidi che funzionano come messageri 
intercellulari, per esempio l'interleukine 1 (IL-1), tumor necrosis factor 
(TNF) e gamma-interferone (IFNy). Dopo veniva dimostrato che anche 
queste sostanze erano capaci di indurre una aumentata resistenza 
aspecifica alle infezioni. La scoperta della capacità di IL-1 a fare 
aumentare nei topi la resistenza alle infezioni costituiva il punto di 
partenza della presente ricerca. 
Interleukine-1 e il nome collettivo per due 17-kDa peptide, IL-Ια e IL-Iß, 
che vengono codati da geni diversi. Malgrado la limitata omologia sul 
livello di amino-acidi (26%), essi si combinano con gli stessi ricettori 
cellulari, e gli effetti biologici di IL-la e IL-lß sono quasi uguali. IL-1 è un 
mediatore chiave di infiammazione, di danneggiamento a tessuti e di 
reazioni immunologiche. IL-1 ha molti effetti biologici, incluso diversi 
alterazioni ematologici e metabolici tipici della risposta dell'ospite alle 
infezione (febbre, neutrofilia, ipoferremia, sintesi di "acute phase 
proteins" epatici e di glucocorticoidi). Nei topi è stato dimostrato che un 
pretrattamento con nanogram-quantità di interleukine-1 protegge contro 
una notevole varietà di microorganismi, incluso batteri Gram-positivi e 
Gram-negativi, funghi, protozoi e virus. Di conseguenza, l'IL-1 potrebbe 
essere un eccellente modo terapeutico per aumentare la resistenza 
aspecifica nell'uomo. Tuttavia anche la somministrazione di IL-1 ha 
prodotto effetti collaterali nell'uomo, come febbre, brividi, anoressia, 
mialgia e ipotensione. Nonostante questi effetti collaterali, attualmente 
l'effetto di IL-1 viene valutato nella terapia del cancro come stimolante 
della megakariopoiesi. 
Per poter applicare l'IL-1 in forma terapeutica о preventiva è necessario 
capire i meccanismi della aumentata resistenza aspecifica prodotta dall' 
IL-1. La loro conoscenza ci darebbe la possibilità di sviluppare metodi 
terapeutici diversi, possibilmente meno tossici. Perciò, la ricerca qui 
presentata è stata programmata per chiarire i meccanismi dell'aumento 
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della resistenza aspecifica verso i Gram-negativi indotti dall' IL-1. Come 
modello ne è stato usato uno già preesistente, cioè l'aumento di 
sopravvivenza dei topi dopo un pretrattamento con 30 μg/kg IL-lß, 
somministrato per via intraperitoneale (i.p.) 24 ore prima di una dose 
intramuscolare letale di Klebsiella pneumoniae (in topi normali) о 
Pseudomonas aeruginosa (in topi profondamente neutropenici, cioè con 
numeri di globuli bianchi (neutrofili) molto bassi). 
Nel Capitolo 2 si presenta una panoramica dei modulatori (sia prodotti 
batterici che citokini) del sistema immunitario che possono aumentare la 
resistenza aspecifica contro le infezioni. Inoltre vengono enumerati 
alcuni meccanismi potenziali dell'effetto di IL-1 sulla resistenza 
aspecifica già esclusi prima: IL-1 non ha un effetto diretto sui batteri in 
vitro, non funziona attraverso riduzione di numeri di batteri in vivo, о 
attraverso accelerazione del restauro del midollo osseo nei topi 
neutropenici. Nemmeno c'è un ruolo della febbre о della ipoferremia 
indotta da IL-1. 
Nel Capitolo 3 è stato studiato il ruolo di interleukine-8 (IL-8), un citokine 
che viene prodotto dopo la somministrazione dell' IL-1. IL-8 produce 
chemotassi ed attivazione di neutrofili, globuli bianchi che hanno un 
ruolo nella difesa contro microorganismi. La mancanza di effetto 
protettivo contro una infezione letale dopo un pretrattamento con IL-8 
anziché IL-1 suggerisce che l'effetto di IL-1 non viene effettuato via IL-8. 
Questo non significa che IL-8 non può avere un effetto protettivo in altre 
circostanze: in topi non-neutropenici, la somministrazione di IL-8 
simultaneamente alla dose letale di batteri prolungava la vita. Questo 
accade possibilmente attraverso l'inibizione della adesione di neutrofili 
all 'endotelio, così riducendo il danno infiammatorio prodotto 
dall'interazione neutrofilo-endotelio. In altre circostanze comunque, 
presentate in questo capitolo, IL-8 può avere persino un effetto negativo 
sulla soppravivenza di infezioni. 
Nel Capitolo 4 si valuta il ruolo dei glucocorticosteroidi, ormoni prodotti 
dalle ghiandole surrenali dopo iniezione di IL-1, nell'effetto protettivo di 
IL-1 nei modelli di infezione con K. pneumoniae e P. aeruginosa. 
Glucocorticosteroidi potrebbero mediare l'effetto protettivo dell' IL-1 
moderando la reazione eccessiva del corpo all'infezione ("citokinemia 
letale"), riducendo la produzione di citokini ed altri mediatori. 
Comunque, l 'osservazione che ACTH, un al t ro indut tore di 
glucocorticosteroidi, non riproduceva l'effetto protettivo contro infezioni di 
IL-1 suggerisce che questi ormoni non mediano questo effetto di IL-1. 
Il ruolo di "acute phase proteins", proteine epatiche con diversi effetti 
protettivi, e la mancanza di un ruolo dell'IL-6 e di alterazioni 
dell'omeostasi di glucosio vengono dimostrati nel Capitolo 5. Il blocco di 
produzione di "acute phase proteins" usando galactosamine quasi 
completamente annullava l'effetto protettivo dell' IL-1. La produzione di 
IL-6, invece, non veniva bloccata da galactosamine, e la 
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somministrazione di IL-6 non prolungava la vita dopo una infezione 
letale. 
Nel Capitolo 6 si esclude il ruolo di diversi mediatori infiammatori indotti 
dall' IL-1 (GM-CSF, PAF, prostaglandini, Leukotriene B4). TNFa, pero, è 
un mediatore parziale, perchè il pretrattamento con un anticorpo capace 
di bloccare TNFa prima della somministrazione di IL-1 diminuisce 
l'effetto protettivo di IL-1. Paradossalmente, dosi molto alte di questo 
anticorpo producevano un effetto protettivo per se, presumibilmente per 
l'interferenza con il ruolo di TNFa nella "citokinemia letale" svillupata 
durante l'infezione. 
Nel Capitolo 7 si dimostra che l'effetto protettivo del pretrattamento con 
l'IL-1 contro infezioni Gram-negativi letali occorre a t t raverso 
l'interferenza con effetti nocivi della "citokinemia letale", cioè gli effetti 
della produzione eccessiva di citokini dopo infezioni. Questa interferenza 
avviene a diversi livelli: dopo somministrazione di IL-1 A] la produzione 
di citokini è ridotta sia ex vivo (TNFa e IL-la) che in vivo (TNFa e IL-
6), B] l'espressione dei geni per i ricettori cellulari per IL-1 e TNFa è 
ridotta e C] l'espressione dei geni per IL-IRa, un inibitore competitivo 
degli effetti di IL-1, è aumentata in diversi tessuti al momento 
dell'infezione. 
Nel Capitolo 8 viene dimostrato il ruolo chiave di macrofagi presenti al 
luogo dell'iniezione di IL-1 nell'effetto protettivo di IL-1: depletamento di 
queste cellule usando liposomi contenenti diphosphonate eliminava 
l'effetto di IL-1. Dopo la somministrazione di IL-1, macrofagi isolati e 
coltivati avevano una capacità aumentata di produzione di RNI ma non 
di ROI (entrambi prodotti reattivi che hanno, tra l 'altro, effetti 
microbicidi). Un ruolo effettivo dell'aumento di RNI deve essere ancora 
dimostrato. Inoltre, è stato osservato un leggero però statisticamente 
significativo aumento di ricettori sciolti di TNFa, che avrebbero la 
capacità di inibire gli effetti di TNFa durante la "citokinemia letale". La 
leggerezza di questo effetto, comunque, rende un significato biologico 
improbabile. 
Nel Capitolo 9 il ruolo del ricettore cellulare tipo I per IL-1 (IL-lRI), e non 
del IL-1RII, nell'effetto di IL-1 sulla sopravivenza di infezioni viene 
dimostrato usando l'IL-lRa ed un anticorpo che blocca gli effetti dell IL-1 
attraverso l'IL-lRI. Un nonapeptide-frammento di IL-Iß, che possiede gli 
effetti immunostimolatori però non quelli infiammatori dell 'intera 
molecola, e che non agisce at t raverso i ricettori cellulari, non 
riproduceva l'effetto protettivo di IL-1. Esami istopatologici di topi morti 
dall'infezione dimostrava un miglioramento, specialmente nel fegato, nei 
topi che avevano ricevuto pretrattamento con IL-1. 
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In conclusione, nella presente ricerca sono stati identificati diversi 
meccanismi dell'effetto protettivo di pretrattamento con l'IL-1 contro 
infezioni, mentre altri meccanismi sono stati esclusi. Una scheda dei 
meccanismi identificati viene presentata a p. 162. 
Tutti i meccanismi osservati possono essere riconciliati con il concetto 
che nella patolofisiologia e nella morte di infezioni non soltanto la 
presenza di microorganismi è decisivo, però che ce anche una notevole 
importanza della reazione dell'ospite, che produce eccessive quantità di 
meditatori infiammatori, t ra l'altro citokini ("citokinemia letale"). 
Pretrattamento con IL-1 ha un effetto attenuante a diversi livelli su 
questa iperreazione. 
Visto la tossicità di IL-1 nell'uomo e la necessità di somministrarlo 
prima della infezione, malgrado l'evidente effetto positivo sulla resistenza 
aspecifica contro infezioni, il futuro ci insegnerà se il trattamento con 
questo citokine come supplemento alla terapia con antibiotici troverà una 
strada verso la medicina clinica. 
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Ondanks de beschikbaarheid van een grote variëteit aan antimicrobiële 
middelen blijft de behandeling van ernstige infecties, zoals Gram-
negatieve sepsis, een probleem, vooral in immuun-gecompromitteerde 
patiënten. Derhalve is er gaandeweg steeds meer belangstelling voor een 
alternatieve benadering, namelijk het versterken van de weerstand van 
de gastheer. Reeds vanaf het begin van deze eeuw hebben onderzoekers 
gepoogd om de niet-specifieke weerstand van de gastheer tegen een scala 
van micro-organismen te verhogen. Toediening van afgedode micro-
organismen, zoals mycobacteriën en Candida albicans, of van 
bacteriële producten als endotoxine (lipopolysacharide, LPS), muramyl 
peptiden en protodyne bleken de niet-specifieke weerstand tegen infecties 
te kunnen verhogen. Echter, ten gevolge van de toxiciteit van deze 
producten was gebruik in de geneeskunde niet mogelijk. Aangetoond 
werd dat deze microbiële producten leiden tot productie van cytokinen, 
kleine eiwitten die boodschappen aan andere cellen en aan de 
producerende cel zelf doorgeven. Voorbeelden van cytokinen zijn 
interleukine-1 (IL-1), tumor necrosis factor (TNF) en interferon-γ (IFN-
γ). Vervolgens werd aangetoond dat deze eiwitten de niet-specifieke 
weerstand tegen infecties kunnen verhogen. De bevinding dat IL-1 de 
weerstand tegen infecties in muizen kon verhogen was het startpunt 
van het in dit proefschrift beschreven onderzoek. 
Interleukine-1 is de collectieve naam voor twee 17-kDa eiwitten, IL-la en 
IL-Iß, die gecodeerd worden door verschillende genen. Ondanks hun 
beperkte overeenkomst van aminozuren (26%) binden ze aan dezelfde 
receptoren op cellen en hun biologische effecten zijn vrijwel identiek. IL-
1 speelt een sleutelrol in ontsteking, weefselschade en immunologische 
reacties. Het heeft verschillende biologische effecten waaronder 
hematologische en metabole veranderingen die typisch zijn voor de 
gastheerrespons op infecties (koorts, neutrofïlie, synthese van acute fase 
eiwitten en van glucocorticosteroiden). In muizen is aangetoond dat 
voorbehandeling met nanogram-hoeveelheden IL-1 tot bescherming 
tegen een scala van micro-organismen leidt, waaronder Gram-positieve 
en Gram-negatieve bacteriën, gisten, protozoën en virussen. Derhalve 
zou behandeling met IL-1 een aantrekkelijke therapiemogelijkheid 
vormen voor het versterken van de niet-specifieke weerstand in de mens. 
Maar ook IL-1 heeft in de mens wel enige bijwerkingen, zoals koorts, 
koude rillingen, spierpijn, gebrek aan eetlust en hypotensie. Ondanks 
deze bijwerkingen wordt momenteel onderzoek verricht naar het nut 
van IL-1 in de therapie van kanker als stimulator van megakaryopoiesis 
(bloedplaatjesaanmaak). 
Voor eventueel gebruik van IL-1 in therapie of preventie is opheldering 
van het mechanisme van de verhoging van de niet-specifieke weerstand 
door IL-1 wenselijk. Kennis hiervan zou van nut kunnen zijn voor het 
ontwikkelen van andere, minder toxische behandelingen. Om de 
mechanismen van de door IL-1 geïnduceerde verhoogde weerstand 
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tegen Gram-negatieve infecties te ontrafelen werden twee reeds bekende 
modellen gebruikt, waarbij de vergroting werd gemeten van de 
overleving van muizen als gevolg van een voorbehandeling met IL-1 (30 
μg/kg, intraperitoneaal, d.w.z. in de buikholte geïnjecteerd) 24 h voor 
een letale dosis met bacteriën. Klebsiella pneumoniae werd gebruikt bij 
normale muizen, en Pseudomonas aeruginosa werd toegediend aan 
ernstig neutropene muizen (deze bezitten zeer lage aantallen neutrofiele 
witte bloedcellen). 
Hoofdstuk 2 geeft een overzicht van immuunmodulators die de niet-
specifieke weers tand tegen infecties verhogen. De immuun-
stimulerende effecten van bacteriële producten en van verschillende 
cytokinen die deze effecten tot stand brengen worden besproken, 
waaronder IL-1, IL-2, TNFcc, interferonen en "colony-stimulating 
factors". Sommige mogelijke mechanismen voor de verhoogde 
weerstand die door IL-1 wordt geïnduceerd waren reeds uitgesloten. Zo 
heeft IL-1 geen direct effect op de infecterende bacteriën. Het is niet 
waarschijnlijk dat IL-1 werkt via activering of verhoging van de 
ophoping (Chemotaxis) van neutrofielen, cellen die belangrijk zijn voor 
bacteriële klaring (fagocytose en doden van micro-organismen). 
Argumenten tegen dit mechanisme zijn de effectiviteit van IL-1 in 
neutropene muizen, en, volgens het grootste deel van de publikaties, de 
even grote neutrofiel-aantallen en bacterie-aantallen in organen van IL-
1-behandelde en controlemuizen. IL-1 induceert zijn beschermend effect 
evenmin door het herstel van beenmergcellen in neutropene muizen te 
versnellen. Ook de door IL-1 geïnduceerde koorts is niet van belang voor 
de verhoogde weerstand. Ofschoon LPS, dat ook de niet-specifieke 
weerstand kan verhogen en onder andere IL-1 induceert, wel in enige 
mate werkt via de reductie van serum ijzer (nodig voor de groei van vele 
micro-organismen), ging behandeling met IL-1 niet gepaard met 
hypoferremie. 
Hoofdstuk 3 bespreekt de mogelijke rol van interleukine-8 (IL-8), een 
cytokine dat kort na IL-1 injectie wordt geproduceerd door macrofagen 
en andere celtypen, in de door IL-1 geïnduceerde weerstand tegen 
Gram-negatieve infectie in normale en neutropene muizen. IL-8 
induceert Chemotaxis en activering van neutrofielen, waaronder een 
"oxydatieve burst" (kortdurende productie van zeer reactieve zuurstof 
intermediairen) en degranulatie. Toediening van IL-8 24 h voor een 
letale K. pneumoniae infectie in niet-neutropene muizen, of van een 
letale P. aeruginosa infectie in neutropene muizen, kon de door IL-1 
geïnduceerde verhoogde overleving niet reproduceren. Deze bevindingen 
pleiten tegen een rol van IL-8 in het IL-1 effect en vormen een extra 
argument tegen een rol van neutrofielen in de door IL-1 geïnduceerde 
verhoging van de overleving van infecties. 
Echter, in niet-neutropene muizen werd een protectief effect van IL-8 
geobserveerd wanneer IL-8 en bacteriën tegelijkertijd op dezelfde plaats 
aanwezig waren. Er werden geen verschillen in bacterie- of witte 
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bloedcel-aantallen gevonden. Het toegediende IL-8 remt mogelijk de 
lokale hechting van neutrofielen aan endotheelcellen, die als gevolg van 
de bacteriële infectie geactiveerd werden, en leidt zo tot vermindering 
van de schade door ontsteking ten gevolge van een neutrofiel-
endotheelcel interactie. 
Een onverwacht verslechterend effect van IL-1 werd waargenomen 
wanneer IL-8 intraperitoneaal werd toegediend kort voor (bij neutropene 
muizen) of 6 uur na (bij alle muizen) een eveneens intraperitoneale 
bacteriële infectie. Hierbij werden na IL-8 behandeling zowel in vivo als 
in vitro even hoge bacterie-aantallen gevonden, hetgeen pleit tegen een 
rol van IL-8 als bacteriële groeifactor. De gelijke neutrofiel-aantallen en 
het sterkere negatieve effect van IL-8 in ernstig neutropene muizen in 
vergelijking met normale muizen pleiten tegen een rol van een 
chemotactisch en neutrofiel-activerend effect, waarbij overmatig 
toxische neutrofiel-producten zouden vri jkomen. De meest 
waarschijnlijke verklaring voor de verminderde overleving na IL-8 
behandeling is deelneming van IL-8 aan de "letale cytokinemie", d.w.z. 
de excess ieve p roduc t ie van cytokinen en s e c u n d a i r e 
ontstekingsmediatoren, zoals leukotrienen en zuurstofradicalen, van 
welke aangenomen wordt dat ze een rol spelen in ziekteverschijnselen 
en sterfte. De observatie van meer uitgebreide hersenbloedingen in IL-8-
behandelde muizen strookt met deze hypothese. 
Samenvattend kan gesteld worden, dat weliswaar zowel negatieve als 
positieve effecten van IL-8 op de overleving kunnen optreden, 
afhankelijk van tijd en plaats van injectie en van het aantal 
neutrofielen. Doch het ontbreken van een effect van IL-8 toegediend 24 
uur voor infectie pleit tegen een rol van IL-8 in ons model van door IL-1 
geïnduceerde bescherming. 
Hoofdstuk 4 evalueert de rol van glucocorticosteroiden in de door IL-1 
geïnduceerde verhoogde weerstand tegen letale K. pneumoniae en P. 
aeruginosa infecties in respectievelijk normale en neutropene muizen. 
IL-1 activeert de hypofyse-bijnieras, wat resulteert in verhoogde plasma 
concentraties van adrenocorticotroop hormoon (ACTH) en corticosteron, 
een glucocorticosteroid. Glucocorticosteroiden, hormonen die als gevolg 
van vele vormen van stress geproduceerd worden, hebben verschillende 
potentieel beschermende effecten: ze houden bijvoorbeeld excessieve 
afweerreacties na infectie en trauma onder controle door het remmen 
van de productie van cytokinen en andere ontstekingsmediatoren. Zo 
leidt het geven van hoge doses glucocorticosteroiden tot verhoging van de 
overleving van dieren met sepsis. Het door IL-1-geïnduceerde 
corticosteronpatroon werd gemeten in zowel normale als neutropene 
muizen op 24 uur na IL-1 toediening, het tijdstip van infectie met 
bacteriën. Echter, wanneer deze corticosteronpieken vervolgens 
nagebootst werden d.m.v. injectie met synthetisch ACTH χ.24 werd het 
IL-1 effect op de overleving niet waargenomen, hetgeen pleit tegen een 
rol van g l u c o c o r t i c o s t e r o i d e n in di t IL-1 effect. De 
corticosteronconcentraties werden tevens bepaald in de infectiefase. 
171 
Deze waren significant lager in muizen die voorbehandeld waren met 
IL-1; waarschijnlijk weerspiegelen ze de betere lichamelijke conditie 
van deze muizen. 
De rol van acute fase eiwitten en IL-6 en van glucose homeostase in de 
door IL-1 geïnduceerde bescherming wordt beschreven in Hoofdstuk 5. 
Levercellen (hepatocyten) produceren acute fase eiwitten na stimulatie 
door IL-1, IL-6 of TNFa binnen een zelfde tijdsbestek als dat nodig voor 
het induceren van bescherming tegen een letale infectie door IL-1. Acute 
fase e iwi t t en bez i t t en verschi l lende an t i -on t s t ek ings - en 
ontgiftigingseffecten. Zo kunnen ze werken als zuurstofradicaal 
wegvangers, proteaseremmers, stollingsfactoren en Opsoninen, en 
daardoor een rol spelen in de niet-specifieke weerstand van de gastheer 
tegen infecties. De door IL-1 geïnduceerde verhoogde weerstand tegen 
infecties was geassocieerd met verhoogde productie van acute fase 
eiwitten, waarbij gekeken werd naar serumamyloïd A (SAA) en 
fibrinogeenproductie. D-Galactosamine (GALN), een specifieke remmer 
van eiwitsynthese door de lever, remde de productie van SAA en 
fibrinogeen, en remde vrijwel geheel (P. aeruginosa) of ten dele (K. 
pneumoniae) de door IL-1 verhoogde weerstand, terwijl GALN injectie 
op zich de overleving niet beïnvloedde. Derhalve lijken acute fase 
eiwitten een cruciale rol te spelen in de door IL-1 geïnduceerde 
bescherming tegen infectie. 
IL-1 induceert IL-6 in veel celtypen en voor verschillende effecten van 
IL-1 is een rol van IL-6 als mediator beschreven. IL-6 oefent potentieel 
protectieve effecten uit, waaronder de inductie van een serie acute fase 
eiwitten. Verschillende waarnemingen echter pleiten tegen een rol van 
IL-6 in de door IL-1 geïnduceerde weerstand tegen infectie. Ten eerste 
remde GALN wel de door IL-1 geïnduceerde bescherming, doch het had 
geen effect op de door IL-1 geïnduceerde IL-6 productie. Ten tweede had 
voorbehandeling van geïnfecteerde muizen met een brede serie van 
doseringen met humaan of muis IL-6 niet het effect van de door IL-1 
geïnduceerde protectie, ofschoon hogere IL-6-concentraties in muizen 
optraden na IL-6 dan na IL-1 toediening. Ook trad er geen synergistisch 
effect op tussen IL-1 en IL-6. 
IL-1 oefent op verschillende nivo's en op verschillende wijzen een effect 
uit op de glucosehuishouding. Enerzijds zouden insuline-inducerende 
en insuline-achtige effecten leiden tot hypoglycémie, anderzijds zouden 
toxische effecten van hogere doses IL-1 op ß-cellen van de alvleesklier en 
de inductie van glucagon en stress hormonen door IL-1 de plasma 
glucoseconcentraties doen stijgen. 
De glucoseconcentraties na infectie waren in de controlemuizen lager 
dan in de IL-1 groep, doch bereikten nooit hypoglycemische waarden. 
Deze waarnemingen suggereren dat effecten van IL-1 op de 
glucosehuishouding en op IL-6 productie geen rol spelen in de 
verhoogde weerstand tegen infectie na IL-1 behandeling. Dit IL-1 effect 
wordt echter ten dele tot stand gebracht door acute fase eiwitten. 
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In Hoofdstuk 6 is de rol van verschillende ontstekingsmediatoren die 
door IL-1 geïnduceerd worden inderzocht, met name de tumor necrosis 
factor α (TNFa), de granulocyte-macrophage colony-stimulating factor 
(GM-CSF), en de eicosanoïden platelet-activating factor (PAF) en 
arachidonzuur metabolieten (Prostaglandinen en leukotriene B4 
(LTB4)). Deze mediatoren hebben verschillende beschermende effecten 
die mogelijk van belang zijn. GM-CSF stimuleert de hematopoiese 
(bloedcelaanmaak), activeert macrofagen en neutrofielen, en induceert 
verschillende andere ontstekingsmediatoren. Eicosanoïden bezitten 
cytoprotectieve (cel-beschermende) effecten en reguleren vele aspecten 
van de macrofaagfunctie, onder andere genexpressie van cytokinen en 
differentiatie. Ook PAF kan de cytokineproductie beïnvloeden en 
verhoogt de cytotoxiciteit van verschillende celtypen. Een groot deel van 
de effecten van TNFa overlapt die van IL-1, zoals de inductie van acute 
fase e iwi t t en , de induct ie van verschi l lende secunda i re 
ontstekingsmediatoren, en vermindering van de effecten van de 
overproductie van ontstekingsmediatoren gedurende de letale fase van 
infectie. 
Toediening van fysiologisch relevante doses GM-CSF bootste echter niet 
het beschermende effect van IL-1 op infectie na. Toediening, voor de IL-1 
behandeling, van neutraliserende doses van een selectieve PAF 
receptor-antagonist, van selectieve remmers van de leukotriene 
biosynthese of van verschillende cyclooxygenase remmers verminderde 
het effect van IL-1 behandeling op de overleving niet. Deze resultaten 
pleiten tegen een rol van deze mediatoren in het beschermende effect 
van IL-1. Voorbehandeling met een lage dosis muis TNFa verhoogde de 
overleving van infectie, terwijl dezelfde dosis humaan TNFa geen effect 
had. Voorbehandeling met een lage dosis van een monoclonaal 
antil ichaam tegen muis TNFa 3 uur voor IL-1 verminderde het 
beschermende effect van IL-1. Deze resultaten suggereren dat de 
versterking van de niet-specifieke weerstand door IL-1 deels teweeg 
gebracht wordt door inductie van TNFa. Ogenschijnlijk paradoxaal had 
voorbehandeling met een hogere dosis van dit antilichaam op zich al een 
dosisafhankelijk beschermend efect; dit effect kon verder verhoogd 
worden door een suboptimale dosis IL-1. Een combinatie van optimale 
doses anti-TNFa en IL-1 gaf geen verdere verhoging van de overleving, 
hetgeen wijst op een gelijksoortig mechanisme van bescherming door 
ant i-TNFa en IL-1. Het beschermend effect van deze hoge dosis anti-
TNFa, dat een halfwaardetijd van 24 uur heeft, was van gelijke omvang 
bij toediening 3 uur voor IL-1 (27 uur voor infectie) en bij toediening 3 
uur voor infectie; dit duidt op een effect in de fase van infectie. De meest 
waarschijnlijke verklaring voor deze bevindingen is, dat zowel het 
beschermende effect van IL-1 als dat van anti-TNFa een vermindering 
geeft van de schadelijke effecten van overgeproduceerde inflammatoire 
cytokinen, zoals TNFa ("letale cytokinemie"), gedurende ernstige 
infecties. 
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In Hoofdstuk 7 is verder onderzocht of het beschermende effect van IL-1 
tegen infecties optreedt door vermindering van de schadelijke effecten 
van overproductie van cytokinen gedurende infectie, de letale 
cytokinemie". Regelmechanismen om deze schadelijke effecten van 
cytokinen tegen te gaan zijn theoretisch mogelijk op verschillende 
nivo's. Zo kan de productie van cytokinen geremd worden en de 
gevoeligheid van de gastheer voor cytokine-effecten kan verminderd 
worden door de productie van endogene remmers of door het tolerant 
worden van gevoelige cellen, bijvoorbeeld door verlaging van 
cytokinereceptor-aantallen. Ten behoeve van studies naar deze 
mechanismen werden sensitieve en specifieke radioimmunoassays 
ontwikkeld voor muis IL-la , IL-lß en TNFa. Tevens werd een extra 
muismodel gebruikt, de СЗН/HeJ muissoort; deze muizen produceren 
slechts zeer lage hoeveelheden cytokinen na toediening van 
lipopolysacharide (LPS), de belangrijkste cytokine-inducerende 
component van Gram-negatieve bacteriën, in tegenstelling tot de 
genetisch verwante СЗН/HeN muizen, die een normale cytokinerespons 
produceren. In Swiss en СЗН/HeN muizen was de verhoogde overleving 
na IL-1 voorbehandeling geassocieerd met een verminderde stijging van 
T N F a en IL-6 concentraties na infectie en met verminderde ex vivo 
productie van IL-1 en TNFa door LPS-gestimuleerde macrofagen van 
deze muizen. Als vermindering van endogene cytokineproductie 
inderdaad een essentieel mechanisme van het beschermende effect van 
IL-1 zou zijn, dan zou de verhoogde overleving na IL-1 niet moeten 
optreden in СЗН/HeJ muizen. De bevindingen in СЗН/HeJ muizen zijn 
in overeenstemming met deze aanname: in deze muizen was een gebrek 
aan beschermend effect van IL-1 tegen infectie geassocieerd met lage 
cytokineconcentraties in vivo en lage productie capaciteit ex vivo. Het 
beschermende effect van IL-1 op de overleving zowel als het reducerende 
effect op de in vivo en ex vivo cytokineproductie vertoonden een 
stapsgewijze toename voor СЗН/HeJ, СЗН/HeN en Swiss muizen. Deze 
resultaten suggereren dat een vermindering van de cytokineproductie 
door de voorbehandeling met IL-1 een rol speelt in de verhoogde 
weerstand tegen infectie. 
In verschillende organen van IL-1 behandelde muizen werd een 
verhoging van mRNA voor de IL-1 receptor antagonist (IL-IRa) 
waargenomen op het tijdstip van infectie. De IL-IRa functioneert als een 
competitieve remmer van IL-1 effecten, en derhalve kan deze mRNA 
verhoging nog een mechanisme vertegenwoordigen van het 
beschermende effect van IL-1. 
Van zowel de IL-1 receptor als de TNF receptor zijn twee vormen 
gekarakteriseerd. Op het tijdstip van infectie werd een verlaging 
gevonden het mRNA voor de type I IL-1 receptor (IL-1RI) en de type 1 
TNF receptor (TNFRI), die volgens recente bevindingen elders de 
biologisch relevante receptoren zijn voor resp. IL-1 en TNFa. Dit wijst 
erop dat IL-1 ook beschermend kan werken tegen infectie door de 
gevoeligheid van cellen voor cytokinen te verminderen. In de lever 
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echter werd er een duidelijke verhoging van IL-1RI en TNFRI mRNA 
gevonden op 24 uur na de IL-1 behandeling, en in de nier werd er op dat 
tijdstip een verhoging waargenomen voor de TNFRI. Aangezien de lever 
en nieren een belangrijke rol spelen bij het klaren van TNFa en IL-1, 
zouden de waargenomen effecten op de corresponderende receptoren 
een rol kunnen spelen in de verhoging van de overleving door 
voorbehandeling met IL-1. Daarnaast zou een verhoogd IL-1RI voordelig 
kunnen zijn doordat het de acute fase eiwit productie verhoogt. 
Verhoogde type I IL-1 receptoraantallen op hepatocyten zouden ook van 
belang kunnen zijn voor de vermindering van biochemische en 
histologische tekenen van leverschade (Hoofdstuk 9) na voorbehandeling 
van geïnfecteerde muizen met IL-1. 
In H o o f d s t u k 8 werd de mogelijke rol van macrofagen in de 
bescherming tegen infectie geïnduceerd door intraperitoneaal IL-1 
onderzocht door deze cellen selectief te verwijderen met behulp van 
diphosphonate-bevattende liposomen (DMDPL). Intraper i toneaal 
ingespoten DMDPL, dat peritoneale, lever- en miltmacrofagen 
verwijdert, deed het beschermende effect van IL-1 teniet, terwijl 
intraveneus toegediend DMDPL, dat lever- en miltmacrofagen maar 
niet de peritoneale macrofagen verwijdert, het IL-1 effect niet 
verminderde. Deze resultaten wijzen erop, dat in dit IL-1 effect de 
macrofagen ter plaatse van de IL-1 injectie van essentieel belang zijn. 
Twee belangrijke groepen macrofaag-producten zijn reactieve zuurstof 
in termedia i ren , bijvoorbeeld superoxide, en reactieve stikstof 
intermediairen, onder andere stikstofoxide (NO) en de metaboliet nitriet. 
Deze stoffen bezitten antimicrobiële effecten, echter overproductie is 
schadelijk. Het beschermende effect van IL-1 op de overleving van 
infectie was geassocieerd met een verdubbeling van de nitrietsecretie en 
onveranderde superoxide anion productie door ex vivo gestimuleerde 
macrofagen van IL-1-behandelde muizen. Omdat echter de 
bacterieaantallen in IL-1-behandelde en controlemuizen gelijk zijn 
(Hoofdstuk 2) is het niet waarschijnlijk dat een verhoogde antimicrobiële 
activiteit van macrofagen een rol speelt in de bescherming. NO bezit 
echter nog andere eigenschappen die mogelijk bijdragen aan het 
beschermende effect van IL-1, zoals trombocytactivering en -aggregatie. 
Zowel de rol van TNFa, een macrofaagproduct (Hoofdstuk 6) als de door 
IL-1 geïnduceerde vermindering van het cytokineproducerend 
vermogen van peritoneale macrofagen (Hoofdstuk 7) zijn in 
overeenstemming met de hier waargenomen rol van peritoneale 
macrofagen in het beschermende effect van IL-1. 
In vervolg op het onderzoek naar cytokineremmers in Hoofdstuk 7 
werden, na infectie van IL-1-behandelde en controlemuizen, 
serumconcentrat ies gemeten van afgescheiden, opgeloste TNF 
receptoren (sTNFRs), die TNF kunnen binden en zo de effecten remmen. 
Op vroege tijdpunten waren de sTNFRs in IL-1-behandelde muizen 
licht, maar niet significant, verhoogd. Echter, op latere tijdstippen 
waren in deze muizen de sTNFRs gereduceerd en de vraag is hoe deze 
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bevinding te rijmen zou zijn met de bescherming door IL-1 tegen sterfte. 
De mogelijkheid dat dit een gevolg is van verlaging van hoeveelheden 
sTNFR-inducerende inflammatoire stimuli of van een verminderde 
productie van membraan TNFR moet nader onderzocht worden. 
In Hoofdstuk 9 werd de rol van respectievelijk de type I en II IL-1 
receptoren (IL-1RI en IL-1RII) in het beschermende effect van IL-1 
nagegaan. Wanneer een 1000-voudige molaire overmaat IL-IRa over IL-
1 werd toegediend, wat resulteert in hoofdzakelijk een blokkade van IL-1 
effecten via de IL-1RI, werd een gedeeltelijke vermindering van de 
verhoogde overleving na IL-1 behandeling gevonden. Aangezien hoge 
doses van de IL-IRa ook IL-1 effecten via de IL-1RII, waarvoor het een 
veel lagere affiniteit heeft, kan remmen werden hogere doses IL-IRa 
niet getest. 
Voorbehandeling met een specifiek neutraliserend antilichaam tegen de 
IL-1RI blokkeerde het beschermende effect van IL-1 op de overleving 
volledig. Een nonapeptide fragment van IL-lß, dat wel het immuun-
stimulerende maar niet het inflammatoire effect van het gehele 
molecuul bezit en dat werkt via een niet-receptorgemedieerd signaal 
transductie proces, kon het IL-1 effect op de overleving niet nabootsen. 
Deze resultaten suggereren een cruciale rol van de IL-1RI in de door IL-
1 geïnduceerde verhoogde weerstand tegen infectie. Deze resultaten zijn 
in overeenstemming met de geobserveerde rol van acute fase eiwitten 
(Hoofdstuk 5), die geproduceerd worden door hepatocyten, die de type 1 
receptor bezitten, en met de rol van TNFa (Hoofdstuk 6) dat na 
stimulatie met IL-1 door vele celtypen, waaronder cndotheelcellen en 
fibroblasten, wordt geproduceerd via de IL-1RI, en door monocyten en 
macrofagen via kleine hoeveelheden IL-1RI. Deze bevindingen van een 
sleutelrol van de IL-1RI wordt bevestigd door recente studies, die 
rapporteren dat IL-1 signaal transductie uitsluitend via deze receptor 
wordt bewerkstelligd. 
Histopathologische evaluatie van organen van IL-1-voorbehandelde 
muizen die waren gestorven aan infectie gaf ten opzichte van 
controlemuizen enige verbetering van de morfologie te zien in 
verschillende cruciale organen, en een significante verbetering van de 
histologie van de lever. Dit was geassocieerd met een verlaging van 
biochemische indicatoren van leverschade. Deze bevindingen zouden 
zowel de inductie van beschermende acute fase eiwitten kunnen 
reflecteren (Hoofdstuk 5), als vermindering van cytokincproductie en 
cytokine sensitiviteit en inductie van cytokineremmers na infectie door 
IL-1 voorbehandeling (Hoofdstuk 7). De bescherming door IL-1 
voorbehandeling van de leverfunctie tijdens infectie zou ook van belang 
kunnen zijn voor het handhaven van de klaring van cytokincn en LPS en 
voor ontgiftiging van leukotrienen tijdens infectie. 
Concluderend kan gesteld worden dat in het kader van het onderzoek 
van dit proefschrift verschillende mechanismen van door IL-1 
geïnduceerde verhoogde weerstand tegen infectie geïdentificeerd zijn, en 
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andere mogelijke mechanismen uitgesloten zijn. Bij eerder onderzoek 
waren reeds een direct antimicrobiëel effect van IL-1 en een rol van 
neutrofielen, koorts, hypoferremie en versneld beenmergherstel door 
IL-1 voorbehandeling uitgesloten. De nu beschreven resultaten tonen 
aan, dat ook IL-1-geïnduceerd IL-6, IL-8, GM-CSF, PAF, LTB4, 
Prostaglandinen, superoxide, glucocorticosteroiden en effecten op de 
glucose homeostase of op opgeloste TNF receptors geen rol spelen. 
Een schematisch overzicht van de in dit onderzoek geïdentificeerde 
mechanismen van de door IL-1 verhoogde weerstand tegen infectie is 
gegeven in Fig. 1 (p. 162). Het beschermende effect van IL-1 wordt 
gemediëerd via de type 1 IL-1 receptor. Macrofagen ter plaatse van de 
IL-1 injectie zijn essentieel voor het effect. Een rol van TNFa en acute 
fase eiwitten werd aangetoond. De verhoogde overleving van infectie na 
IL-1 voorbehandeling is geassocieerd met verlaagde plasma cytokine 
concentraties en verlaagde cytokine productiecapaciteit van peritoneale 
macrofagen. Tevens spelen verhoogde genexpressie van de IL-IRa en 
verlaagde genexpressie van de type I receptoren voor IL-1 en TNF naar 
alle waarschijnlijkheid een rol. 
Het mechanisme van het bevorderende effect van IL-1 op de niet-
specifieke weerstand is dus multifactoriëel. Alle geobserveerde 
mechanismen passen in het concept, dat pathologie na en sterfte aan 
infectie vaak uiteindelijk niet zozeer veroorzaakt worden door de micro-
organismen op zich, maar door een overmatige reactie van de gastheer, 
resulterend in "letale cytokinemie", waarop IL-1-voorbehandeling een 
dempende werking heeft. 
Verder onderzoek moet worden verricht naar de rol van de door IL-1 
geïnduceerde NO productie. Het is mogelijk dat, naast de reductie van 
cy tok inen , ook r eac t i eve z u u r s t o f r a d i c a l e n en a n d e r e 
ontstekingsmediatoren gereduceerd zijn in IL-1-voorbehandelde 
ge ïnfec teerde muizen . Ook m e t i n g e n van p l a s m a - en 
weefselconcentraties van het IL-lRa-eiwit zouden verricht moeten 
worden. Naar aanleiding van recentelijk gepubliceerde studies zou het 
van belang kunnen zijn om ook de rol van andere regulators, zoals IL-4, 
IL-10, IL-13 en leukemia-inhibiting factor (LIF) in toekomstig onderzoek 
te betrekken. Ook is een verdere bestudering gewenst van de rol van door 
IL-1 geïnduceerd intracellulair mangaan superoxide dismutase en 
"heat shock" proteïnen, die een celbeschermende functie hebben. 
Gezien de toxiciteit van IL-1 in de mens en de behoefte aan toediening 
voorafgaand aan de infectie zal, ondanks het duidelijk positieve effect op 
de niet-specifieke weerstand, de toekomst moeten leren of behandeling 
met dit cytokine als aanvulling op antimicrobiële therapie een weg zal 
vinden naar de kliniek. 
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